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 i 
Abstract 
γδ T cells play a central role in the detection of epithelial stress as a component of the 
lymphoid stress surveillance response. Despite their implication in a range of conditions, 
including several cancers, little is known about how they interact with their antigenic 
targets, particularly the interaction of γδ TCRs with their ligands. In this thesis I used 
molecular and structural modelling techniques to characterise recognition of an epithelial 
stress ligand, EphA2, by a Vδ1+ γδ T cell, MAU. This resulted in a tripartite model of 
recognition, involving coordinated interaction of EphA2 with both the TCR and its cognate 
A-ephrin ligands on the T cell, and the identification of a surface patch on the ligand binding 
domain of EphA2 that potentially represents a TCR binding site. I also performed sequence-
level TCR repertoire analysis to assess γδ T cell populations in human colon and liver, and 
explored, the effect of chronic cytomegalovirus infection on the Vδ1+ γδ T cell repertoire, 
the first such analysis of its kind. These studies suggested the Vδ2negative repertoire in 
humans is diverse and largely private, but also highlighted a Vγ5Vδ1 population that was 
selectively detected in cytomegalovirus-seropositive individuals, and may be involved in 
cytomegalovirus immunity. 
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Introduction 
1 Introduction 
  
 1 - 2 
1.1 Background 
The cellular adaptive immune response is largely coordinated by αβ T cells. In the 
periphery, mature αβ T cells express a heterodimeric T cell receptor (TCR) at the cell 
surface, which, in conjunction with the co-receptors CD4 or CD8, recognise non-self 
peptidic antigen presented in the context of major histocompatibility complex (MHC) 
molecules on host cells1. In contrast, γδ T cells represent an unconventional subset of T 
cells, which express a heterodimeric TCR consisting of one γ and one δ chain, and unlike αβ 
T cells, recognise ligands in a non-MHC dependent manner2. 
The genes encoding for all four of the TCR chains (α, β, γ and δ) were discovered 
contemporaneously in the 1980s3, and yet specific, in depth knowledge of the function and 
activity of γδ T cells is still severely lacking compared to their αβ counterparts. Both αβ and 
γδ T cells emerged at the same evolutionary time point 400-500 million years ago4, and are 
present in all vertebrates, suggesting that they may have evolved similarly complex, and 
perhaps complementary, roles in the vertebrate immune system. Indeed, γδ T cells have 
been shown to play key roles in immunoprotection, immunoregulation, tumour recognition 
and recognition of cellular stress5. 
Compared to their αβ counterparts, there has been comparatively little progress in γδ T 
cell biology in recent years, especially in the elucidation of physiologically relevant human 
γδ T cell ligands, and the molecular nature of their interactions with TCR. This may largely 
be because many of the principles established from αβ T cell biology, such as the conserved 
recognition of MHC-presented antigen, do not seem to apply to γδ T cells, and an 
understanding of γδ T cell biology may require novel paradigms of immune recognition to 
be established. 
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Key developments in the understanding of the immunobiology of γδ T cells may unlock a 
powerful compartment of the immune system for clinical manipulation, offering significant 
advances in the treatment of conditions such as cancer, complementing a well-established 
body of existing immunotherapeutic strategies6. 
1.2 Lymphoid stress surveillance is mediated by unconventional lymphocyte 
subsets 
Immune surveillance is proposed to play a key role in the early detection and control of 
various insults to tissues, such as infection and transformation7. This process is thought to 
involve the constant monitoring of host tissue by the immune system, allowing for the rapid 
detection of these processes at an early stage. Unconventional T cell subsets, specifically 
γδ T cells, have been shown to contribute towards the immune surveillance of host tissues8. 
Conventional immune surveillance involves the surveying of host tissue for signs of 
infectious agents by cells of the myeloid lineage, such as dendritic cells (DC), macrophages 
(MΦ), and monocytes (MO). These cells express invariant, non-clonal pattern recognition 
receptors (PRRs), which have been shown to recognise a wide range of pathogen-
associated molecular patterns (PAMPs), originating from a broad spectrum of microbes and 
viruses1. Typically, PAMPs are not specific to an individual bacterium or virus, but are 
usually ubiquitous components common to many pathogens, such as lipopolysaccharide 
(LPS), an integral component of the outer membrane of all Gram-negative bacteria, which 
is recognised by toll-like receptor 4 (TLR 4)9. This non-pathogen-specific recognition of 
PAMPs results in the myeloid cells initiating local effector functions, such as cytolysis and 
phagocytosis, as well as undergoing a process of differentiation in order to migrate to local 
lymphoid tissue, wherein they present antigen, in the context of MHC, to cognate naïve T 
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cells. Upon activation, these T cells undergo a process of clonal expansion and 
differentiation, before being trafficked to the affected tissue via the blood1. These 
pathogen-specific T cells are then capable of eliciting specific adaptive immune responses 
towards their targets, as well as performing pleiotropic immunoregulatory functions.  
The surveillance of non-microbial stresses however, is less well elucidated. Damage-
associated molecular patterns (DAMPs) are autologous antigens which are either 
expressed, upregulated or exposed in response to various stresses, such as transformation. 
While some stress signals, such as ureate and ATP, which are released from dying cells10, 
can be recognised by myeloid cells, the majority cannot11. One such DAMP is the MHC class 
I like molecule MICA, the expression of which is upregulated by cellular dysregulation12. In 
principle, lymphoid cells able to recognise such stress signals are able to rapidly initiate 
strong, local effector responses, without the need to migrate, or undergo clonal expansion. 
This interaction leads to a local inflammatory response which increases both the 
bactericidal and cytotoxic activity of lymphocytes8. Although the non-pathogen-specific 
lymphoid stress response is unlikely to completely eradicate a pathogen, it may play a role 
in the containment and maintenance of tissue integrity, while simultaneously shaping the 
downstream adaptive immune response8. Cells suited to such a task would not have to 
undergo the time-consuming processes of migration and differentiation, and might be 
focused during development on the recognition of a limited range of stress-linked antigens. 
Unconventional lymphoid subsets are able to make a key contribution to the immune 
surveillance of stressed tissue. Arguably, the prototypical unconventional T cell is the γδ T 
cell, which exhibits key properties compatible with the fast acting lymphoid stress 
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surveillance model, and research has shown may play a key role in the detection of early 
stages of both infections and cancers. 
1.2.1 γδ T cells survey host tissues for signs of stress 
In mice, certain γδ T cell subsets are thought to exist as resident, pre-expanded 
populations, which display a constitutive ‘active, yet resting’ phenotype, which is likely 
acquired during development13,14. Such properties have also been described for the 
peripheral blood (PB)-associated subset of γδ T cells in humans2. These characteristics 
make these cells ideally suited for the rapid detection of, and initiation of effector 
responses towards, stress, as they bypass the delay required for the clonal expansion and 
migration of conventional adaptive effector cells, thus facilitating a more immediate 
response. This has been demonstrated experimentally in murine xenograft models, in 
which immunodeficient mice injected with human γδ T cells were exposed to bacterial 
infection, and a strong γδ T cell mediated immuno-protective response was observed one 
day after the original infection, and all bacteria were cleared by day six, before cell division 
had taken place15. The intravenous addition of pamidronate, an agonist for these human 
γδ T cells, markedly increased the antibacterial properties of these cells, demonstrating a 
γδ T cell mediated antimicrobial response within one day following initial exposure. 
Resting γδ T cells, like naïve αβ T cells, are not thought to recirculate between the blood 
and lymphatic system in humans. However, upon activation, the PB-associated γδ T cells 
have been shown to switch to a lymph node (LN)-homing chemokine receptor profile, 
characterised by the upregulation of the LN-homing marker CCR7, and a decrease in 
peripheral tissue-association markers16. Furthermore, the authors also identified γδ T cells 
in gastrointestinal lymphoid tissues, suggesting that this LN-homing phenotype is indeed 
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trafficking γδ T cells to LNs. Interestingly, the presence of CCR7-expressing γδ T cells in 
gastrointestinal lymphoid tissues was not found to increase upon acute infection, 
suggesting that these cells provide continual immune surveillance16. 
Human PB-associated γδ T cells have also been convincingly shown to act as professional 
antigen presenting cells (pAPCs). This was first described after the observation that, after 
short term co-culture with a PB-associated γδ T cell agonist, these cells were able to uptake 
protein antigens and subsequently process and present them as peptides, in the context of 
MHC class II, to naïve CD4+ T cells17. 
Subsequent studies have also demonstrated the ability of these cells to cross-present 
tumour-associated antigens to CD8+ αβ T cells. Daudi lymphoma cells, opsonised with an 
anti-CD20 monoclonal antibody (mAb), were shown to be lysed by PB-associated γδ T cells. 
Subsequently, tumour-associated antigens were internalised by these PB-associated γδ T 
cells, processed and presented as peptide antigens to CD8+ αβ T cells in the context of MHC 
class I. This process appears to be tightly controlled by the interaction of the Fc receptor 
CD16 on the surface of the γδ T cells, with antibodies. This requirement is proposed to 
represent the ‘licensing’ of these γδ T cells to perform their adaptive pAPC roles, as a result 
of their innate killing and internalisation of target cells18. 
As a further example of how γδ T cells may mediate systemic immune responses, a recent 
study has revealed a link between stress induced lymphocyte activation and IgE mediated 
atopy in mice19. Ligands encountered at the same time as cutaneous epithelial stress 
induced strong T helper 2 (Th2)-associated atopic responses, and required NKG2D mediated 
signalling between the stressed epithelia and γδ T cells. This process may serve as an 
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example of the role of lymphoid stress surveillance in shaping downstream immune 
responses. 
Collectively, the studies demonstrate the ability of γδ T cells, in the context of local stress 
surveillance responses, interact with the systemic immune compartment in order to 
polarise appropriate downstream adaptive immune responses, an area which, overall, is 
still poorly understood. 
1.3 Different tissues are enriched with γδ T cells exhibiting distinct V region 
usages 
γδ T cell subsets are enriched in discrete anatomical sites, depending on their particular 
variable (V) region usages, resulting in relatively homogeneous, but distinct, antigen 
receptor repertoires for each tissue2. This is most apparent and well documented in the 
mouse, in which V region usage can reliably be mapped to distinct anatomical sites20. 
Throughout this thesis, γδ TCR chains will be identified using the nomenclature of Heilig 
and Tonegawa21 for murine γδ T cells and Lefranc and Rabbitts22 for human γδ T cells. 
1.3.1 Murine epidermis is enriched with invariant Vγ5Vδ1+ γδ T cells 
Arguably the best characterised γδ T cell subset in mice express the invariant Vγ5Vδ1 TCR, 
which account for more than 90% of mouse dendritic epidermal T cells (DETCs)23. These 
cells are derived from the first wave of rearrangements of the Vγ locus, and their selection 
is dependent on the presence of the butyrophilin-family protein Skint-1 in the embryonic 
thymus24. This Vγ5Vδ1+ DETC subset has been shown to be important in the maintenance 
of tissue integrity25, protection against chemically induced skin carcinoma26, and have also 
been shown to suppress cutaneous graft versus host disease (GVHD)27. Despite the amount 
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of evidence signifying the importance of Vγ5Vδ1+ DETCs in the control of body-barrier 
homeostasis in mice, any peripheral ligands which interact directly with the TCR have yet 
to be conclusively identified. 
A recent study using intravital dynamics-immunosignal correlative microscopy has revealed 
that Vγ5Vδ1 DETC TCRs are constitutively clustered, and functionally activated in the steady 
state in vivo28. These TCR clusters were found to localise to anchored T cell projections at 
the tight junctions of squamous keratinocytes. In response to tissue stress, in the form of 
full-thickness wounding, the T cells redistribute their TCR towards the basal epidermis and 
tissue resident Langerhans cells. This suggests that the Vγ5Vδ1 DETC TCR is likely to 
constitutively interact with self-ligands in the steady state, and the involvement of integrin-
dependent tight junction projections, suggests that the TCR may be monitoring the spatial 
pattern of the putative ligand at cell-cell junctions. 
In contrast to this, a study using Vγ5Vδ1 DETC TCR tetramers to stain mouse tissue sections 
suggested that Vγ5Vδ1 TCR ligands are not constitutively expressed in healthy tissue, yet 
are rapidly upregulated in response to wounding, in a tightly controlled fashion29. 
Interestingly, blocking of the DETC TCR/ligand interaction with this tetramer following 
injury delays wound healing, supporting the role of DETCs in the early stages of response 
to cutaneous injury. It is unclear whether this methodology shows true upregulation of 
ligand, or re-localisation from tetramer inaccessible cell-cell junctions post-injury, 
consistent with the findings of Chodaczek et al.28 These studies provide an insight into the 
potential nature of Vγ5Vδ1+ DETC TCR ligands, and provide a platform from which further 
studies may reveal the identity of the much sought-after ligands. 
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Other potential ligands for different murine γδ T cell subsets are also being investigated. 
Binding assays using soluble-multimeric recombinant TCRs (smTCR) derived from murine 
invariant Vγ6Vδ1+ and Vγ1Vδ6.3+ T cell clones have been suggested to reveal a ligand, or 
ligands, which are constitutively expressed on resident peritoneal MΦ in healthy tissue, 
and is common to at least two distinct TCRs30. Infection with the bacterium Listeria 
monocytogenes invoked the rapid upregulation of this ligand, consistent with a stress 
ligand which can activate cells of the lymphoid stress surveillance compartment. The ligand 
has not yet been identified, but it is known to be independent of β2 microglobulin (β2M), 
an essential subunit of some MHC-like molecules31. 
1.3.2 Most human peripheral blood γδ T cells express a Vδ2+ TCR 
γδ T cell subsets and their tissue localisation is less well understood in humans than in mice, 
markedly more so than the knowledge gap in the understanding of αβ T cell populations 
between the two species32. This likely because there appears to be little overlap between 
the two species with regards to γδ T cell subset TCR chain usages, properties and ligands 
they recognise33. 
The best characterised of the human γδ T cell subsets is the Vδ2+ PB-associated subset, 
which constitute on average between 2% and 5% of CD3+ cells in the PB of humans, 
although this is highly variable depending on the individual2. The vast majority of PB-
associated γδ T cells (>70%34) display the pairing of the Vδ2 chain with the Vγ9 chain , and 
cells bearing this receptor are referred to interchangeably as either the Vγ9Vδ2+ or PB-
associated γδ T cell subset. 
Despite the increasing appreciation for the diverse role Vγ9Vδ2+ γδ T cells play in the 
immune system, detailed information on how these cells interact with their target cells is 
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still unclear. Vγ9Vδ2+ γδ T cells have been shown to be activated, in a TCR-dependent 
manner, by low levels of low-molecular weight, non-peptidic phosphoantigens (pAgs)35. 
One such molecule is isopentenyl pyrophosphate (IPP)36, a host-derived metabolite of the 
mevalonate isoprenoid biosynthesis pathway, which is found in all host cells, and is 
essential for cell survival37. 
Vγ9Vδ2+ γδ T cell reactivity is not limited to host-derived antigens however. One of the 
most potent activators of these cells is hydroxy-methyl-butenyl pyrophosphate (HMBPP), 
which has been demonstrated to be 30,000-fold more potent activator of Vγ9Vδ2+ cells 
than IPP38. HMBPP is a metabolite in the bacterial-specific 2-C-methyl-D-erythritol 4-
phosphate (MEP) isoprenoid biosynthesis pathway, which is distinct form the host 
mevalonate isoprenoid biosynthesis pathway from which IPP is derived. This striking 
difference in activation potential between microbial and self-derived pAgs likely allows for 
the detection of small amount of infecting pathogen, without reacting against healthy host 
tissue which expresses basal levels of the weakly stimulatory host-derived metabolites. 
Furthermore, following transformation, components of the mevalonate pathway are often 
disrupted, and this can increase the production of pAg metabolites to levels sufficient to 
activate Vγ9Vδ2+ T cells36. This mechanism therefore potentially allows Vγ9Vδ2+ T cells to 
recognise both stress and infection of host cells via pAg metabolites. 
In keeping with this observation, Vγ9Vδ2+ γδ T cells are capable of recognising, and killing 
a range of myeloma and lymphoma cell lines in vitro, such as Daudi39 and K56240, in a TCR-
dependent manner. The magnitude of responses to these cells was increased by the 
addition of amino bisphosphonates (such as zoledronate), which result in the accumulation 
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of IPP by the inhibition of the enzyme farnesyl pyrophosphate synthase (FPPS), which 
catalyses the metabolism of IPP derived metabolites in the mevalonate pathway36. 
In addition to pAg recognition, some data suggest that Vγ9Vδ2+ γδ T cells can also recognise 
whole protein antigens via their TCR, although convincing molecular data for these 
interactions is largely lacking. Such whole protein antigens include the mitochondrial F1-
ATPase, which is ectopically expressed on the cell surface in a range of cancers41, heat shock 
proteins42, as well as viral proteins such as the herpes virus glycoprotein-I (gI)43. More 
recently, a study has highlighted human MutS homolog 2 (hMSH2), a nuclear protein and 
prominent cancer biomarker which plays a central role in DNA mismatch repair 
mechanisms, as a potential Vγ9Vδ2 TCR ligand44. hMSH2 was found to be ectopically 
expressed on the surface of a panel of epithelial tumour cells, as well as Epstein–Barr virus 
(EBV) infected cells, and these cells elicited cytolytic effector functions of Vγ9Vδ2 γδ T cells 
in a TCR and NKG2D dependent manner. 
Collectively, these data suggest a role for Vγ9Vδ2+ γδ T cells in the detection of, and 
protection against both cellular stress and infection through the recognition of pAgs and, 
potentially, other less well-characterised whole protein antigens. 
1.3.3 Human Vδ2negative γδ T cells represent a potentially diverse subset of γδ 
T cells 
Non-PB-associated γδ T cells are referred to as Vδ2negative γδ T cells, as the Vδ2 chain is 
almost exclusively used by Vγ9Vδ2+ γδ T cells in adults. Vδ2negative γδ T cells form a 
substantial component of the intraepithelial lymphocyte (IEL) compartment, and in human 
colon can constitute up to 20% of epithelial CD3+ lymphocytes, 90% of which express Vδ1+ 
γδ TCRs, although these numbers are highly variable between individuals. 
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The Vδ1+ classification is occasionally used synonymously with the Vδ2negative classification, 
but this is incorrect as the Vδ2negative γδ T cell population also includes cells expressing Vδ3+ 
and Vδ5+ TCRs, and there is currently no evidence to suggest that these cells have identical 
properties to Vδ1+ γδ T cells. 
Vδ2negative cells have been found to be enriched within several epithelial tumours, such as 
kidney and colon carcinomas45, and also are involved in the immune response to 
cytomegalovirus (CMV) infection46. Despite an increasing appreciation for the diverse role 
Vδ2negative γδ T cells play in the immune system, few physiologically significant ligands, and 
the precise molecular nature of their interaction with TCR, have been characterised 
Vδ1+ γδ T cells have repeatedly been associated with recognition of CD1 molecules, a family 
of MHC-like proteins which are typically associated with presenting self and bacterial lipids 
to natural killer T (NKT) and other unconventional T cells47. This finding is particularly 
interesting as CD1 molecules are the only ligands to which both murine and human γδ T 
cells display reactivity33. 
Vδ2negative γδ T cells demonstrating reactivity towards CD1c, which is upregulated during 
the process of inflammation-induced differentiation of MO into DC48, were isolated by 
stimulating peripheral blood lymphocytes (PBLs) with autologous CD1c expressing DC and 
Mycobacterium tuberculosis extract49. Subsequently, several independent studies have 
also isolated human Vδ1+ γδ T cells which appear to detect specific lipid antigens, both 
host-derived and microbial, presented by CD1d50,51. These cells were isolated by staining 
γδ T cells with lipid-loaded CD1d tetramers, and the majority of these cells (>80% in some 
instances) expressed a Vδ1+ γδ TCR. 
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Two of the TCRs isolated from these studies have been characterised in detail. The DP10.7 
TCR (Vγ4Vδ1) was isolated from healthy PBMCs stained by CD1d tetramers loaded with the 
self-lipid, sulfatide. The 92C TCR (Vγ5Vδ1) was isolated from PBMCs stained by CD1d 
tetramers loaded with the microbial glycolipid α-galactosylceramide (αGalCer). These TCRs 
were subsequently used in molecular and structural studies to elucidate the γδ TCR binding 
mode, and these studies provide further insight into the immunobiology of CD1d-reactive 
γδ T cells, and this will be discussed in detail in section 1.4.1. 
The apparent affinity for MHC-like molecules by Vδ2negative γδ T cells suggests that these 
cells may be restricted to recognition of these molecules. This is unlikely, as in these study 
only a small percentage (<1% in some instances) of Vδ1+ γδ T cells could be stained by lipid-
CD1d tetramers50,51. Furthermore, the ability of Vδ1+ γδ T cells to discriminate between 
lipids presented by CD1d is also unclear, as staining of Vδ1+ γδ T cells with non-lipid-loaded 
CD1d tetramers was also observed in these studies. 
Collectively, this suggest that attempts to identify new ligands for Vδ2negative γδ T cells 
should not be restricted to MHC-like molecules, and that non-MHC-like molecules are still 
viable candidates for recognition by Vδ2negative γδ T cells. 
1.3.3.1 Vδ2negative γδ T cells are involved in the immune response to CMV 
Vδ2negative γδ T cells have been convincingly argued to play a role in the immune response 
to CMV. CMV is a double stranded DNA β-herpes virus which is known to chronically infect 
between 50% and 90% of the population52. Following acute infection, CMV enters a non-
symptomatic latent phase, characterised by a decrease in the production and expression 
of viral proteins53. Initiation and maintenance of this latent cycle is thought to be largely 
influenced by chronic immune control of the CMV lytic processes53. Therefore, CMV 
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reactivation often occurs in immunocompromised patients, and can result in severe clinical 
implications54. 
CMV infection has repeatedly been shown to cause the specific expansion of highly 
differentiated Vδ2negative γδ T cells in the PB, while Vδ2+ subsets remain largely unaffected. 
Furthermore, expansions of γδ T cells in CMV reactivation in immunocompromised 
transplant patients is correlated with resolution of viraemia, suggesting a protective 
antiviral role for these cells55. 
Despite the potential importance of these populations, little is currently known regarding 
the TCR usage profile and ligand recognition by these cells. Spectratyping studies have 
characterised these expansions as oligoclonal46,56, which suggests that the expansion is 
antigen-driven. However, such studies provide no information on the particular γδ TCR 
chains present in these populations, nor their antigen-recognition profiles. Advances in this 
area are necessary to increase the understanding of how γδ T cells interact with this 
important model virus. 
1.4 The molecular basis of γδ TCR ligand recognition 
The γδ TCR is a heterodimeric antigen receptor, consisting of one γ and one δ chain, 
expressed on the surface of γδ T cells. The genes which encode these receptors are located 
within three loci, the TCRγ and TCRβ loci are located separately on chromosome 7, whereas 
the TCRδ and TCRα genes share a single locus on chromosome 1457. Somatic recombination 
between the variable V-J and V-D-J gene segments for γ and δ respectively provides 
diversity for the receptor, similarly to α and β chain recombination in αβ T cell 
development. The human β locus spans ~0.6Mb and contains 62-65 V gene segments, of 
which around 40 have been shown to be functional2. In contrast, the human γ locus spans 
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only 0.1Mb, and contains 6 functional V gene segments57. The V gene segments contain the 
germline-encoded complementarity determining regions (CDR) CDR1 and CDR2. The CDR3 
region constitutes the recombined V-J segments (for γ) or V-D-J (for δ), as well nucleotides 
inserted randomly by P- and N-nucleotide addition57. Theoretically there are approximately 
1016 possible TCRs which can be produced from these genetic components, however 
individual T cell subsets show biased use of TCR V gene segments, with some subsets 
expressing invariant/semi-invariant TCRs with identical/highly-similar junctional 
sequences20. 
Structurally, each TCR chain consists of two immunoglobulin (Ig) folds, one for each of the 
variable (V) and constant (C) regions, and each fold constitutes around 7 β strands arranged 
in two antiparallel β sheets and, and the CDR regions of the V region are exposed, flexible 
loops58. V regions in the γ and δ chains are structurally similar to αβ V regions, however the 
C regions are drastically different, owing to differences in the formation of disulphide bonds 
between the γ and δ chains. Also unique is the orientation of the C and V regions, which is 
due to an unusually small angle between the two domains58. This is interesting because it 
implies that γδ TCRs may be able to form different signalling complexes than αβ TCRs, due 
to different structural constraints. 
Several structures of γδ TCRs have been completed, and they have aided our understanding 
of the potential molecular nature of their interactions. The first structure determined of a 
human Vγ9Vδ2+ pAg-reactive γδ TCR was published in 2001, and described an antigen 
receptor with similarities to both αβ TCRs, as well as antibodies58. 
Analysis of the structure suggested that all six CDR loops are potentially important for the 
binding of pAgs, which has subsequently been confirmed by mutational studies59, and this 
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may explain the canonical usage of the Vγ9 and Vδ2 chains by pAg-reactive T cells. Such 
structures of receptors alone, however, cannot reveal the details molecular nature of the 
interaction between TCR and ligand. Indeed, over ten years since the publication of this 
structure, it is still not known precisely how Vγ9Vδ2 TCRs interact with pAg-sensitised 
targets, although this is starting to be uncovered, and is discussed in detail in section 1.4.1. 
The role of the γδ TCR as the sole facilitator of peripheral ligand recognition in γδ T cells 
has recently been bought into question. A study identified a population of murine CD27+ 
γδ T cells whose peripheral activation was not mediated by the TCR, but solely by cytokines, 
leading them to suggest that, for this subset, the γδ TCR may predominantly be required 
for the selection, maturation and trafficking of the γδ T cells60. In contrast, CD161+ human 
γδ T cells have been shown to be TCR-hyporesponsive unless given co-stimulation through 
CD16161, and so perhaps the costimulatory requirements of the CD27+ murine population 
have yet to be established. However, overall these studies indicate that gaining an 
improved understanding of γδ immunobiology is likely to shed light on novel paradigms of 
immune regulation relative to conventional αβ T cell subsets. 
 
1.4.1 Human Vγ9Vδ2+ γδ T cells recognise pAgs via BTN3A1 
It has long been established that VγVδ2+ γδ T cells are specifically activated by both host-
associated and pathogen-associated pAgs, however the molecular nature of this 
interaction has only recently begun to be uncovered. Direct binding has not been observed 
between pAgs and VγVδ2 TCRs, and this therefore suggests that other molecules may be 
involved in the host cell in order to facilitate activation. This is supported by the observation 
that cell-cell contact is required between the VγVδ2+ T cell and the pAg-treated cell for 
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activation62,63, and that murine cells are unable to activate VγVδ2 T cells in this way, 
suggesting that these critical molecule(s) are primate specific64,65. 
Butyrophilin-3A1 (BTN3A1) has since been identified as a molecule essential for VγVδ2+ γδ 
T cell activation by pAgs. BTN3A1 knockdown studies in Vγ9Vδ2+ γδ T cell-activating cell 
lines have been shown to prevent activation, and subsequent reintroduction can re-confer 
sensitivity66. BTN3A1 is a member of the BT3 family, an Ig superfamily of transmembrane 
proteins implicated in many biological processes67. All members contain IgV (N terminal) 
and IgC (C terminal) extracellular domains, and all but BTN3A2 contain an intracellular 
B30.2 domain. When cross-linked with an agonist antibody, all BTN3A family members can 
activate VγVδ2 T cells in vivo, however only BTN3A1 can activate when exposed to pAgs66. 
This suggests that pAg-mediated stimulation may activate Vγ9Vδ2+ T cells via alterations in 
the rearrangement of the BTN3A1 ectodomain. 
However, it is still unclear exactly how this molecule confers the signal to Vγ9Vδ2+ T cells, 
and which domains are involved. A study by Vavassori et al.68 suggested BTN3A1 acts as an 
antigen presenting molecule, binding pAgs in its extracellular IgV domain for recognition by 
Vγ9Vδ2 TCRs, providing an X-ray crystal structure of pAgs IPP and HMBPP bound to the 
extracellular IgV domain of BTN3A1. However, since publication, the studies’ 
crystallographic data has been called into question, particularly with regard to the 
modelling of the pAgs into the electron density69. 
A competing theory, published subsequently, indicates that it is the intracellular B30.2 
domain of BTN3A1 which directly binds pAgs, and the authors provide more convincing X-
ray crystal data to support this69. Using these X-ray crystal complexes they identified a 
small, positively charged pocket which they propose binds the pAgs. Amino acid residue 
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differences in this region could explain why BTN3A3 fails to activate Vγ9Vδ2+ γδ T cells, 
despite the presence of a B30.2 domain. The authors subsequently suggest that BTN3A1 
potentially translates this as a signal to the TCR via a reduction in membrane mobility and 
clustering, which had been previously observed in cells exposed to intracellular pAgs66. 
Unpublished data from the Willcox group provides further support for this second model, 
as nuclear magnetic resonance (NMR) has demonstrated interactions formed between IPP 
and the intracellular B30.2 domain of BTN3A1. However, despite this increased 
understanding of pAg sensing, definitive molecular mechanisms are unclear and conclusive 
TCR binding to BTN3A1 has not been shown. 
1.4.2 Structural analyses of γδ TCR/ligand complexes 
The first complex structure to demonstrate a γδ TCR bound to ligand was the murine G8 γδ 
TCR in complex with the nonclassical MHC class I molecule, T2231, and structural analysis 
of this interaction suggests a convergence of innate and adaptive recognition strategies. 
Adams et al. reported that G8 utilises a combination of both genetically diverse and 
germline-encoded regions of its CDR3δ loop to bind to the side of T22. The majority of the 
interacting residues originate from the germline-encoded Dδ2 segment, suggesting an 
innate-like pre-disposition for T22 binding. Shin et al. used T22 tetramers to identify and 
clone T22-reactive γδ T cells, and have demonstrated that this full length Dδ2 segment is 
present in a substantial population of mouse γδ T cells, and use the reading frame which 
encodes the sequence SEGYE70.  
The use of the recombination-derived diverse residues in the CDR3δ chain may 
complement the innate-like ligand recognition by allowing rapid coevolution of the TCR 
along with its ligand, allowing for the adaptation to rapid changes within an individual, 
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while providing the framework for broader innate-like recognition among the whole 
species. These data suggest that γδ TCRs that recognise ligand in this manner can recognise 
a limited range of antigens (perhaps one Dδ segment for each), with affinity being fine-
tuned by random recombination components.  
It is important to consider how representative this mechanism may be when considering 
the other potential γδ TCR/ligand interactions identified. G8 recognition of T22 requires 
the presence of β2M, yet mice deficient in β2M do not display the immunodeficiency 
phenotypes of γδ-/- mice, indicating that there are other mechanisms available for the 
recognition of ligands by γδ TCRs in mice2. Furthermore, the small contribution of CDR1 
and CDR2 towards T22 reactivity is not easy to reconcile with the importance of V regions 
in the distribution and tissue localisation of γδ T cell subsets. 
1.4.2.1 Structural analyses of Vδ1+ γδ TCRs interacting with CD1d 
As discussed in section 1.3.3, structural complexes have recently been determined for the 
interaction of two Vδ1+ γδ TCRs, 92C51 and DP10.750, with lipid-bound CD1d. Despite some 
similarities, these complexes surprisingly demonstrate remarkable differences in both the 
binding modes of the two TCRs with CD1d and well as lipid discrimination strategies. In 
both structures, contacts between the TCR and CD1d are largely facilitated by interactions 
between the CDR1 loop of the Vδ1 chain and the α2 helix of the CD1d lipid binding 
platform. This is supported by van der Waals interactions between the Vδ1 CDR3 loop, and 
to an extent the Vδ1 CDR2, and the α1 helix of the CD1d lipid binding platform. In both 
structures, lipid specificity is conferred by interactions between CDR3 junctional residues 
of either the γ (92C) or δ (DP10.7) chain and the lipid head groups. 
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Strikingly, the two structures reveal different requirements for the Vγ chains of the TCRs 
for binding to CD1d. The 92C TCR uses 3 residues of the γ chain CDR3 loop to facilitate 
antigen specificity by forming polar-contacts the αGalCer head group, whereas the γ chain 
of the DP10.7 TCR does not form interactions with either CD1d or sulfatide. This apparent 
minimal contribution from the γ chain may explain the lack of conservation of γ chains of 
CD1d interacting TCRs identified in both studies, as well as a further, independent, study71. 
These differences in CDR involvement result in different TCR footprints on the CD1d lipid 
binding platform, and although in both instances the Vδ1 CDR1 loop forms contacts with 
the α1 helix of the binding platform, the region of the helix they interact with differs 
between the complexes. 
The disparity of binding mode between the two structures calls into question the 
conclusions from both studies that these Vδ1+ γδ T cells have a physiological role in 
specifically recognising lipids presented by CD1d. Although seemingly similar to the mode 
of recognition of MHC-presented peptides by αβ T cells (where in broad terms the 
germline-encoded CDR1 and CDR2 loops of the α and β chains form contacts with the 
peptide binding platform whereas the variable CDR3 loops confer antigen specificity72), 
there are several key differences. Primarily the non-conserved TCR footprint appears to 
defeat the evolutionary purpose of a conserved presentation molecule, which one would 
expect to enable invariant interactions with the presenting molecule, allowing the 
recombined elements of the immune receptor to differentiate between a diverse range of 
presented antigens. However, the binding mode observed not only differs between each 
receptor considerably, but in each case is perhaps more reminiscent of antibody binding of 
three-dimensional epitopes, which happen to be similar on both the sulfatide- and 
αGalCer-bound CD1d lipid-binding platform regions. 
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Collectively, these studies provide great insight into the molecular nature of interactions of 
γδ TCRs with their ligands, although work is still needed to fully characterise the role of 
individual TCR elements, such as the CDR loops, particularly in antigen recognition by 
Vδ2negative γδ T cells. 
1.5 The expansion of dually reactive Vδ2negative γδ T cells following renal 
transplant 
In 2005, Halary et al. reported the expansion of Vδ2negative γδ T cells in the blood of 
immunocompromised renal transplant patients following acute infection with CMV73. In 
these patients, the circulating γδ T cell repertoire comprised up to 50% of total PB T cells.  
Clones were generated from the Vδ2negative γδ T cells which demonstrated strong reactivity 
towards CMV-infected fibroblasts in vitro, in an MHC- and NKG2D-independent manner. 
Individual Vδ2negative clones also showed strong reactivity to various cancer cell lines, such 
as HT29 and 293T73, and subsequent unpublished data from the laboratories of Julie 
Déchanet-Merville and David Vermijlen have shown that there seems to be considerable 
diversity in the pattern of cancer cell lines these Vδ2negative clones recognise. These 
interactions were shown to be TCR-dependent, as determined by the use of antibodies to 
block CD3 and γδ TCRs (Cδ domain). Furthermore, the TCR was found to become 
downregulated following activation, as is typically observed in TCR-mediated responses74. 
Finally, transduction of the TCR genes from the dually-reactive clones into Jurkat (JRT)-T3.5 
cells, conferred reactivity towards the same set of cell lines. 
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These findings led to the hypothesis that these γδ T cell clones were recognising stress 
ligands induced by both viral infection and transformation, via their γδ TCRs. In order to 
fully understand these interactions, identification of these ligands was required. 
1.5.1 The identification of TCR ligands for dually reactive Vδ2negative γδ T cells 
Two of the clones isolated from these expanded populations of vδ2negative γδ T cells were 
selected for further study, designated MAU (Vγ9Vδ1) and LES (Vγ4Vδ5). To determine the 
ligands for these two clones, an antibody blocking screen was conducted by immunising 
BALB/c mice with the activating HT29 cell line, and CMV infected fibroblasts. Two of the 
antibodies generated in this screen displayed immunofluorescence staining profiles of 
recognised target cells for these clones. The 6G8 antibody was able to block reactivity to 
such cell lines by the MAU clone, but did not affect reactivity of the LES clone. Conversely, 
the 2E9 antibody blocked reactivity by the LES clone, but not the MAU clone. Based on this 
observation, it was therefore assumed that the ligands for the blocking antibodies 2E9 and 
6G8 were the ligands for LES and MAU respectively. 
In the Willcox laboratory, the 2E9 and 6G8 blocking antibodies were then used in co-
immunoprecipitation (co-IP) experiments to isolate their respective ligands. The molecules 
co-immunoprecipitated from activating cell lysates were analysed by mass spectrometry, 
and were identified as endothelial protein C receptor (EPCR) and ephrin receptor A2 
(EphA2) for LES and MAU respectively. It was therefore proposed that these molecules are 
the ligands for the LES and MAU γδ TCRs. 
The most striking feature of these two ligands is that they are not only expressed on cells 
infected by CMV in vivo, but also up regulated on transformed epithelial cells73. This raises 
 1 - 23 
the possibility that these molecules act as major targets for γδ T cell stress surveillance, or 
are prototypic of the type of ligand recognised in this context. 
Subsequent studies from our group have confirmed the status of EPCR as a ligand for the 
LES TCR by virtue of surface plasmon resonance (SPR) binding analyses, and the interaction 
has partly been characterised through mutagenesis studies. Confirmation of an interaction 
between the MAU TCR and EphA2 however, has yet to be established, and the molecular 
mechanisms underpinning the potential interaction remain elusive. 
1.5.2 EphA2: A target for epithelial stress surveillance γδ T cells? 
EphA2 has been implicated in the progression and maintenance of several cancers, and is 
a major target for current immunotherapeutic approaches75. The understanding of its role 
as a stress surveillance ligand for Vδ2negative γδ T cells may reveal additional methods for 
the clinical manipulation of this molecule. 
EphA2 belongs to the largest subfamily of tyrosine kinase receptors (RTKs), the ephrin 
receptors. The 16 identified ephrin receptors have a distinct and diverse range of 
physiological roles, including in embryonic development, nervous system development and 
angiogenesis75. The ephrin receptors were first identified in 1987, in a series of screens 
designed to identify RTKs involved in various cancers76. Initially classed as orphan receptors, 
it was not until 7 years later that the first ligands of the ephrin receptors were identified by 
soluble receptor affinity methods (reviewed in77). 
The cognate ligands of ephrin receptors are the ephrins which are classified as either A- or 
B-ephrins, and like the ephrin receptors, have been shown to be involved with many 
developmental processes75. B-ephrins are transmembrane proteins, with small cytosolic 
regions. A-ephrins are small proteins, of around 200 amino acids, which are tethered to the 
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cell surface via glycophosphatidylinositol (GPI) anchors, and so possess neither 
transmembrane nor cytosolic regions78. GPI anchors are a post translational modification 
added to the C terminal end of a diverse group of proteins during production and 
processing, and act as a crucial determinant of signalling activity and localisation78. EphA2 
promiscuously binds all A-ephrins, but does not interact with the TM B-ephrins. EphA4 
however, a structurally similar ephrin receptor family member, binds all A-type ephrins, 
and also all transmembrane B-ephrins79. 
All ephrins share a conserved core region, including 4 invariant cysteine residues near the 
C terminus, which may represent a semi-conserved receptor binding motif. Unusually for 
RTK ligands, the ephrins also have high sequence homology, with approximately 30-70% 
identity77. Ephrin receptors bind their ligands with high affinity, with many interactions 
having a dissociation constant in the nM range77. Furthermore, there is much evidence for 
the clustering of ephrin receptors and ligands during the formation of signalling 
complexes80. 
The structure of EphA2 and the molecular nature of its interactions with ligands is well 
understood80. EphA2 is a 130kDa transmembrane protein, with 5 extracellular domains. 
The N terminal domain is the ligand binding domain (LBD), a 173 residue domain 
responsible for binding A-ephrins. The ectodomain also possess a cysteine rich domain 
(CRD) consisting of a Sushi and epidermal growth factor (EGF) like domain, as well as two 
fibronectin (FN) repeats proximal to the membrane. Intracellularly, EphA2 contains a kinase 
and sterile α motif (SAM) domain, which mediate the proteins signalling functions. LBDs for 
the different ephrin receptors seem to bind their respective subset of ligands in distinct 
ways, which explains the unique ephrin ligand repertoire for each ephrin receptor79,81,82. 
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1.5.2.1 The role of EphA2 in tumour formation and progression 
EphA2 has been linked to the formation and progression of several cancers75,78. Despite 
this, its role in the development and maintenance of transformation is complex, and only 
just beginning to be understood. Unlike other members of the ephrin receptor family, 
which are largely limited to expression during development, EphA2 is primarily located on 
dividing epithelial cells in the lung, skin and small intestine83,84, where it is suspected to play 
roles in the regulation of cell growth, survival, migration, and angiogenesis (reviewed in85). 
EphA2 is tightly confined to areas of cell-cell contact, and is heavily dependent on E-
cadherins for correct localisation and ligand interactions86. Immunofluorescence 
microscopy experiments revealed that the decreased expression of E-cadherins resulted in 
EphA2 being redistributed away from areas of cell-cell contacts. Furthermore, this resulted 
in the exposure of EphA2 epitopes previously inaccessible by antibodies86. The exposure of 
previously hidden epitopes in response to the inhibition of E-cadherins, which is a key 
process in epithelial-mesenchymal transition (EMT) in cancers87, suggests that the immune 
system may have evolved to recognise these epitopes via γδ T cells, as their exposure 
indicates the breakdown of cell-cell junctions.  
The complex role of EphA2 in the progression and maintenance of malignancies seems to 
depend heavily on cell type and micro-environment88. EphA2 is located in chromosomal 
region 1p36, for which loss of heterozygosity is observed in many cancers89. Furthermore, 
EphA2 expression has also been shown to be controlled by mRNA stability90 and p53 
mediated transcription91. 
Immunohistochemistry (IHC) analysis shows that EphA2 is strongly overexpressed in 61% 
of glioblastoma (GBM) patient tumours92, 76% of ovarian cancers93 and 85% of prostate 
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adenocarcinomas94. Furthermore, the increased expression of EphA2 has been linked with 
increased malignancy and poor clinical prognosis78. In some cases however, such as in HeLa 
cervical cancer cell lines and U373MH glioma cells, EphA2 levels are decreased compared 
to healthy cells90. Interestingly, gene profiling analyses show that EphA2 message levels are 
decreased in a range of cancers compared to benign tissue, several of which show 
increased levels by immunohistochemistry approaches83, suggesting a complex role for 
EphA2 in cancer governed by mechanisms at both the message and protein level. 
It is suggested that in healthy tissue EphA2 provides a tumour suppressive function, 
whereby it negatively regulates tumour growth upon binding with its ligands, which results 
in receptor phosphorylation78. Upon transformation, EphA2 displays dramatic alterations 
in subcellular localisation and is located in sites of membrane ruffling in aggressive tumour 
cells95. Similarly, loss of E-cadherin results in re-localisation of EphA2 away from areas of 
cell-cell contact. These unstable cell contacts are thought to prevent effective 
ligand/receptor interactions, and therefore promote the growth of the tumour as a result95. 
This is supported by the observation that EphA2 overexpressed on tumours is usually found 
in an un-phosphorylated form, suggesting limited interactions with ligand96. Furthermore, 
the expression profile of ephrinA1 in many cancers suggests that ephrinA1 is 
downregulated from the cell surface, again, preventing sufficient EphA2/ligand 
interactions, and hence supressing its tumour suppressive functions97. 
1.5.2.2 EphA2 as a target for immunotherapy 
Due to its overexpression in a wide range of cancers, and strong association with clinical 
progression, EphA2 has become a major target for cancer immunotherapy, and a large 
body of research is dedicated to delivering such strategies (reviewed in75). There are 
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currently two categories of approaches being investigated for the clinical targeting of 
EphA2. The first is the use of EphA2 as a target for delivery of exogenous anticancer 
compounds and novel chimeric antigen receptors (CARs). For example, use of bacterial 
toxins bound to ephrinA1 have shown promising results, enabling them to be targeted to 
EphA2 bearing tumours 98. A second approach is to directly manipulate and inhibit the 
transforming properties of EphA2 to treat cancers, such as the use of specific monoclonal 
antibodies which are able to bind EphA2 and induce receptor phosphorylation and 
downregulation, restoring tumour suppressive functions99. 
Clearly the close association of EphA2 expression to the establishment and progression of 
tumours, and association with poor prognosis, increased metastasis and decreased survival 
has established it as a key cancer therapeutic target. It is therefore interesting to speculate 
that γδ T cells may have evolved to target EphA2 for precisely the same reasons, as part of 
their role in surveillance of epithelial stress in the context of the ‘lymphoid stress response’ 
hypothesis. In order to explore this possibility further, it is important to consider the 
potential molecular mechanisms of such an interaction, and build on the structural and 
functional knowledge base of EphA2 and its ligands to identity key components required 
for the formation of an active γδ T cell recognition complex. 
1.6 Clinical applications of γδ T cells 
There is a growing body of evidence supporting the potential significance of γδ T cells in 
the treatment of various cancers34,100. γδ T cell based therapies are particularly attractive 
as they circumvent the requirement for MHC-restriction demanded by conventional αβ T 
cell based approaches34, and also avoids immune evasion following MHC downregulation, 
as is observed on many tumours101. Furthermore, these cells often exhibit high levels of 
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cytotoxicity and high potential for cytokine release, likely due to their existence as pre-
expanded populations in some contexts34. Promising results from phase I and II clinical 
trials have fuelled a growing interest in the development of γδ T cell-based cancer 
immunotherapies102-104. 
Studies in mice have heavily implicated γδ T cells in the protection from carcinogenesis, 
particularly DETCs, which are involved in body-barrier surveillance28. γδ T cell deficient 
(TCRδ-/-) mice are more susceptible to chemically induced skin carcinoma26 and colorectal 
carcinoma105 than control mice. More recently, IL-17 producing circulating γδ T cells (γδ 
T17) have been shown to play a pivotal role in in the efficacy of chemotherapy induced 
anticancer immune responses106. 
Research is not limited to murine models however, as human Vγ9Vδ2+ γδ T cells show 
strong MHC-unrestricted cytotoxic activity against tumours and prostate cancer cell lines 
in vitro107,108. Vγ9Vδ2+ cells expanded ex vivo and then adoptively transferred into severe 
combined immunodeficiency (SCID) mice, demonstrated responses towards B cell 
lymphoma and melanoma, as well renal, pancreatic, and nasopharyngeal carcinomas34. 
Furthermore, there are currently three phase I clinical trials in place involving the ex vivo 
manipulation of the human Vγ9Vδ2+ γδ T cell subset, each showing signs of promising 
results, and in each case improved clinical outcomes correlate with the expansion of γδ T 
cells102-104. Several of the studies include the administration of aminobisphosphonates, 
such as zoledronate, which sensitise the tumour cells to Vγ9Vδ2+ γδ T cells36. 
The knowledge of Vγ9Vδ2 TCR ligands, and the availability of established pharmaceuticals 
to augment their anticancer functions, has resulted in substantial attention being devoted 
towards them. Recently however, there has been increasing interest in Vδ2negative subsets, 
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due to the striking observation that certain Vδ2negative γδ T cell subsets display dual reactivity 
towards both CMV-infected cells and various tumours73,109. This subset may also play a role 
in immunosurveillance of cancer development, as immunocompromised kidney transplant 
patients who have expansions of Vδ2negative γδ T cells have a decreased risk of post-
transplant malignancies in the 6 years following surgery110. 
These trials and investigations suggest that there is considerable potential to exploit the 
tumour surveillance and anti-tumour properties of γδ T cells clinically. Ultimately, however, 
the molecular basis of target cell recognition by γδ TCRs is unclear, and advances in this 
area are essential if we are to understand the mechanism behind their involvement in anti-
tumour effects, and potentially manipulate these mechanisms to develop novel cancer 
treatments. 
1.7 Summary and thesis aims 
γδ T cells have been shown to play a pivotal role in the detection and maintenance of 
cellular stress, and form a key component of the lymphoid stress surveillance 
compartment. The emerging potential of γδ T cells in the therapeutic treatment of cancers 
suggests that γδ T cell biology is a key area to develop, potentially allowing the 
manipulation of a powerful immune compartment, to complement a successful body of 
αβ-based therapeutic strategies34. 
Although several γδ TCR ligands have been characterised, the structural features and 
recognition modalities of the majority of γδ TCR ligands remain largely undetermined. In 
humans, despite recent progress in the understanding of Vγ9Vδ2+ γδ T cell recognition of 
antigens, our understanding of the Vδ2negative recognition strategies is less clear. Despite 
documented recognition of MHC-like molecules, such as CD1d, by some Vδ2negative γδ T 
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cells, the diverse recognition modes involved suggest that ligand identification studies 
should not be confined to such molecules, as there likely exist several distinct modalities of 
ligand interactions with γδ TCRs. 
The further characterisation of Vδ2negative TCR mediated reactions will hopefully provide a 
molecular framework for the detection of further ligands, allowing for the accelerated 
detection of more epithelial stress-related molecules. The regulation and expression 
patterns of these molecules, as well information regarding how they interact with the 
immune system, may reveal more about how damaged tissues communicate with local 
immune cells, as well as revealing previously unknown characteristics of molecules which 
are used as stress signals, thus unveiling potentially clinically exploitable mechanisms.  
In summary, several key questions remain unanswered regarding Vδ2negative γδ T cells, in 
regard to the nature of relevant TCR ligands, how they are recognised. In this thesis I aim 
to characterise the molecular nature of the interaction between the Vδ1+ γδ TCR MAU and 
an epithelial stress ligand EphA2, to establish whether this interaction aligns with the 
general principles of γδ TCR recognition discussed so far, or represents a novel recognition 
strategy.  
I also aim to explore the potential of using various sequence-level TCR repertoire analysis 
techniques to analyse γδ T cell populations in human tissue and blood samples, and this 
will include an analysis of the effect of chronic CMV infection on the receptor usage of Vδ1+ 
γδ T cells in PB.  
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2.1 Molecular cloning and construct design 
2.1.1 Construct design and protein modelling 
Where applicable, information useful for the design of recombinant proteins (such as 
domain boundaries) was obtained from published studies and the protein data bank (PDB). 
If available, protein structures were analysed using WinCoot V0.8111 to determine the 
suitability of potential constructs by assessing at the surrounding amino acid environment 
and structural constraints. 
If protein structures were not available, predictive models were generated by inputting the 
protein’s amino acid sequence into Phyre112, which predicts protein structures by 
comparing their primary sequence to structures with high sequence identify. 
Predictive models of protein-protein interactions were generated using WinCoot111 and 
PyMol V1.7 (Schrödinger). Surface electrostatics models were generated using DelPhi113. 
Sequence alignments diagrams were generated using PRALINE114. 
2.1.2 Expression and shuttle plasmids 
The pMT/Bip/V5-His (Invitrogen) plasmid was used for stable transfection of γδ TCR genes 
into D. melanogaster S2 cells. pMT/Bip/V5-His contains a metallothionein (MT) promoter 
for CuSO4 inducible expression of the gene of interest, a poly-hisitidine (6xHis) tag for 
detection and purification of the protein, and an ampicillin resistance gene (Figure 2.1A). 
pMT/Bip/V5-His was co-transfected with the selection plasmid pCoHygro (Life 
technologies), containing the bacterial hygromycin B phosphotransferase gene, under 
control of the constitutive D. melanogaster Copia 5’-LTR promoter. 
 2 - 35 
pHL-Avitag3 and pHL-FcHis115 plasmids were used to transiently express biotin and human-
Fc-tagged recombinant proteins in HEK293T cells respectively. Target genes were 
expressed under the chick β-actin promoter and were flanked 3’ by a 6xHis tag and either 
a biotin ligase (BirA) recognition site sequence or a human IgGγ1 hinge and Fc sequence. 
pHL plasmids also contain and ampicillin resistance gene (Figure 2.2). 
pCR-Blunt (Life Technologies) was used as a blunt-ended product shuttle vector to more 
easily manipulate blunt ended PCR products, and contains a kanamycin resistance gene 
(Figure 2.1B).  
2.1.3 PCR amplification and primers 
Custom primers were designed for each construct and ordered desalted to 50nmol scale 
(Life Technologies). Primers were reconstituted in 10mM Tris pH8/1mM EDTA and stored 
at -20°C. Primer sequences are listed in Tables 2.1 and 2.2. The construct designs are 
detailed Figures 2.3 and 2.4. Template DNA was acquired as fully sequenced cDNA clones 
(Thermo Scientific) and amplified by transfection into competent DH5α Escherichia coli 
cells (Bioline). Amplified sequences were isolated using the ISOLATE II Plasmid Mini Kit 
(Bioline).  
Polymerase chain reaction (PCR) was facilitated by either of the two proofreading enzymes 
Q5 (New England Biolabs) or Pfu Turbo (Agilent). PCR mixtures typically contained 200nM 
dNTPs (Life Technologies), 20pmols of each forward and reverse primers, 1X polymerase 
buffer, 2.5U of enzyme, 200ng DNA template and finally made up to 50μl with molecular 
grade water (Sigma). Thermocycling was performed using a 2720 thermal cycler (Applied 
Biosystems), with cycling conditions used as per manufacturer’s instructions. 
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2.1.4 Restriction enzyme digestion 
Restriction enzyme digestion of DNA was achieved with various restriction endonucleases 
(Figures 2.1 and 2.2, New England Biolabs) using the manufacturer recommended buffers 
and incubation times. Where compatible buffers and conditions unavailable for two or 
more enzymes for a double digest, single digests were performed sequentially. DNA was 
purified at each stage using the QIAquick Gel Extraction Kit (Qiagen). 
2.1.5 DNA agarose gel electrophoresis and gel purification 
DNA samples were diluted in 1X loading dye (40% sucrose, 0.5% bromophenol blue) and 
loaded into an agarose gel (1% agarose (Sigma)) in TBE Buffer (89mM Tris base, 89mM Boric 
acid and 2mM EDTA) with the addition of ethidium bromide for visualization by ultraviolet 
(UV) light. Samples were separated by size by the application of 80V across the gel until the 
desired separation was achieved. The 1kb plus ladder (Life technologies) was used for 
fragment size determination. DNA bands were extracted from the agarose gel using the 
QIAquick Gel Extraction Kit (Qiagen). Digital images of separations were captured using the 
Gene Snap platform (Syngene). 
2.1.6 DNA ligation 
DNA was digested by restriction endonucleases as previously described. Digested vectors 
were treated with alkaline phosphatase (Roche) for 30 minutes at 37°C to prevent self-
ligation. Inserts and vectors with complementary cohesive ends were incubated at a ratio 
of 5:1 using T4 DNA ligase (Roche), in a total volume of 10µl in ligase buffer. Samples were 
incubated at 16°C overnight.  
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Blunt-ended ligation of PCR products into the pCR-Blunt vector was achieved using the Zero 
Blunt PCR Cloning Kit (Life Technologies) and the ExpressLink T4 DNA Ligase, as per the 
manufacturer’s instructions. To achieve optimal efficiency, inserts were ligated overnight. 
2.1.7 Site directed mutagenesis  
For mutation of the MAU TCR, overlapping primers of ~42 nucleotides covering the desired 
mutation site were designed, with complementary base changes (1-3bp per primer set, 
Table 2.2). 15 pmoles of each primer was used in a PCR reaction, along with the wild type 
(WT) TCR template sequence, as previously described. 
Amplification was achieved using the Q5 polymerase (NEB), resulting in nicked circular 
strands. Dpn1 (New England Bioloabs) was used to digest methylated template DNA, 
leaving the mutated PCR product undigested. These constructs were then transformed into 
competent DH5α cells (Bioline), where repair of the nicks in the mutated plasmid occurs. 
To generate the EphA2R103E mutant, an alternative split PCR methodology was used (Figure 
2.4). To achieve this, mutant site directed mutagenesis (SDM) primers were combined with 
their corresponding forward or reverse primer for the WT construct and amplified, 
resulting in two PCR amplification products which cover the gene of interest and possessed 
the R103E mutation. These two amplification products were then used as the template in 
a further PCR, in which the forward and reverse WT primers were used to create a full 
length PCR product containing the mutations. This amplification product was then 
restricted digested and cloned as previously described. 
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2.1.8 Gibson assembly cloning 
EphA2 domain-swap mutants were generated using the Gibson Assembly Master Mix Kit 
(Figure 2.3C and D, New England Biolabs). The EphA2 and EphA4 ligand binding domains 
(LBD) were amplified as previously described, with primers containing 20bp vector-specific 
overlaps for the desired vector insertion sites. pHL-Fc vectors containing either EphA2 or 
EphA4 sequences lacing the LBD (ΔLBD) were linearized using AgeI (New England Biolabs, 
Figure 2.2) and the LBD sequences were inserted as per the manufacturers instructions. 
Briefly, 50ng of linearized vector was combined with a 3-5 fold excess of insert DNA, 10µl 
of 2X Master Mix and dH20 up to a total volume of 20µl. Samples were heated at 50°C for 
15 minutes and transformed into competent DH5α cells (Bioline) as previously described. 
2.1.9 Lysogeny broth media and pouring LB agar plates 
LB-EZ Mix power (Sigma) was used to make Lysogeny broth (LB) (10g in 500ml dH20, and 
autoclaved). To create LB agar plates, 7.5g of agar (Sigma) was added to the LB-EZ Mix 
powder prior autoclaving. For resistance selection, media was allowed to cool to 55°C and 
the desired antibiotic was added (Ampicillin (Sigma) 100µg/ml or Kanamycin (Sigma) 
50µg/ml). The warm LB agar was then poured into petri dishes, allowed to cool to room 
temperature and stored at 4°C. 
2.1.10 Transformation of competent bacteria 
DH5α chemically competent E. coli (Bioline) were thawed on ice. 10-50ng of purified DNA 
was added to 20ul of cells and incubated for 30 minutes on ice. Cells were then heat 
shocked for 90 seconds in a waterbath at 42°C to allow internalisation of the DNA. 
Immediately, 250µl of SOC medium (Bioline) was added, and then incubated at 37°C for 1 
hour at 200 rpm to allow for expression of the antibiotic resistance genes. 100ul of this 
 2 - 39 
suspension was then spread onto a pre-warmed agar selection plate, and incubated 
overnight at 37°C. 
2.1.11 DNA purification 
Single colonies were picked from LB-agar plates and grown in 5mls of antibiotic-containing 
LB overnight (37°C/200rpm). Bacterial pellets were harvested by centrifugation and the 
ISOLATE II Mini Kit (Bioline) was used to isolate plasmid DNA. To purify large amounts of 
DNA, 500ml of culture was grown overnight and, and plasmid DNA was isolated using the 
Plasmid Mega Kit (Qiagen). Yield and purity of the DNA was analysed by measuring A260/280 
using a spectrophotometer and agarose gel electrophoresis, as previously described. After 
successful cloning, constructs were validated by test digestions with restriction 
endonucleases to determine whether the restriction fragments match those predicted. 
2.1.12 Di-deoxy terminator sequencing 
DNA sequencing of clones was carried out by the Functional Genomics Facility at the 
University of Birmingham using the Bigdye Terminator Sequencing platform (Applied 
Biosystems). Sequencing histograms were analysed using the Sequencher V5.3 program 
(Agilent Technologies) 
2.2 Eukaryotic protein production 
2.2.1 Transfection of S2 Drosophila cells 
Drosophila Schneider 2 (S2) cells were transfected with DNA constructs using the Calcium 
Phosphate Transfection Kit (Invitrogen). Parental (non-transfected) S2 cells were seeded at 
a density of 1x106 cells/ml in complete growth media (CGM, Schneider's Drosophila 
Medium, Modified, with L-glutamine (Lonza), supplemented with 10% FCS (Sigma)) in a 6 
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well tissue culture plate. Cells were incubated at 27°C until they reach a density of 2-4x106 
cells/ml, which was typically reached after 36 hours. 
Due to excessive cell death at the recommended concentrations, half the amount of DNA 
and reagents suggested by the manufacturer were used for transfection. 9.5µg of construct 
DNA was mixed with 2M CaCl2, sterile water and the pCoHygro (Invitrogen) selection 
plasmid. This solution was then slowly added drop wise to HBS solution (Invitorgen), using 
a slow vortex, resulting in a fine precipitate forming after 40 minutes. This solution was 
then added drop wise to the parental S2 cells, which were then incubated for 24h at 27°C. 
The following day, media was removed from the cells which were subsequently washed 
twice with fresh CGM. Cells were then pelleted by centrifuged at 100g for 10 minutes and 
replaced in the same well with fresh CGM. Two days later, cells were washed as before and 
replaced with CGM containing 300µg/ml of the selection agent hygromycin B (Selection 
media, Invitrogen). The selection media was replaced approximately every 4-5 days until 
cells were seen to be dividing (typically after 3-4 weeks). At this stage, cells were 
transferred to a 25ml tissue culture flask in 6ml of selection media. 
2.2.2 Expression in S2 Drosophila cells 
To induce protein expression, transfected cell cultured were scaled up to 500ml shaking 
cultures in 1L vented flasks. Cells were seeded at a density of 1x106 cells/ml and to prevent 
cell clumping 0.05% Pluronic F-68 surfactant (Life Technologies) was added. Flasks were 
incubated at 80rpm at 27°C. Cells were induced during their logarithmic growth phase (as 
determined by cell density, typically 4-10x106 cells/ml) by the addition of 500µM CuSO4. 
Cell supernatants were then harvested after 5 days, and clarified by centrifugation, firstly 
at 100g for 10 minutes to pellet the S2 cells and finally at 5000g for 10minutes to pellet any 
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other non-soluble media components. If not being used immediately, clarified supernatant 
was stored at 4°C after addition of 0.02% sodium azide. 
2.2.3 Transient expression in mammalian HEK293T cells 
HEK293T cells were grown in DMEM + 8% FCS (Sigma) on a 10cm tissue culture dish until 
they reached ~90% coverage. For small-scale test expressions, cells were grown in a 6 well 
tissue culture plate and the recombinant construct was transfected using polyethylenimine 
(PEI). Prior to transfection, media was removed from the cells and replaced with Optimem 
(Life Technologies). 2µg of DNA and 15µg of PEI were mixed vigorously for 10 minutes in 
150µl of Optimem. The transfection solution was then added drop wise to the HEK293T 
cells. After 5 days, the supernatant was tested for the presence of specific protein by a 
western blot, using an anti-C terminal poly histidine specific antibody.  
For large-scale expression, cells were transferred to a 2L roller bottle in 250ml of DMEM + 
8% FCS until confluence was reached. Media was then removed and replaced with 250ml 
DMEM + 2% FCS. The transfection solution was prepared in a similar fashion to test 
expressions, containing 435µg DNA, 2.7mls PEI in 27 ml of Optimem. On day 5, the 
supernatant was harvested and centrifuged at 5000g to remove debris. Unless being used 
immediately, supernatant was stored with 0.02% sodium azide at 4°C. 
2.2.4 SDS-PAGE 
SDS-PAGE 12.5% resolving gels (5.74ml 12.5% gel mix (0.765M Tris pH8.8, 0.2% SDS in 
dH2O), 4.16ml 30% acrylamide (Geneflow), 100µl 0.1% ammonium persulphate (APS) and 
4µl TEMED (Sigma)) were injected into 1mm Biorad glass cassettes. 1ml 100% isopropanol 
was added to level the mixture and remove any air bubbles. Once dried, the stacking gel 
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(3.2ml stacking gel mix (150mM Tris pH6.8 + 0.12% SDS), 40µl 0.1% APS, 4μl TEMED) was 
added along with a 1.0mm 10 well comb (Biorad).  
Protein samples were prepared by mixing 1-10µl of protein suspension with 5X loading 
buffer (125mM Tris pH8, 8M urea, 10% glycerol and 6% SDS, bromophenol blue) up to a 
final volume of 20µl with dH20. 200mM DTT was also added to reducing samples. Samples 
were then vortexed, boiled at 95°C for 5 minutes, briefly centrifuged and then loaded onto 
the SDS-PAGE gel, which was inserted into an SDS-PAGE tank containing SDS-PAGE running 
buffer (0.1% SDS, 90g Tris and 183g Glycine). Samples were passed through the stacking 
gel with the application of 100V across the gel, and subsequently through the resolving gel 
at 180V. Proteins were visualised with Instant Blue stain (Expedion) and de-stained after 
10 minutes with dH20. 
2.2.5 Western blot 
Protein samples were separated by SDS-PAGE as previously described. Proteins were 
transferred from the acrylamide gel to PVDF membrane (GE Healthcare) for one house 
(300v/400mA) in transfer buffer (10% Ethanol, 190mM Glycine and 25mM Tris). The 
membrane was incubated for 1 hour at room temperature with either 5% milk or 2.5% 
bovine serum albumin (BSA, Sigma) to minimise non-specific antibody binding. The 
membrane was then washed 3 times with TBS-T (20mM Tris pH 7.5, 150mM NaCl and 0.1 
% Tween-20 (Sigma)). The membrane was then incubated with the primary antibody 
(mouse anti-C terminal poly-HIS (Invitrogen), 1:5000 dilution in 1xTBS, 0.1% Tween and 3% 
BSA) for 40 minutes at room temperature, before being washed a further three times with 
TBS-T. The secondary antibody (HRP-conjugated goat anti-mouse mAb (Sigma)) was added 
to the membrane in 5% milk + TBS-T (1:1000) for a further 40 minutes at room temperature. 
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HRP was detected using the EZ-ECL chemiluminescence kit (Biological Industries) and 
exposing the blot to light sensitive film (Amersham) in a dark room, which was 
subsequently developed. 
2.2.6 Ni-NTA chromatography 
Supernatants containing specific protein were placed into dialysis tubing (10kDa, Sigma) 
and dialysed in PBS overnight at 4°C to remove excess amino acids, which may compete for 
binding to the nickel beads. 1ml of nickel beads (Ni-NTA, Qiagen) was added to an Econo 
column (BIO-RAD) and washed with 10ml PBS + 10mM Imidazole. Dialysed supernatant was 
passed over the beads by gravity flow at 4°C at a rate of 1ml/minute. Afterwards the 
column was washed with 500ml PBS + 10mM imidazole to remove non-specific proteins, 
and this was determined by measuring A280 at various time points. Specific protein was then 
removed from the beads by 10ml PBS + 250mM Imidazole applied by gravity flow. Protein 
concentration was quantified by measuring A280. To separate the protein from Imidazole, 
the protein solution was passed through a desalting column (GE Healthcare) and eluted 
into PBS. 
2.3 Detection of protein binding 
2.3.1 Biotinylation of proteins 
Ni-NTA purified proteins expressed with a BirA recognition site were exchanged into 3ml 
of biotinylation buffer (100mM Tris pH7.5, 20mM NaCl, 5mM MgCl2) using PD10 desalting 
columns (GE Healthcare). Biotinylation was achieved using 0.56mM biotin (Sigma), 1mM 
ATP (Sigma), 1X protease inhibitors (Roche) and BirA enzyme (non-commercial) for four 
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hours at room temperature. Finally, the proteins were buffer exchanged back into PBS 
using PD10 columns to remove excess biotinylation reagents. 
2.3.2 Surface plasmon resonance overview 
Surface plasmon resonance (SPR) assays were conducted using a BIAcore 3000 (GE 
Healthcare). All reactions were carried out at 25°C in HBS-EP buffer (10mM HEPES pH 7.4, 
150mM NaCl, 3.4mM EDTA, 0.005% surfactant P20) unless otherwise stated. Data was 
collected at 10Hz and analysed using the BIAevaluation software (GE Healthcare). 
2.3.3 Immobilisation of biotinylated proteins 
Biotinylated proteins were immobilized onto a CM5 sensor chips. Briefly, the chip was 
normalised by the addition of 500µl BIAnormalising solution to all flow cells at a rate of 
10µl/min. Streptavidin was then amine coupled to the chip at pH 5.0. 50µl of both 0.2M N-
ethyl-N5 (3-diethylaminopropyl)-carbodiimide (EDC) and 0.5M N-hydroxysuccinimide 
(NHS) were combined and injected at 10µl/min over all flow cells. Next, 60µl of streptavidin 
(0.5mg/ml in 10mM sodium acetate pH 5.5) was injected, followed by an injection of 70µl 
of 1M ethanolamine pH 8.5 to block excess carboxy-esters on the chip surface. Finally, the 
chip surface was washed with 800µl of glycine-HCL pH2.5 to remove any uncoupled 
streptavidin. Biotinylated proteins were diluted in HBS-EP and injected over individual flow 
cells at a rate of 5µl/min to bind to the streptavidin. Comparable levels of proteins were 
immobilized onto each flow cell as measured by resonance units (RU). Reference cells were 
left without bound protein. 
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2.3.4 Immobilisation of Fc-tagged proteins 
Fc-tagged proteins were immobilised using the R10Z8E9 anti human Fc monoclonal 
antibody. The antibody was amine coupled to a CM5 chip in an identical fashion to 
streptavidin, at 25 µg/ml in 10mM Na Acetate, at pH 4.5. 
2.3.5 Binding studies 
Analytes were stored on ice and centrifuged at 13k RPM immediately prior to use to pellet 
any aggregates. Depending on the experiment, analytes were either injected at one 
concentration or serially diluted prior to injection. Typically, analytes were injected at 
10µl/min until equilibrium was reached. For antibody binding experiments, the antibody 
analyte was removed from the immobilised protein using Gentle Ag/Ab Binding Buffer 
(Pierce). 
2.3.6 AlphaScreen 
To detect protein-protein interactions the AlphaScreen assay was also used. The 
AlphaScreen IgG (Protein A) detection kit (PerkinElmer) was used, which contains Protein 
A coated acceptor beads and streptavidin coated donor beads. Samples were diluted in 
alpha buffer (12mM Tris pH 7.4, 10mM NaCl, 5mM MgCl2, 0.1% BSA, 0.05% Tween). All 
readings were taken using the PHERAstar FS plate reader (BMG Labtech) with the default 
AlphaScreen assay settings. Samples were prepared and read in a half-area 96 well white 
microplate (PerkinElmer). For each experiment, proteins were either titrated within the 
experiment or used at concentrations identified in previous titration experiments. 
Reagents were added in 10µl increments to a total volume of 40µl/well. dH20 was used in 
place of samples as controls. Firstly, the Fc-tagged proteins were added to each well, 
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immediately followed by the biotin conjugated molecules. Plates were left to incubate at 
room temperature for 20 minutes, gently shaking. Donor and Acceptor beads were 
vortexed, pulse centrifuged at 13k rpm before being diluted into alpha buffer to a final 
concentration of 100µg/ml. 10µl of each bead suspension was then added to each well, 
resulting in a final well volume of 40µl. To ensure samples were mixed effectively, plates 
were centrifuged at 2000 rpm for 5 minutes, and incubated for 2 hours at room 
temperature under gentle agitation before being analysed 
The raw emission output for each sample was then divided by the highest value of either 
of the single proteins on their own (with the beads), to give a signal:background ratio which 
accounts for inherent stickiness of the reagents. 
2.4 Cellular assays 
2.4.1 Flow cytometry 
Flow cytometry was performed using either an LSR II (BD Bioscience) or Accuri (BD 
Biosciences) depending on the number of fluorophores needing to be used. Cells were 
stained and stored in chilled MACS buffer (Miltenyi Biotech), except for the pacific blue 
viability stain (Invitrogen), which was performed in PBS. Samples were also stored for up 
to 3 days in 1% PFA at 4°C. Unless otherwise stated, cells were stained for 20-30 minutes 
at 4°C and washed twice with excess, chilled MACS buffer. 
Single colour controls were obtained by using anti-mouse Ig, κ/Negative control 
compensation particles set (Invitrogen). 
Samples were collected using either FACsDiva (BD Biosciences) or the C6 Acquisition 
program (BD Biosciences) depending on whether the LSRII or Accuri C6 was used 
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respectively. All further analysis was performed on exported FCS files using FlowJo V7 (Tree 
Star Inc). 
2.4.2 The activation assay 
Flat-bottomed 96 well tissue culture plates were incubated overnight with Fc-tagged 
proteins at 50µg/ml in 100µl PBS (except for EphA4-Fc and OKT3 at 10µg/ml) at 4°C. The 
following day, wells were washed three times with PBS. JRT3.5 T cells retro-virally 
transducted with γδ TCR genes (Described in73) were added to the wells in 100µl RPMI +8% 
FCS at a concentration of 0.5x106 cells/ml and, incubated for 4 hours at 37°C + CO2. 
Afterwards, cells were removed to a 96 well V-bottomed plate. Wells were washed 
vigorously with PBS to remove any cells adhered to the plate surface. Cells were washed 3 
times with MACS buffer (Miltenyi Biotec) and stained with 5µl of anti CD69-PE (BD 
Biosystems) in 195µl MACS buffer for 20 minutes. Cells were then washed a further three 
times with MACS buffer before being transferred into sample tubes in either MACS buffer 
or 1% PFA if they were to be stored for up to 3 days at 4°C. Samples were then read on the 
flow cytometer as previously described. 
2.5 γδ T cell isolation from human Tissues 
2.5.1 Colon 
Colorectal resection patients were recruited from the Queen Elizabeth II hospital, 
Birmingham, UK. Informed written consent was obtained from all patients and local ethical 
permission (South Birmingham Local Regional Ethics Committee) was obtained prior to the 
study. Samples were classified as normal colon, and were resected tissue distal from the 
tumour site. 
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Samples were washed three times in RPMI media (Sigma) and vigorously shaken to remove 
any remaining mucous and faecal matter. Samples were then cut into ~3mm3 pieces using 
scalpels. The diced samples were then incubated in 20ml CRM (RPMI, 10% FCS + 
streptomycin (Sigma)) with 0.1mM EDTA and 0.1mM DTT at 37°C for 20 minutes under 
agitation. To ensure maximum dissociation, samples were vortexed intermittently 
throughout the incubation. Media was then removed from the sample and stored at 4°C, 
and this process was repeated 5 times. The pooled media was then passed through an RPMI 
moistened nytal mesh (65µm, John Stanniar) to obtain a single cell suspension. This 
suspension was then centrifuged at 1500 rpm and re-suspended in 10ml RPMI + 10% FCS. 
The remaining tissue was washed twice with serum-free RPMI and then incubated in a 
similar fashion in serum-free RPMI (SF-RPMI) containing 0.5mg/ml collagenase A (Roche), 
for 30 minute incubations. After 4 washes, media was pooled, filtered and centrifuged as 
previously described.  
Lymphocytes were enriched from each of the single cell suspensions by discontinuous 
gradient centrifugation using Percoll (Sigma). Percoll SIP was prepared by mixing 9 parts 
Percoll with 1 part 2.5M NaCl. Percoll SIP was then diluted to both 30% and 70% solutions 
using 0.25M NaCl. In a 50ml tube, 15ml of 30% SIP was gently layered over 15ml 70% SIP 
whilst taking care not to mix the solutions. Each of the 10ml cell suspensions was then 
gently layered over the Percoll gradient, and the tubes were centrifuged at 1,500 RPM for 
25 minutes with the brake off, enriching lymphocytes at the 70:30 Percoll interface. The 
white lymphocyte cloud was then removed using a Pasteur pipette into a 50ml tube, 
topped up with 50ml MACS buffer and washed three times by centrifugation to remove the 
Percoll. 
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Cells were then stained with antibodies for magnetic sorting and flow cytometry analysis. 
Following the three MACS washes, cells were re-suspended in residual volume and stained 
with 10µl CD3-APC , 10µl αβ-PE (Miltenyi Biotec) and 3µl γδ FITC antibodies for twenty 
minutes at 4°C in the dark. Cells were then washed with an excess of MACS buffer and again 
re-suspended in residual volume, before addition of 20µl anti-PE microbeads (Miltenyi) and 
incubation for 20 minutes at 4°C in the dark. Finally the cells were washed with excess 
MACS buffer. 5% of pre-sorted cells were removed for flow cytometry analysis. 
Magnetic separation of cells was achieved using a MidiMACS magnet (Miltenyi Biotec), with 
LD magnetic depletion columns (Miltenyi Biotec) as per the manufacturer’s instructions. 
Briefly, columns were attached to the magnet and washed twice with 1ml of MACS buffer. 
The labelled cells were resuspended in 500µl of MACS buffer and added to the columns, 
and the elutant was collected. The eluted fraction was then washed in MACS buffer, with 
5% of cells being kept for flow cytometry analysis. Remaining cells were then pelleted by 
centrifugation at 13,000 rpm with a microfuge. Supernatant was removed and the pellets 
were stored at -80°C. For samples to be analysed by DNA-based sequencing, genomic DNA 
was isolated using the QIAamp DNA mini kit as per the manufacturer’s instructions. DNA 
samples were also stored at -80°C. 
2.5.2 Liver 
Liver samples were obtained from patients suffering from various non-viral liver diseases 
at the Queen Elizabeth II Hospital, Birmingham, UK. Written, informed consent was 
obtained for all patients. Samples were washed thoroughly and vigorously in RPMI (Sigma) 
several times to remove any mucous, contaminants and non-tissue-associated 
lymphocytes. Samples were then diced using scalpels into 3mm3 sections before being 
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washed again in RPMI, and then in 200ml of PBS. The Stomacher (Seward) apparatus was 
then used to dissociate the tissue fully. Briefly, RPMI was added to the liver in a 2:1 ratio 
(~250ml) in a Stomacher bag. The air was removed from the bag and sealed by heat using 
an impulse sealer. The bag was then placed in the Stomacher machine and homogenised 
at 230 rpm for 5 minutes (260rpm for particularly fibrous tissue). 
The tissue was then filtered using an RPMI dampened nytal mesh (63µM, John Stanniar), 
and washed with PBS several times to ensure all media has passed through, resulting in a 
single cell suspension. This suspension was then transferred into 50ml tubes and 
centrifuged at 2000rpm for 5 minutes. This was repeated until the supernatant became 
clear. Lymphocytes were then enriched from this suspension using Lympholyte (Cedarlane 
Labs). 25ml of these samples was layered over 25ml of Lympholyte in a 50ml tube before 
being centrifuged at 800g for 20 minutes with the brake off. White blood cells were 
enriched at the lymphocyte interface, and were removed into PBS using a Pasteur pipette.  
Samples were then stained and sorted using magnetic beads as previously discussed for 
the colon samples.  
2.5.3 Peripheral blood 
Healthy lab donors, under the age of 30, were recruited from the School of Cancer Sciences, 
University of Birmingham, UK. Informed, written consent was obtained from all donors and 
ethical permission was obtained prior to the study. Peripheral blood (PB) samples (60ml) 
were obtained from donors, and mononuclear cells were obtained by density gradient 
centrifugation using Lymphoprep (Nycomed). Briefly whole blood was diluted to double 
volume with SF-RPMI (Sigma) and layered using Lymphoprep, before being centrifuged at 
1500 rpm for 25 minutes (with minimal acceleration and no brake). To obtain plasma, the 
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top layer was removed, further centrifuged (1500 rpm, 10 minutes) and stored in 1ml 
aliquots in cryovials at -80°C. 
Mononuclear cells were removed from the intermediate layer and washed 3x with RPMI + 
8% FCS. Cells were counted and stored in freezing media (90% FCS, 10% DMSO, 0.45µm 
filtered) in ~10x106 cells/1ml aliquots. Samples were stored for short term at -80°C and for 
longer periods in liquid nitrogen. 
2.5.4 FACS and phenotyping of PBMCs 
PBMCs were analysed by flow cytometry as previously described, using the antibody panels 
detailed in Table 2.3. FACS to isolate γδ T cell populations was conducted by Professor 
David Price and colleagues from the University of Cardiff. 
2.5.5 CMV IgG ELISA 
To determine the CMV-serostatus of donors, a CMV IgG ELISA kit was used (Biocheck) as 
per the manufacturer’s instructions. Wells coated with lysed CMV infected cells were 
exposed to the plasma obtained previously to check for the presence of CMV antigen 
specific antibodies. After the assay, A450 was measured using the Pherastar Fs (BMG 
Labtech). Donors with a CMV index of 1.0 or higher were deemed to be CMV-seropositive. 
2.6 γδ T cell repertoire analysis 
2.6.1 DNA-based repertoire analysis (immunoSEQ) 
Recombined δ chain sequences of γδ T cells isolated from liver and colon samples were 
sequenced by immunoSEQ116 (Adaptive Biosystems). This technologies utilises a 
proprietary mixture of primers specific for the different variable (V) and joining (J) γ chain 
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recombination elements to amplify the diverse γ CDR3 regions of genomic DNA (Figure 2.5). 
Results were analysed using the immunoSEQ analysis software (Adaptive Biosystems), R (R 
Foundation for Statistical Computing) and Excel (Microsoft). 
2.6.2 RNA-based repertoire analysis (Anchored 5’-RACE) 
Sequencing of γ and δ chain CDR3 regions from the mRNA of γδ T cells derived from the PB 
of healthy lab donors was conducted by Professor David Price and colleagues from Cardiff 
University117. This approach utilises template-switch anchored reverse transcription 
polymerase chain reaction (RT-PCR) to amplify rearranged γδ TCR transcripts. Briefly, cDNA 
is generated from extracted mRNA using an oligo(dT) primer. The reverse transcriptase (RT) 
adds a short deoxycytidine (dC) sequence to the 3’ end of the antisense cDNA strand, to 
which a SMART II oligonucleotide primer binds. The RT then transcribes the 5’ section of 
the. SMART II oligonucleotide onto the 3’ end of the cDNA molecule, which acts as an 
anchor for specific amplification (Figure 2.6). 
Touchdown PCR is then performed on the single cDNA strand using a combination of γδ C 
region specific and anchor-complementary primers. These amplification produces are then 
sub-cloned into cloning vectors and transformed into competent E. coli. Finally, plasmids 
from individual colonies are then sequenced.117 Results were analysed using R (R 
Foundation for Statistical Computing) and Excel (Microsoft). 
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2.7 Tables 
  
Table 2.1: Primers used for the amplification of ephrin receptor constructs 
Primer identifier corresponds to the primers in the overview of the constructs (Figures 2.3 and 
2.4). Blue = Restriction endonuclease overhangs. Red = AgeI or KpnI restriction sites. 
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Chain CDR Round F/R Primer I.D
Forward 619 5' GTGGTGTCTGGAATAACACGTTCTGCAACATCTGTATATTGG 3'
Reverse 620 5' CCAATATACAGATGTTGCAGAACGTGTTATTCCAGACACCAC 3'
Forward 621 5' GGTGTCTGGAATAACACGTTATGAAACATCTGTATATTGGTATCG 3'
Reverse 622 5' CGATACCAATATACAGATGTTTCATAACGTGTTATTCCAGACACC 3'
Forward 623 5' GGTGTCTGGAATAACACGTTATGAAAAATCTGTATATTGGTATCG 3'
Reverse 624 5' CGATACCAATATACAGATTTTTCATAACGTGTTATTCCAGACACC 3'
Forward 625 5' CAGTTCCTAGTGTCCATTCTATCTGACGGCACTGTCAGAAAGG 3'
Reverse 626 5' CCTTTCTGACAGTGCCGTCAGATAGAATGGACACTAGGAACTG 3'
Forward 627 5' CTAGTGTCCATTCTATCTAACGGCCTTGTCAGAAAGGAATCCGG 3'
Reverse 628 5' CCGGATTCCTTTCTGACAAGGCCGTTAGATAGAATGGACACTAG 3'
Forward 629 5' CTGTGCCTTGTGGGAGGTGTGGCGTGTTGAGAAACTCTTTGGCAG 3'
Reverse 630 5' CTGCCAAAGAGTTTCTCAACACGCCACACCTCCCACAAGGCACAG 3'
Forward 631 5' CTGTGCCTTGTGGGAGGAGTGGCGTGATGAGAAACTCTTTGGCAG 3'
Reverse 632 5' CTGCCAAAGAGTTTCTCATCACGCCACTCCTCCCACAAGGCACAG 3'
Forward 633 5' GAACTGCCTGTATGAAACACGTTGGCGGTCATATTATATTTTTTG 3'
Reverse 634 5' CAAAAAATATAATATGACCGCCAACGTGTTTCATACAGGCAGTTC 3'
Forward 635 5' GAACTGCCTGTATGAATCACGTTCGCGGTCATATTATATTTTTTG 3'
Reverse 636 5' CAAAAAATATAATATGACCGCGAACGTGATTCATACAGGCAGTTC 3'
Forward 637 5' GAACTGCCTGTATGAATTACGTTCGCGGTCATATTATATTTTTTG 3'
Reverse 638 5' CAAAAAATATAATATGACCGCGAACGTAATTCATACAGGCAGTTC 3'
Forward 639 5' GATTTTCCTTATTCGCCGGGGTTCTCGTGAACAGAATGCAAAAAG 3'
Reverse 640 5' CTTTTTGCATTCTGTTCACGAGAACCCCGGCGAATAAGGAAAATC 3'
Forward 641 5' GATTTTCCTTATTCGCTGGGGTTATCGTGAACAGAATGCAAAAAG 3'
Reverse 642 5' CTTTTTGCATTCTGTTCACGATAACCCCAGCGAATAAGGAAAATC 3'
Forward 643 5' GATTTTCCTTATTCGCTGGGGTTATCGTAAACAGAATGCAAAAAG 3'
Reverse 644 5' CTTTTTGCATTCTGTTTACGATAACCCCAGCGAATAAGGAAAATC 3'
Forward 645 5' GGGGACCTTACCGGCGTACCTATCCTCAACAAACTCATCTTTGG 3'
Reverse 646 5' CCAAAGATGAGTTTGTTGAGGATAGGTACGCCGGTAAGGTCCCC 3'
Forward 647 5' GGGACCTTACCGGCGAACCTAAGCTCAACAAACTCATCTTTGG 3'
Reverse 648 5' CCAAAGATGAGTTTGTTGAGCTTAGGTTCGCCGGTAAGGTCCC 3'
1
2
1
2
3
1
2
3
2
3
1
2
1
2
Sequence
Vγ9
Vδ1
CDR1
CDR2
CDR3
CDR1
CDR2
CDR3
1
Table 2.2: Primers for site directed mutagenesis of the MAU TCR CDR loops 
Each forward and reverse (F/R) primer pair was used in combination for each round of SDM, 
which were performed sequentially. Each mutant contained one mutated CDR. 
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Table 2.3: Antibodies used to stain and phenotype PBMCs 
PBMCs were stained with one of three panels, ‘γδ/αβ’, ‘FACS’ or ‘Phenotyping’. Volume of 
reagent used to stain 1x106 cells is listed in the right-most column. If stock solutions were 
diluted with MACS buffer prior to use, the dilution ratio is shown in the ‘Dilution’ column. 
Antibody Source Dilution µl/10
6 Cells
αβ-FITC BD Biosciences 10
γδ-PE Beckman Coulter 7
CD3E-APC Invitrogen 1:10 2
Viability-Pacific Blue Invitrogen 1
Vδ2-FITC Biolegend 1:10 3
γδ-PE Beckman Coulter 7
CD3E-APC Invitrogen 1:10 2
Viability-Pacific Blue Invitrogen 1
Vδ1-FITC Thermo Fisher 3
Vδ2-PE Biolegend 1:10 1
Vγ9-PE-Cy5 Beckman Coulter 1:10 1
CD3E-APC Invitrogen 1:10 2
Viability-Pacific Blue Invitrogen 1
CD45RA AF700 Biolegend 1:10 1
CD27-APC-Cy7 eBioscience 2
CD16 PE-Cy7 Biolegend 1:10 3
γδ/αβ
FACS
Phenotyping
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2.8 Figures 
   
Images provided by118.  
Figure 2.1: Maps of vectors used in transfection and cloning experiments 
(A) The pMT/Bip/V5-His (Invitrogen) vector was used to transfect Drosophila melanogaster 
S2 cells with recombinant γδ TCR constructs for protein expression. (B) pCR-Blunt was used 
as a shuttle vector for the cloning of recombinant constructs. 
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Figure 2.3: Primers used for the generation of ephrin receptor constructs 
The three digit primer reference refers to primers used for PCR amplification of ephrin 
receptor constructs, as shown in Table 2.1. (A) EphA2
WT
 (572) and EphA2
ΔLBD 
(615) forward 
primers were paired with the 573 reverse primer. (B) EphA4
WT
 (617) and EphA4
ΔLBD 
(677) 
forward primers were paired with the 618 reverse primer. (C+D) EphA2 LBD swap mutants 
were generated by combining LBD sequences with ΔLBD sequences using the Gibson 
assembly methodology. Blue domains are derived from EphA2, and Red domains are derived 
from EphA4. 
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Figure 2.4: Cloning of the EphA2R103E mutant 
The EphA2R103E mutant was generated using a split PCR methodology. Primers containing 
the desired R103E mutation (668 and 669, Table 2.1) were paired with the corresponding 
forward and reverse EphA2WT construct primers to generate two PCR products. These 
products were then combined and used as a template in another PCR using the EphA2 WT 
forward and reverse primers, yielding a full length amplification product containing the 
R103E mutation. 
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Figure 2.5: Overview of the immunoSEQ TCR sequencing methodology 
(A) Multiple Vγ and Jγ gene segments exist in the germline γ TCR locus. (B) These gene 
segments recombine during development to produce a single V-J combination. Additional, 
non-template diversity is introduced at the junctions by insertion of random nucleotides (N). 
immunoSEQ utilise a combination of primers specific for different V and J gene segments to 
selectively amplify the V-J junction, which is then sequenced. Figure provided by immunoSEQ. 
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Image adapted from117 
Figure 2.6: Schematic representation of the Anchored RACE PCR 
An Olio dT primer is used to initiate the reverse transcription of mRNA transcripts. The 
terminal transferase activity of the reverse transcriptase (RT) results in the adition of a 
short deoxycytidine (dC) sequence to the 3’ end of the antisense cDNA chain. The SMART 
II oligo primer binds to this sequence, and the RT transcribes the 5’ section of the SMART 
II oligo to the 3’ end of the antisense cDNA strand. Cγ and Cδ specific primers are used in 
conjunction with and anchor–complementary primer (i.e. the 3’ region) to amplify the TCR 
chains. 
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3.1 Introduction 
γδ T cells contribute towards immunoprotection and the maintenance of epithelial integrity 
as part of the lymphoid stress surveillance compartment8. Despite their implications in a 
range of immunological responses, including cancer immunosurveillance20, there is limited 
molecular data with respect to how γδ T cells interact with target cells. 
Typically, T cells interact with target cells using a combination of surface molecules which 
collectively provide multiple signals, both antigen specific and non-specific, which 
contribute towards initiating a signalling cascade, resulting in relevant effector functions119. 
Specificity is usually conferred by the TCR, an antigen-specific receptor which is produced 
by somatic recombination events, although alternative TCR independent mechanisms have 
been described for γδ T cells60.  
In αβ T cells, which constitute the majority of the adaptive arm of the immune system, the 
primary signal is initiated by the binding of TCR to peptide-MHC complexes. This primary 
signal is enhanced by secondary signals provided by non-antigen-specific co-receptors, 
which simultaneously bind the MHC molecule. The role of co-receptors has not been well 
defined in γδ T cells120, and their relevance to the activation of γδ T cells as a whole is 
unclear. 
This comprehensive knowledge of both the molecular nature of the interaction of αβ T cells 
with their targets and the signalling apparatus involved has led to the development of a 
wide array of biomolecular and cellular techniques which have rapidly accelerated the 
understanding of αβ T cell biology. For example, the use of MHC tetramers121 has only been 
possible due to an in depth molecular understanding of the αβ TCR recognition events. 
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If similar paradigms were established for γδ T cells, it could facilitate comparable advances 
in the understanding of γδ T cell immunobiology, potentially bridging the knowledge gap 
between the two fields. This could lead to new immunotherapeutic strategies utilising γδ T 
cells which, unlike αβ T cells, are not restricted to specific MHC-haplotypes, and so could 
be used more broadly. 
Previous studies from our group and collaborators have identified EphA2 as a potential 
ligand for a Vδ2negative γδ T cell clone called MAU. MAU (also known as clone 5-4) was 
derived from a CMV-seropositive renal transplant patient, following polyclonal stimulation 
and cloning by limiting dilution73. The MAU clone responded to CMV-infected fibroblast 
and various cell lines. EphA2 was identified as a potential ligand by using blocking 
antibodies to immunoprecipitate the ligand from activating cell lysates. 
EphA2, a member of the ephrin receptor family of receptor tyrosine kinases (RTK), has been 
implicated in a range of biological processes, including the initiation and progression of 
several cancers75. This suggests that EphA2 is a highly plausible candidate as a stress ligand 
for recognition by the immune system. Indeed, EphA2 has been targeted in a range of 
immunotherapeutic strategies, such as targeting glioblastoma with EphA2-specific chimeric 
antigen receptors (CARs) in pre-clinical models, with promising results122. Understanding 
how the immune system interacts with such biologically important molecules is therefore 
important, especially as no interaction has previously been characterised between an 
immune receptor and ephrin receptors, and so this may represent a completely novel 
interaction modality. 
The aim of this chapter is to establish the broad criteria for the recognition of EphA2 by 
MAU, and define the molecules involved. Improved understanding of the surface molecules 
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involved is vital in order to fully comprehend the nature of this potentially important 
recognition of an epithelial stress ligand by a Vδ2negative γδ T cell. 
3.2 Results 
3.2.1 Plate bound EphA2-Fc is sufficient to activate JRT MAU 
Both αβ and γδ T cells are typically activated via their TCR, and so it was important to 
determine whether MAU is activated by EphA2 in this way. To achieve this, JRT3-T3.5 (JRT3) 
cells were established by our collaborators which had been transduced with various TCR 
genes using a lentiviral transduction system123. JRT3 cells are a derivative of the Jurkat αβ 
T cell leukaemia cell line, which contain a mutation in the β chain locus, and therefore do 
not natively express a TCR complex at the cell surface124. Once these cells become activated 
via their TCR, they signal through the CD3 complex and express CD69, an early T cell 
activation marker62. Since JRT3 cells are less dependent on other activatory and 
costimulatory receptors than primary T cell clones, any observable activation should be 
largely dependent on the TCR. 
To determine whether the interaction of EphA2 with MAU is TCR dependent, the MAU TCR 
was isolated in the JRT3 cell line, and exposed to EphA2. Recombinant EphA2 protein 
expressed with a human Fc-tag (EphA2-Fc, R&D Systems) was immobilised on a 96 well 
plate, and the JRT3 cells transduced with either the MAU or control TCR (LES, a Vγ4Vδ5 
TCR) were incubated in the plate for 4 hours. JRT3 activation was then measured by 
detecting surface expression of CD69 by flow cytometry. This technique is referred to 
throughout this thesis as the “activation assay”. OKT3, an anti-CD3ε monoclonal antibody 
which activates TCR transduced JRT3 cells was used as the positive control in these 
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experiments. Plate bound EphA2-Fc was sufficient for activation of JRT MAU (Figure 3.1). 
In contrast, JRT3 cells transduced with either the LES (Figure 3.1) or a range of other γδ TCR 
genes (data not shown) failed to be activated by EphA2-Fc. This showed that the 
recognition of EphA2 by MAU is TCR mediated, as recognition could be specifically 
conferred to JRT3 cells by transducing MAU TCR genes. These experiments also 
demonstrated that the costimulatory ligands or adhesion molecules on the surface of the 
stressed cell are not necessarily required for EphA2 mediated activation of JRT MAU. 
EphA4, a fellow ephrin receptor family member which is structurally homologous to EphA2 
(77% sequence similarity125) failed to activate JRT MAU (Figure 3.1), highlighting that this 
interaction is not applicable to all ephrin receptors. 
3.2.2 Production of recombinant EphA2-Fc using 293T cells 
It is important when using recombinant proteins to ensure reproducibility between various 
protein sources. For example, protein misfolding and contamination can occur during 
protein production, which may impact downstream experiments126. Furthermore, 
verification that EphA2 constructs could be reliably produced in our laboratory was 
essential in order to plan EphA2 mutagenesis approaches later in this study. For this reason, 
the activation assay was repeated with both commercially available EphA2-Fc from R&D 
Systems used in the preceding section (R&D EphA2-Fc), which was produced from an NS0-
derived mouse myeloma cell line, and EphA2-Fc produced in the Willcox laboratory by 
transient transfection of human HEK 293T cells (293T EphA2-Fc). 
The 293T expression system provides a protein production and folding pathway very similar 
to that undertaken by proteins in vivo in humans, rendering it more physiologically relevant 
than non-mammalian production systems115. For example, bacterial expression systems 
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lack glycosylation machinery, and insect cells generate only simple glycosylation compared 
to mammalian cells, and so the glycosylation signature of recombinant proteins produced 
in these systems would not necessarily represent what is present physiologically127. To 
ensure a representative comparison, the negative control protein EphA4-Fc was also 
obtained from both sources. 
The EphA2 ectodomain is 507 residues long and comprised of 5 globular domains. The 
ligand binding domain (LBD) is a 172 residue domain at the N terminus of EphA2 which is 
responsible for binding the A-ephrin ligands of EphA2. To the C terminus of the LBD is a 
Sushi domain followed by an EGF domain, which collectively form a cysteine rich domain 
(CRD). Finally, two membrane proximal fibronectin domains (FN1 and FN2) are located at 
the C terminus (Figure 3.2A+B)80. The cytoplasmic region of EphA2 contains several 
signalling domains, including a kinase domain. EphA2 and EphA4 ectodomain constructs 
were designed using a combination of domain prediction features of the UniProt tool128 
and existing construct information which has been used to clone these constructs 
successfully in the literature80. Based on this data, the N-terminal residues G25 and N26 of 
the R&D EphA2-Fc construct were omitted from the 293T EphA2-Fc construct (E27-N534) 
(Figure 3.2C). The 293T EphA4-Fc construct incorporated residues V20 to N529 (Figure 
3.2C). Inserts were cloned into the pHL-Fc vector (which contains 6His- and a human IgG 
Fc-tags)115 and used to transfect HEK 293T cells. His tagged EphA2-Fc was then purified 
using Ni-NTA chelate chromatography.  
3.2.2.1 Verification of EphA2-Fc folding  
In order to verify that the 293T-derived EphA2 was folded in its native state, several 
approaches were used. Establishment of reliable techniques to measure 293T EphA2 
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folding was crucial in order to confidently appraise folding of EphA2 mutants produced 
later in the study. 
Superficially, early indicators of successful folding can be determined during the protein 
purification process. For example, a well expressed protein hints at correct folding, since 
protein accumulating in the cytoplasm is an indicator of misfolding as the protein enters 
the cellular recycling machinery. Using HEK 293T cells, high levels of EphA2-Fc expression 
were observed at day 5 post transfection (Figure 3.3A). Other approaches, such as a 
comparison between reduced and non-reduced samples on SDS PAGE gels, ensure proteins 
are migrating correctly for their predicted sizes, and dimerising in the correct fashion. For 
example, reduced EphA2-Fc samples derived from Ni-NTA purification migrated at 
approximately 100kDa, higher than its predicted monomer size of 83kDa (53kDa EphA2 + 
30kDa Human IgGγ1) (Figure 3.3B). This difference between observed migration and that 
predicted from the primary sequence suggests that EphA2 is glycosylated in some capacity. 
Interestingly, this was also observed with the NS0-derived R&D EphA2-Fc (Figure 3.3B) and 
is highlighted on the product specification. In contrast, the non-reduced EphA2-Fc sample 
migrated at approximately twice the size of the reduced sample, consistent with an EphA2-
Fc dimer facilitated by the Fc-tag. Purity of EphA2-Fc produced in this system was high, with 
no discrete contaminant bands visible by SDS PAGE (Figure 3.3B). Typical yields of EphA2-
Fc eluted from the Ni-NTA column were 1.5mg from 250ml of supernatant (Figure 3.3B). 
The non-reducing sample of R&D EphA2-Fc contained several contaminant bands, likely 
protein degradation products resulting from long term storage. These bands were not 
present in the 293T EphA2 sample. 293T EphA4-Fc purification was equivalent to 293T 
EphA2-Fc (data not shown). 
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A more robust method to determine correct protein folding was to analyse 293T EphA2-Fc 
with quantifiable approaches. Firstly, binding of an anti-EphA2 goat IgG polyclonal antibody 
(pAb, R&D Systems) to EphA2-Fc was measured by surface plasmon resonance (SPR) using 
the BIAcore platform. SPR measures changes in protein concentration via alterations in 
refractive index adjacent to a sensor surface, with measurements given in resonance units 
(RU). Typically, antibodies specifically recognise tertiary structure epitopes on proteins, and 
therefore their binding would indicate correct folding, at least in the domain containing the 
specific epitope. pAbs are less suited for this approach however, as they can also contain 
antibodies specific for short secondary structure sequences, which do not require native 
folding for binding. However, as a comparison between identical proteins this approach 
can still provide useful information on folding.  
To test the binding of the anti-EphA2 pAb to 293T EphA2-Fc, a CM5 BIAcore chip was coated 
with R10Z8E9 (a mouse monoclonal antibody (mAb) specific for the human Fc fragment129) 
by amine coupling (Figure 3.4). 293T EphA2-Fc and control proteins were then immobilised 
on the R10Z8E9 coated chip in individual flow cells (Figure 3.5A). The anti-EphA2 pAb was 
subsequently injected over the chip as the analyte. These experiments showed that the 
anti-EphA2 pAb bound to both 293T and R&D-derived EphA2-Fc constructs (Figure 3.5B), 
suggesting that 293T EphA2-Fc is correctly folded. Interestingly, the 293T EphA2-Fc bound 
approximately 150 RU more anti-EphA2 pAb than the R&D construct. This observation 
could be due to the different mammalian expression systems used to produce the two 
constructs, or that the R&D protein was purchased over a year previously, and so may have 
degraded whilst in storage. Indeed, evidence for the latter can be observed in Figure 3.3B, 
which shows nonspecific bands in the non-reducing sample of R&D EphA2-Fc, which may 
represent protein degradation products. 
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The second quantitative analysis of correct protein folding was to determine whether the 
293T EphA2-Fc was able to bind its natural ligands, A-ephrins. EphA2 binds A-ephrins with 
nM affinity77, and requires the presence of a hydrophobic binding pocket in the LBD82, 
therefore it can be assumed that if 293T EphA2-Fc successfully binds ephrins, it is correctly 
folded. Initially, BIAcore was attempted in order to demonstrate successful binding of 293T 
EphA2 to ephrinA1. In these experiments, ephrinA1-Fc was injected over the immobilised 
ephrin receptors. However, since it has proven difficult to produce non-Fc-tagged ephrinA1 
in the 293T system (data not shown), the analyte also bound the R10Z8E9 antibody. In 
order to circumvent this, two approaches were employed. Firstly, the R10Z8E9 coated CM5 
chip was saturated with receptor protein. Despite these efforts, binding of ephrins to the 
negative control cells were observed, suggesting ephrinA1-Fc bound to R10Z8E9. Secondly, 
irrelevant ephrinB1-Fc (which does not bind EphA2) was used to saturate the chip prior to 
ephrinA1-Fc injection. This approach also yielded an increase in RU on the control flow cell, 
demonstrating that ephrinA1-Fc was still binding the R10Z8E9 coated on the chip (data not 
shown). 
As an alternative to BIAcore, ephrin binding by 293T EphA2-Fc was determined by surface 
staining of JRT3 cells, which are known to express ephrins A1 and A4 (J Déchanet-Merville, 
unpublished). 293T and R&D-derived EphA2-Fc were used to stain the surface of JRT MAU 
and the Fc-tag was bound by an AF488 conjugated goat anti-human Fc secondary antibody 
(eBioscience), which was detected by flow cytometry. 293T EphA2-Fc was able to stain the 
surface of JRT MAU at equivalent levels to R&D EphA2-Fc (Figure 3.6). The secondary 
antibody alone was used as an isotope control. Similarly, 293T EphA4-Fc stained JRT LES 
cells at equivalent levels to the commercial R&D counterpart (data not shown). 
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To verify that this staining was not as a result of the EphA2/MAU TCR interaction, 293T 
EphA2-Fc was used to assess whether it could stain JRT LES, a clone that is not activated by 
EphA2. These results highlighted that 293T EphA2-Fc stained JRT LES at equivalent levels to 
JRT MAU and thus demonstrating that staining is not TCR specific (Figure 3.6B). 
Furthermore, 293T EphA4-Fc, which does not activate either JRT MAU or LES, stains both 
cell types equivalently (Figure 3.6B). Finally, previous experiments in our laboratory using 
PI-PLC to cleave GPI-linked A-ephrins from JRT MAU and LES completely abrogated staining 
by both EphA2-Fc and EphA4-Fc, confirming that staining is not mediated by the TCR, and 
demonstrating that 293T EphA2 successfully binds surface ephrins. Collectively, the 
BIAcore and surface staining experiments showed that 293T EphA2-Fc is correctly folded; 
as it was bound by an EphA2 pAb and recognised its cognate ligands equivalently to 
commercial R&D EphA2-Fc. 
Finally, further verification was achieved with the activation assay as 293T EphA2-Fc 
activates JRT MAU to the same extent as R&D EphA2-Fc (Figure 3.7). Non-Fc-tagged EphA2 
(EphA2-Avi, cloned into the pHL-AviTag vector), which was also produced in the 293T 
expression system, activated JRT MAU equivalently to the Fc-tagged constructs, 
demonstrating that activation is not dependent on Fc-tag mediated EphA2 dimerization 
(Figure 3.7). Collectively, these data revealed that activation is not an artefact of a specific 
protein production batch or methodology, and is reproducible with a range of verified 
protein sources. Furthermore, 293T production of EphA2 mutants is a viable approach for 
future experiments. For all subsequent experiments, 293T EphA2-Fc and EphA4-Fc were 
used, and will be referred to as EphA2-Fc and EphA4-Fc respectively. 
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3.2.3 No binding detected between MAU TCR and EphA2 using BIAcore. 
Since EphA2-Fc is sufficient for activating JRT MAU in a TCR dependent manner, this 
strongly implied that the MAU γδ TCR specifically recognises EphA2. In order to 
unequivocally demonstrate that the MAU TCR forms direct contacts with EphA2, the 
subsequent step was to show direct binding between these two molecules. 
BIAcore has previously been used to successfully demonstrate binding between γδ TCRs 
and their ligands51,123, and is a useful tool for quantifying molecular interactions, including 
those of low affinity. To test for binding, recombinant MAU TCR protein was produced using 
the Drosophila S2 expression system130. Soluble TCRs are historically difficult to produce, 
and mammalian expression systems like 293T have largely been ineffective131. Despite not 
being as physiologically comparable as the 293T expression system, TCRs can be produced 
in relatively large amounts using this Drosophila system. The γ and δ chain of MAU were 
separately cloned into pMT/Bip/V5-His vectors, which contain either acidic or basic leucine 
zipper motifs to facilitate heterodimeric chain pairing132 (Figure 3.8). These constructs were 
then transfected into S2 Drosophila cells, and the supernatant was harvested after 5 days. 
The protein was then purified using Ni-NTA chelate chromatography, which binds the His 
tag on each chain. Yields were typically around 1.5mg from 1L of S2 supernatant (Figure 
3.9A). SDS-PAGE analysis of fractions eluted from the Ni-NTA column revealed two discrete 
bands at approximately 45kDa each. These bands migrated higher than would be predicted 
from their primary sequence (33.6 kDa and 34.4 kDa for the γ and δ chains respectively), 
which suggested the TCR is glycosylated. Purity of TCR obtained varied between protein 
batches, with a mixture of high and low molecular weight contaminants. Under non-
reducing conditions, the MAU γ and δ chains revealed a single band which migrated at 
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approximately 90kDa, suggesting the formation of a γδ dimer. At this stage however, it was 
not possible to establish if this was a heterodimeric TCR, as the molecular weight of the γ 
and δ chains are similar, and the 90kDa band in the non-reducing sample may represent a 
homodimer (Figure 3.9A). 
The purified MAU TCR was biotinylated using the BirA enzyme in the presence of biotin and 
ATP, which acts on the BirA signal sequence engineered onto the C terminus of the δ 
chain133. Biotinylation was confirmed by western blot, using HRP-conjugated streptavidin 
(Figure 3.9B). 
To confirm that the TCR chains were folded correctly, and dimerising to form a γδ TCR 
heterodimer, BIAcore was used to measure binding of Vγ9, Vδ1 (both Beckman Coulter) 
and pan-γδ (BD Biosystems) specific mAbs to the purified recombinant protein. A CM5 
BIAcore chip was coated with streptavidin by amine coupling (Figure 3.10A), and 
biotinylated MAU-TCR (MAU-Bt) and control proteins were immobilised to individual flow 
cells. Protein levels were standardised to around 2000 RU for consistent analysis across 
samples (Figure 3.10B). Each antibody was then flowed over the cell individually and 
binding was detected by the increase in RU of the flow cell containing the immobilised TCR. 
Antibodies were stripped after each injection using Gentle Ag/Ab Elution Buffer (Pierce), 
which indiscriminately removed bound antibodies without altering the pH, and so should 
have minimal impact on the folding of the bound receptors. Both MAU-Bt and the control 
LES-Bt bound the pan-γδ antibody equivalently, suggesting correct conformation for the 
MAU γδ heterodimer (Figure 3.11A). Secondly, MAU-Bt specifically bound the anti Vγ9 and 
Vδ1 mAbs, whereas LES-Bt (Vγ4Vδ5) did not (Figure 3.11B+C). Collectively, these results 
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suggested that both the γ and δ chains of MAU-Bt were independently folded correctly, 
and they combined to form a complete γδ TCR heterodimer. 
The binding of EphA2-Fc to MAU-Bt was analysed using BIAcore, with a previous TCR 
immobilisation strategy as described for the antibody confirmation experiments. With 
MAU-Bt immobilised to the sensor chip, binding with EphA2-Fc could not be detected when 
injected over the cell at concentrations up to 6µM (Figure 3.12).This technique has 
successfully been previously used to detect interactions between γδ TCRs and ligands123, 
but lack of detectable binding does not necessarily suggest there is no interaction between 
the proteins, as some recognition events are difficult to detect using this system. For 
example, the interaction between CD4 and MHC class II is undoubtedly physiologically 
relevant, but is undetectable by SPR as it has a low dissociation constant (KD) (150–200 
µM)134. Also, due to the immobile nature of proteins bound to the chip, the interactions 
detected by BIAcore often cannot account for clustering or multimeric interactions. 
This binding study was also conducted in the reverse orientation, with EphA2-Fc 
immobilised to an R10Z8E9 coated CM5 chip and monomeric MAU-Bt injected over the 
immobilised EphA2 at concentrations over 100µM. In addition, this experiment was 
repeated by injecting dextramer-multimerised MAU TCR (>20 TCRs/molecule) (C. Willcox, 
unpublished). Neither experiment demonstrated specific binding between EphA2-Fc and 
MAU-Bt (data not shown). This suggests either a very weak affinity interaction, or that 
conformational constraints of the BIAcore system are preventing the detection of binding. 
This lack of detectable BIAcore binding suggests that, if there is an interaction between 
EphA2 and MAU TCR, it may be facilitated by clustering, or other cell surface components 
may be involved. Since the activation assays showed that plate bound EphA2-Fc alone is 
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sufficient to induce activation of JRT MAU (Figure 3.1), if other factors are required they 
are likely to be located on the JRT3 cell surface. Likely candidates for such a molecule are 
the ephrins, the cognate ligands for the ephrin receptors, which bind with high affinity, with 
many interactions having a dissociation constant in the nM range77. Also, such a strong 
interaction may allow EphA2 to induce TCR triggering in spite of the low affinity of the MAU 
TCR/EphA2 interaction. 
3.2.4 Interaction of ephrins with EphA2 is essential for the activation of MAU 
The presence of ephrinA1 and ephrinA4, both ligands of EphA2, on the surface of JRT3 cells 
has been demonstrated using polyclonal antibodies (J Déchanet-Merville, unpublished). 
Furthermore, EphA2-Fc and EphA4-Fc demonstrated TCR-independent binding of surface 
ephrins on JRT3 cells previously in this chapter (Figure 3.6), a finding which is also reported 
by another group135. This group also proposed that A-ephrins are present on CD4+ T cells, 
which were stained with EphA2-Fc ex vivo following culturing for five days, demonstrating 
that expression is not limited to the JRT3 cell lines, and may be expressed by T cells in vivo. 
Collectively, these results strongly suggest that ephrins are present on the surface of JRT 
MAU, and therefore could potentially be involved in the interaction between EphA2 and 
MAU.  
To investigate the potential role of ephrins in the interaction between EphA2 and MAU, a 
number of strategies were employed to disrupt the well-characterised interaction between 
EphA2 and its A-ephrin ligands. In a previous study from our group, preliminary 
experiments indicated the importance of ephrins for this interaction. Briefly, these included 
the use of PI-PLC to cleave GPI-linked surface proteins (such as the A-ephrins) from the 
surface of JRT3 cells and pre-blocking EphA2-Fc with soluble ephrinA1-Fc in the activation 
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assay. These experiments are summarised in Figure 3.13. These initial experiments, 
although useful for indicating the potential importance of A-ephrins, were not specific 
enough to directly implicate them in the interaction between EphA2 and MAU. For 
example, the PI-PLC cleavage indiscriminately cleaves all GPI-linked proteins, some of 
which may be required for activation, independently of ephrins. Also, the Fc-tag on the 
ephrinA1 used in the experiment may have blocked other sites distinct from the ephrin 
binding site preventing TCR binding to EphA2, implying that ephrin binding could not 
specifically be implicated. In order to build on these results, a mutant EphA2-Fc molecule 
was produced in 293T cells which specifically lacked the ability to bind A-ephrins.  
Himanen and colleagues used X-ray crystallography to extensively characterise the EphA2 
ephrin binding pocket of the ligand binding domain (LBD) by studying complexes with the 
ligand ephrinA182. The EphA2-ephrinA1 interface exhibits a buried surface area of 2350Å2 
and is dominated by a several polar and non-polar interactions. This study identified 4 
residues within the EphA2 ephrin binding pocket which are critical for binding ephrinA1. 
The EphA2 binding pocket is predominantly hydrophobic, and the surface-exposed 
hydrophobic residues T101, A190 and L192 mediate non-polar interactions with the 
aliphatic groups of Q109, P113, F114 and T115 of the G-H loop of ephrinA1, which provides 
the majority of the binding energy (Figure 3.14). The biological significance of these 
residues was assessed in another study, in which EphA2 binding pocket residues T101, A190 
and L192 were mutated, and cells transduced with these mutants failed to exhibit EphA2 
clustering when exposed to ephrin stimulus80. In addition to these hydrophobic 
interactions, EphA2 binding pocket residue R103 forms a salt bridge with E119 of the G-H 
loop of ephrinA1, which the authors describe as a ‘latch’ to stabilise the binding facilitated 
by the hydrophobic interactions (Figure 3.14). Interestingly, ephrinA1 residue E119 is 
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conserved in all A-ephrins (Figure 3.15). Furthermore, residues at positions 109, 113, 114 
and 115 of ephrinA1 which provide the majority of the hydrophobic interactions with the 
EphA2 LBD are also highly conserved within the A-ephrin family, and so this mechanism of 
binding and stabilisation is likely applicable to binding of all A-ephrin ligands of EphA2, not 
just ephrinA1135 (Figure 3.15). This suggested that disruption of these interactions should 
ablate binding of all A-ephrin ligands to EphA2. With this in mind, an EphA2-Fc mutant 
incorporating charge reversal of R103 to glutamic acid (EphA2R103E) was generated by 
altering the WT codon GAG to CGT. It was envisaged that the introduction of E103 may 
prevent binding to ephrins due to electrostatic repulsion effects (Figure 3.14). This 
construct was cloned into the pHL-Fc vector, expressed in 293T cells and purified as 
previously described for the WT EphA2-Fc construct. Expression levels, yield, SDS PAGE 
migration and purity for EphA2R103E-Fc were equivalent to the WT construct (Figure 3.16). 
Further BIAcore experiments were performed in order to confirm that the R103E mutation 
had not compromised the natural conformation of EphA2. These results established that 
EphA2R103E-Fc bound the anti-EphA2 pAb equivalently to the WT protein when analysed by 
BIAcore, implying correct folding (Figure 3.17A). This suggested that molecules which 
interact with other regions of EphA2 are likely to remain unaffected by this mutation. Next, 
the surface of JRT MAU and JRT LES were stained with the mutant to test the ability of 
EphA2R103E-Fc to bind ephrins. In contrast to WT protein, EphA2R103E-Fc failed to stain the 
surface of the JRT3 cells (Figure 3.17B), suggesting that ephrin binding had been completely 
ablated. The charge reversal mutation seemed to provide enough repulsive energy to 
negate the other hydrophobic interacting residues in the pocket, and thus significantly 
reduce binding to ligand.  
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Finally, EphA2R103E-Fc failed to activate JRT MAU when used in the previously described 
activation assay (Figure 3.18A). This strongly implicates ephrins as being vital to the 
interaction of EphA2 with MAU, as a single specific amino acid substitution deep in the 
ephrin binding pocket can completely knock out activation of JRT MAU by EphA2-Fc. 
Moreover, this finding also enforces that the ephrin receptor staining of JRT3 cells (Figure 
3.6) is due solely to ephrin binding, as staining is completely abrogated by the R103E 
mutation, thus further supporting the observation that ephrins are present on the JRT3 cell 
surface.  
3.2.5 TCR and ephrin interactions need to occur on the same EphA2 molecule 
At this stage it was established that activation of JRT MAU by EphA2-Fc requires the 
interaction of at least two cell surface molecules with EphA2, the MAU TCR and ephrins. To 
further characterise this interaction, it was important to determine whether these 
interactions take place on the same EphA2 molecule, or if they could be provided 
separately. This is an important distinction as it has implications for not only the spatial 
restrictions involved in the formation of such a complex, but also for the intracellular 
signalling pathway used by activation. 
In order to determine this, the two required signals (ephrin and TCR) were divided between 
two molecules in an activation assay, with both EphA4-Fc and EphA2R103E-Fc placed in the 
same well on a 96 well plate. In this experiment, EphA4-Fc would bind ephrins on the cell 
surface (as EphA4 binds the same ephrins as EphA288) providing the ‘ephrin signal’ and 
EphA2R103E-Fc would provide the ‘TCR signal’. EphA2R103E is identical to the WT EphA2 with 
the exception that it incorporates a single amino acid substitution which abrogates ephrin 
binding and prevents activation of JRT MAU. This approach assumes that the MAU TCR 
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does not bind within the ephrin binding pocket in a way that is dependent on R103. Indeed, 
the R103E substitution is buried deep within the binding pocket and therefore is unlikely 
to be able to contact the TCR. Despite using various ratios and concentrations of both 
reagents activation of JRT MAU was not observed in this experiment, suggesting that both 
ephrin and TCR interactions are required to take place on the same EphA2 molecule for the 
initiation of signalling (Figure 3.18B). These models are shown as a schematic in Figure 3.19. 
3.3 Discussion 
Unlike for αβ T cells, there is currently no widely accepted paradigm for the molecular 
nature of the interactions between γδ TCRs and their ligands, and so it is still unclear 
whether there is a conserved recognition modality, shared between various receptors, or 
different modalities are used depending on the TCR, ligand and physiological context. 
Therefore it is important to gain an in-depth understanding of a wide range of γδ TCRs and 
how they interact with their ligands in order to identify common features which may be 
shared by multiple receptors.  
γδ T cells likely play a key role in the detection of stress as part of the lymphoid stress 
surveillance compartment8, and an improved understanding of how they interact with their 
target molecules on a molecular level will allow for rapid advances in this field, equivalent 
to what has been achieved with αβ T cells. 
The results detailed in this chapter have outlined the broad molecular requirements for the 
interaction of a Vδ2negative γδ T cell MAU with EphA2, an epithelial stress ligand. Recognition 
of EphA2 by MAU is TCR specific, and successful interaction with ephrins on the γδ cell 
surface by EphA2 is also required. Finally, these interactions need to take place on a single 
EphA2 molecule, suggesting the formation of a tri-partite recognition complex. 
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The MAU TCR was shown to be essential for the activation of JRT3 cells by EphA2, as JRT3 
cells transduced with other γδ TCR genes failed to be activated. It was important to 
determine whether the MAU TCR is involved in MAU interactions with target cells, as 
although there is a consensus that the TCR mediates the interaction between γδ T cells and 
their targets, this is not always the case. For example, most γδ T cells express NKG2D, an 
activatory receptor typically found on natural killer (NK) cells which recognises stress 
ligands such as MICA and the ULBP family, which have been shown to activate γδ T cells 
independently of their TCR12. More recently, it has been suggested that in mice, certain 
subsets of γδ T cells predominantly use their TCR during T cell development in the thymus, 
and peripheral effector functions, including killing, are mediated solely by cytokines60. 
Interaction of ephrins with EphA2 was shown to be essential for the activation of JRT MAU 
by EphA2-Fc, because mutation of R103, a residue deep in the ephrin binding pocket of 
EphA2, completely ablates activation. It was also demonstrated that the ephrins and MAU 
TCR had to interact with the same molecule of EphA2-Fc, as activation of JRT MAU by 
EphA2R103E-Fc could not be rescued by the addition of EphA4-Fc. Beyond providing a 
potential framework for Vδ2negative γδ T cell interactions with their ligands, this specific 
interaction with the epithelial stress ligand EphA2 may represent a key component of the 
lymphoid stress surveillance response. The formation of this tri-partite complex represents 
a novel approach to ligand recognition by using a combination of γδ TCR and ephrin ligand 
to detect the presence of a stress ligand. 
EphA2 and its ligands are implicated in many biological pathways, and have a complex role 
in the initiation and development of several cancers85. Broadly, the literature suggests that 
in healthy epithelium, EphA2 is bound to ephrins in a trans manner, and restricted to cell-
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cell contacts86. Several studies suggest that this results in a formation of a complex 
signalling cluster80. When bound in its native state, EphA2 has been shown to possess 
tumour suppressor properties78, and when unbound from ephrin, oncogenic characteristics 
have been demonstrated97. A key process of epithelial cancer progression is epithelial to 
mesenchymal transition (EMT), whereby cells lose their epithelial properties, such as E-
cadherin expression. E-cadherin has been shown to modulate EphA2 localisation and 
function95, and during EMT EphA2 becomes separated from its ligands and is dispersed 
evenly around the cell surface, whereas it is usually restricted to cell contacts. Furthermore, 
it has been demonstrated that distinct EphA2 epitopes are available for antibody binding 
on normal and malignant cells86, supporting that this molecule could be recognised by the 
immune system only in its non-clustered state. Therefore the role of EphA2 as a stress 
ligand may be to signal these conditions by being exposed in an unbound form and available 
for both TCR and ephrin binding.  
It is conceivable that MAU T cells specifically recognise unbound EphA2 by virtue of the 
ephrins on their cell surface. This chapter clearly shows that the MAU γδ TCR is key to this 
interaction, and it may be that it specifically recognises ephrinA1-bound EphA2, although 
this was not detected by BIAcore (C. Willcox, unpublished). This would bring TCR signalling 
components towards the cell’s existing contact with a stress ligand, with the potential to 
initiate effector functions. It has also been demonstrated that A-ephrins can associate with 
the Src family kinases Lck and Fyn136, which are key to the initiation of the TCR signalling 
cascade137, typically a task associated with the co-receptors CD4 and CD8 in αβ T cells138. 
However CD4 and CD8 are not commonly expressed on γδ T cells, and it can therefore be 
envisaged that the establishment of this tri-partite signalling complex can bring these Src 
family kinases to the TCR-EphA2 complex. Previous studies from our group have shown 
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phosphorylation of key signalling components such as ZAP70 when MAU is activated by 
EphA2, demonstrating that the TCR signalling cascade is indeed initiated by this interaction. 
Because the GPI-linked A-ephrins do not possess a cytoplasmic region, their association 
with intracellular signalling machinery is likely due to their association with transmembrane 
proteins, such as the p75 neurotrophin receptor139, although the adapter proteins on T cells 
have not yet been identified135. This therefore adds the possibility that a fourth molecule 
may be involved in this interaction, as an intermediary between GPI-linked A-ephrins and 
cytoplasmic kinases. A schematic of this model is shown in Figure 3.20. 
This model could represent a novel recognition modality utilised by the lymphoid stress 
surveillance system. Unlike αβ T cells which specifically recognise MHC-bound peptide by 
their TCR, MAU may recognise a stress signal by a non-immune receptor molecule, which 
then recruits the TCR as a method of initiating T cell signalling for effector functions. Such 
an approach could conceivably be used by a range of receptors, relying on specific TCR for 
development, trafficking and almost as co-receptor for initiating signalling. 
To advance these findings, it is important to further characterise the role of ephrins in this 
interaction. Although these results indicate that ephrins are required for activation, it is still 
not apparent which ephrins are capable of facilitating this interaction. EphA2 can bind all 
of the GPI-linked A-ephrins, which have a diverse biological and signalling profile, which 
may have implications for their involvement in this interaction77. Furthermore, although 
this study clearly demonstrated the presence of A-ephrins on the surface of JRT3 cells, 
there is little evidence on the presence of A-ephrins on γδ T cells in vivo. Characterising 
their expression on such cells is an obvious extension to this study. One study 
demonstrated the presence of A-ephrins on ex vivo CD4+ T cells by staining with soluble 
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EphA2-Fc, however expression was only apparent after culturing in human serum for 5 
days135. If this expression pattern extends to γδ T cells, perhaps surface expression of A-
ephrins can be altered, adding a layer of control to the recognition strategy. 
The lack of detectable binding between EphA2-Fc and MAU-Bt provides some key insights 
into this interaction, and ultimately led to the finding that ephrins are central to activation 
by EphA2. BIAcore is a reliable application for detecting binding between proteins, but does 
have limitations for certain types of interactions. Therefore, although binding cannot be 
detected, it does not necessarily mean that there is no physiologically relevant interaction 
between EphA2 and MAU TCR. For example, the interaction of CD4 with MHC class II 
molecules cannot be detected by BIAcore, yet CD4 is a well-established and characterised 
co-receptor in CD4+ T cells, and its ectodomain has even been crystallised in complex with 
class II MHC140. It is important to consider the wider physiological context in these 
situations, and immobilised proteins on a BIAcore chip are not very representative of this, 
and factors such as clustering, which is a key component of EphA2/ligand interactions, 
cannot be accounted for. It could also be that intracellular signalling components are 
required for binding, as demonstrated by the importance of Lck association for the co-
receptor function of CD4 and CD8138. 
It would be useful to expand these findings beyond the MAU JRT3 transductant, which 
serves as a model for TCR based activation. Jurkat cells cannot be used for in depth analysis 
of effector functions, such as cytokine production profiles, which would provide 
information on how MAU may interact with target cells and other immune cells after 
activation. Unfortunately, the MAU clone is no longer available, which provides a limit on 
how physiologically relevant these models can be. Isolation of further EphA2-reactive 
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clones would enable these experiments to be undertaken. Interestingly, the Vγ9Vδ1 chain 
pairing has frequently been observed in the peripheral blood of both healthy donors (see 
Chapter 6) and chronic myeloid leukaemia (CML) patients (D. Lewis, unpublished). This 
suggests that if this chain paring is required for EphA2 reactivity, this recognition modality 
may be common within the population, allowing for the isolation of further reactive clones. 
These broad requirements identified for the recognition of EphA2 by MAU TCR provided 
key insights into the molecular nature of this interaction, and has led to the development 
of a model for the recognition of an epithelial stress ligand by a Vδ2negative γδ T cell, which 
may be applicable to other γδ T cells. 
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3.4 Figures 
  
Figure 3.1: EphA2-Fc specifically activates JRT MAU 
EphA2-Fc, EphA4-Fc and OKT3 were immobilised on a 96-well plate and incubated with 5x105 
of either JRT MAU or JRT LES for 4 hours. Activation was then measured by CD69 upregultion 
using flow cytometry. (A) Representative histograms showing the shift in peaks when JRT3 
cells were exposed to different stimulants. (B) Quantification of experiments. (n=3, error bars 
=SD). 
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Figure 3.3: Expression and purification of EphA2-Fc using the 293T expression system 
(A) Western blot showing the expression levels of EphA2-Fc at day 5 post transfection, probed 
using an HRP conjugated anti-His antibody. (B) SDS PAGE gel (Instant Blue) showing reduced 
(R) and non-reduced (NR) Ni-NTA purified EphA2-Fc. The non-reducing R&D EphA2-Fc sample 
shows several lower molecular weight bands, potentially representing degradation products. 
Yields were typically 1.5mg from 250ml of 293T supernatant. 
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Figure 3.4: Amine coupling of the R10Z8E9 mAb to a CM5 BIAcore chip 
The chip surface was first activated using EDC/NHS to generate surface esters. The R10Z8E9 
anti-Fc mAb was then immobilised onto the chip surface by binding of primary amines to the 
surface esters. Ethanolamine was then used to saturate any remaining surface esters. Finally, 
NaOH and Gly-HCl were used to remove any non-covalently bound molecules and adjust the 
pH of the flow cell for the experiment. 
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Figure 3.5 : Verification of the intact conformation of EphA2 using anti-EphA2 pAb 
(A) Immobilisation of Fc-tagged ephrin receptors to the R10Z8E9 coated CM5 chip. Protein 
levels were normalised to approximately 2000 RU. (B) Binding of the anti-EphA2 pAb to the 
immobilised ephrin receptors. The anti-EphA2 pAb bound R&D EphA2-Fc and 293T EphA2-
Fc, and failed to bind the EphA4-Fc control. 
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Figure 3.6 : Cell surface staining of JRT MAU and LES by EphA2-Fc 
(A) 293T EphA2-Fc and R&D EphA2-Fc were used the stain the surface of JRT MAU cells, which 
were detected using an AF488 conjugated goat anti-human Fc secondary antibody. The two 
constructs stained the surface equivalently. (B) JRT MAU and JRT LES were stained equivalently 
by EphA2-Fc and EphA4-Fc. (Representative, n=3). 
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Figure 3.7 : 293T EphA2-Fc activates JRT MAU equivalently to R&D EphA2-Fc 
Fc-tagged ephrin receptors were immobilised on a 96-well plate and incubated with JRT MAU 
cells for 4 hours. Activation was then measured by CD69 upregulation. 293T-derived EphA2-
Fc activated JRT MAU equivalently to R&D EphA2-Fc. EphA2 engineered to a biotinylation 
AviTag instead of a dimerising Fc-tag (EphA2-Avi), also activated JRT MAU. (Representative, 
n=3). 
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Figure 3.8 : MAU γδ TCR construct 
Schematic of recombinant MAU γδ TCR construct expressed in S2 Drosophila cells. The open 
circles represent the Ig domains of either the constant (C) or variable (V) domains. SS denotes 
a disulphide bond. The basic and acidic leucine zipper motifs ensure heterodimeric TCR 
formation. 
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Figure 3.9 : Production of MAU TCR using the Drosophila S2 expression system 
(A) Reducing (R) and non-reducing (NR) SDS PAGE analysis (instant blue) of Ni-NTA purified 
MAU TCR. The γ and δ chains are visible as discrete bands in the non-reducing sample, 
migrating at approximately 45kDa. The dimeric construct migrates at approximately 90kDa in 
the non-reduced sample. Yield was typically 1.5mg from 1L of S2 supernatant. (B) Western 
blot of MAU-Bt to show successful biotinylation of MAU TCR, probed using a HRP-conjugated 
streptavidin construct. 
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Figure 3.10 : Immobilisation of MAU TCR on a CM5 BIAcore chip 
(A) Amine coupling of streptavidin to the CM5 chip, highlighting the reagents used for each 
injection. First the surface was activated using EDC/NHS to generate surface esters. 
Streptavidin was then immobilised onto the chip surface by the binding of primary amines to 
the surface esters. Ethanolamine was then used to saturate any remaining surface esters. 
Finally, Gly-HCl was used to remove any non-covalently bound molecules and adjust the pH 
of the flow cell. (B) Immobilisation of biotinylated MAU TCR to the streptavidin coated CM5 
chip. 
Time (s) 
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Figure 3.11 : Verification of MAU-Bt folding using BIAcore 
Biotinylated TCRs were immobilised to a streptavidin coated CM5 chip and γδ TCR specific 
mAbs were injected over the flow cells. (A) The pan-γδ mAb binds both MAU-Bt and LES-Bt. 
Anti-Vγ9 (B) and anti-Vδ1 (C) mAbs specifically bind the Vγ9Vδ1 MAU TCR, but not the Vγ4Vδ5 
LES TCR. Number in brackets represents amount of TCR immobilised on the chip. 
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Figure 3.12: Analysis of the MAU-Bt/EphA2-Fc interaction using BIAcore 
LES-Bt and MAU-Bt were immobilised onto a streptavidin coated CM5 chip, and EphA2-Fc was 
injected over the chip with a peak concentration of 6µM. EphA2-Fc demonstrated no specific 
binding to MAU-Bt when compared to the control LES-Bt. Number in brackets represents RU 
of TCR immobilised on CM5 chip. 
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Figure 3.13 : Binding of EphA2 to ephrins is required for the activation of JRT MAU 
Schematic summary of previous experiments. PI-PLC cleavage of GPI-linked A-ephrins from 
the surface of JRT MAU (A) and blocking of the EphA2 ephrin binding pocket with soluble 
ephrinA1-Fc (B) prevents activation of JRT MAU. 
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Figure 3.14 : Ribbon representation of the interaction between EphA2 and ephrinA1 
(A) Binding is largely facilitated by hydrophobic interactions between the hydrophobic pocket 
of EphA2 LBD and the G-H loop of ephrinA1. (B) Close-up view of the binding pocket. Binding 
is secured by the salt bridge formed between R103 in the EphA2 binding pocket and E119 of 
the G-H loop of ephrinA1 (black dotted line). T101, A190 and L192 of the EphA2 binding 
pocket provide the majority of the hydrophobic interactions with residues T115, P113, F114 
and Q109 of the G-H loop of ephrinA1 (Structure obtained from the Protein Dank Bank, PDB: 
3HEI). 
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Figure 3.16: SDS-PAGE analysis of 293T-derived EphA2R103E-Fc 
EphA2R103E-Fc was purified using Ni-NTA chromatography. Reduced (R) sample migrates at 
approximately 100kDa, equivalent to the WT EphA2-Fc construct. The non-reduced (NR) 
samples migrates at approximately twice this size. Proteins visualised with Instant Blue. 
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Figure 3.17: Validation of the EphA2R103E-Fc construct  
(A) Fc-tagged ephrin receptors were immobilised on a R10Z8E9 coated CM5 BIAcore chip. 
Anti-EphA2 pAb was then injected over the chip. Equivalent binding to the WT EphA2-Fc was 
observed. Figure in brackets represents RU of receptor immobilised on the chip. (B) Fc-tagged 
ephrin receptors were used to stain either JRT MAU or JRT LES cells, and were detected using 
an AF488 conjugated goat anti-human Fc secondary antibody. EphA2R103E-Fc failed to bind 
the surface of either cell type. (Representative, n=3). 
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Figure 3.18: Characterisation of the EphA2R103E-Fc construct 
(A) Fc-tagged ephrin receptors were immobilised on a 96-well plate and incubated with JRT 
MAU cells for 4 hours. Activation was measured by CD69 upregulation. (B) EphA2R103E-Fc and 
EphA4-Fc were coated onto a 96 well plate at various concentrations and incubated with JRT 
MAU cells for 4 hours. Activation was measured by CD69 upregulation. EphA2R103E-Fc was 
unable to rescue activation of JRT MAU by EphA2-Fc. (n=3, error bars =SD). 
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Figure 3.19 : The TCR and ephrin signal from EphA2 have to occur on the same EphA2 
molecule 
(A) EphA2R103E-Fc (E103 designated by red cross) fails to activate JRT MAU in the presence of 
EphA4-Fc. MAU TCR is able to bind EphA2R103E-Fc and EphA4-Fc is able to bind surface 
ephrins. (B) JRT MAU can only be activated when the TCR and ephrin signal originate from 
the same EphA2-Fc molecule. 
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Figure 3.20: Schematic of the proposed tri-partite EphA2 recognition complex 
Schematic of model demonstrating the tri-partite recognition complex formed by EphA2, 
MAU and ephrins. In this model, GPI linked ephrins associate with TM proteins which can 
recruit intracellular Src family kinases suck as Lck. These kinases then phosphorylate the 
ITAMs of the CD3 complex, initiating a TCR signalling cascade. 
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4.1 Introduction 
In the previous chapter, the broad requirements for recognition of an epithelial stress 
ligand by a Vδ2negative γδ T cell were established. EphA2 recognition requires the MAU γδ 
TCR and successful binding of ephrins, on the same molecule. This is unlike any previously 
characterised immune receptor interaction, and the unusual nature of this recognition 
modality warrants further investigation. The aim of this chapter is to expand upon these 
findings, and define the role of the TCR in this interaction, by identifying the TCR binding 
site and which regions of the MAU TCR are involved. 
There have been limited studies on the structure of γδ TCRs, with 5 structures reported to 
date31,50,51,58,141. All of these structures strongly suggest that one or more of the CDR loops 
projecting out from the receptor are likely to mediate contacts with their ligands. Of these 
5 γδ TCR structures, three are complex structures of γδ TCRs bound to ligand, one 
describing the interaction of murine G8 γδ TCR with the stress inducible T22 MHC-like 
molecule31, and two describing Vδ1+ γδ TCRs interacting with lipid-loaded CD1d50,51. The 
complex structures invariably implicate the γδ TCR CDR loops as direct mediators of 
recognition, specifically the CDR3δ loops. The exact role of these CDR loops is not 
conserved between these interactions however, with the two structures of γδ TCRs 
complexed with lipid-loaded CD1d proposing different recognition modalities and 
involvement of the γ chains.  
How representative these studies are for the γδ TCR repertoire is unclear. For example, 
typically less than 1% of the Vδ1+ population can be stained by lipid-loaded CD1d 
tetramers71. Potential γδ TCR ligands identified to date have demonstrated considerable 
structural diversity and can be broadly categorised into one of two groups, MHC-like and 
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non-MHC-like (Figure 4.1). It is easy to envisage how these recognition modalities may 
apply to the MHC-like ligands, but their extension to the non-MHC-like ligands, such as 
EphA2, is less well defined.  
However, even within the MHC-like γδ TCR ligands, recognition seems to be considerably 
diverse. For example, EPCR, a lipid presenting MHC-like molecule is specifically recognised 
by a γδ TCR in a lipid-independent manner, on the underside of lipid binding platform123. 
This is in contrast to T22 and CD1d, which interact with their respective γδ TCR via the lipid 
binding groove, and CD1d presents lipids to γδ T cells31,50,51. 
Increased understanding of the molecular basis for the recognition of EphA2 by MAU is 
potentially important for outlining paradigms for the structural basis of the γδ TCR 
interaction with non MHC-like molecules, which could be used to fully characterise the 
interaction of γδ TCRs with currently known ligands. This improved knowledge could also 
expedite ligand identification by identifying structural characteristics within ligands 
associated with γδ T cell recognition. For example, other members of the ephrin receptor 
family may be recognised by γδ T cells, and this data may allow for a more directed 
approach at detecting such interactions. Furthermore, there is also potential to exploit such 
findings to develop approaches with an aim to mimic or enhance such an interaction 
clinically. Indeed, EphA2 is a significant cancer target, and the subject of a number of 
therapeutic approaches142, and therefore understanding how the immune system interacts 
with this molecule could prove a significant development. 
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4.2 Results 
4.2.1 AlphaScreen suggests binding between EphA2 and MAU TCR 
Direct binding data between recombinant versions of proteins is a powerful indication that 
two molecules interact. Early attempts at BIAcore SPR experiments to detect binding 
between EphA2 and MAU TCR in our laboratory have proven unsuccessful, as discussed in 
the previous chapter. In order to overcome the limitations of BIAcore, AlphaScreen 
technology was subsequently explored. AlphaScreen is a microplate-based bead assay in 
which recombinantly tagged proteins are bound to either a donor or an acceptor bead. If 
the two recombinant proteins bind, the donor and acceptor beads are brought into close 
proximity. The donor bead is then excited with light at 680nm, causing it to emit a singlet 
of oxygen (1O2). If the acceptor bead is close enough to the donor bead, this 1O2 causes the 
acceptor to emit light at a wavelength of between 580nm and 620nm, which is detected by 
the plate reader (Figure 4.2A). For this study, biotinylated MAU TCR (MAU-Bt) was bound 
to streptavidin-coated donor beads and EphA2-Fc was bound to protein A-coated acceptor 
beads. Production of these recombinant proteins was discussed in detail in Chapter 3. 
Since the use of AlphaScreen to detect protein-protein interactions was a new technology 
adopted by the group, several steps were undertaken to validate this approach. Firstly, the 
AlphaScreen beads were supplied with a biotinylated rabbit IgG fragment (IgG-Bt), which 
binds both the streptavidin donor and protein A acceptor beads simultaneously. This 
control produced large emissions when incubated with the AlphaScreen beads across a 
range of concentrations, in line with the product documentation (Figure 4.2A). Secondly, 
to examine the system with recombinant proteins produced in our laboratory, binding of 
the anti-Vγ9 antibody to MAU-Bt was assessed. This experiment showed strong evidence 
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of specific binding between these two reagents (Figure 4.2B). Collectively, these 
experiments demonstrated that the AlphaScreen methodology could be successfully 
utilised with our recombinantly expressed proteins. 
Initial screens for interaction between EphA2-Fc and MAU-Bt were performed as a titration 
of both proteins, which allows for the assessment of binding behaviour over a range of 
protein concentrations, as well as for the determination of the correct concentration of 
reagents to use for future experiments. This process is particularly important for the 
AlphaScreen assay, due to the ‘hooking effect’. Because AlphaScreen beads are not washed 
after binding to the tagged proteins, any residual protein following saturation remains free 
in solution. These unbound proteins are then available to bind their bead-bound partners, 
and thus prevent a bead bound protein from binding. This results in a decrease in signal as 
the concentration of protein increases, as fewer beads are brought into close proximity to 
facilitate 1O2 transfer. A similar effect was also observed in the control experiment 
performed with biotinylated rabbit IgG at antibody concentrations over 1.5nM (Figure 
4.2A), caused by an excess of IgG fragments. 
Controls in these experiments were designed to account for non-specific stickiness of the 
proteins with the beads. Therefore, the results for this technique are represented as a ratio 
of emission to background (emission:background). With this approach, background is 
defined as the highest emission of either of the two protein partners individually, at the 
same concentration, with both donor and acceptor beads. 
These titration experiments demonstrated a clear dose-dependent binding pattern 
between EphA2-Fc and MAU-Bt (Figure 4.3A), with the hooking effect apparent at EphA2-
Fc concentrations above 0.15µM. MAU-Bt does not appear to reach sufficiently high 
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concentrations to achieve the hooking effect. This is consistent with a low affinity 
monomeric MAU-Bt, in contrast to the dimeric EphA2-Fc. EphA4-Fc, which failed to activate 
JRT MAU in the previous chapter, was used as a control and produced much lower 
emission:background ratios when used with MAU-Bt over identical concentration ranges 
(data not shown). As confirmation of this approach for detection of binding between γδ 
TCRs and ligands, binding of the LES γδ TCR with its ligand EPCR, which has been 
demonstrated by BIAcore, shows a similar pattern (J Déchanet-Merville, unpublished). The 
ideal concentration of EphA2-Fc and MAU-Bt was then determined by selecting two 
concentrations which produce a considerable emission:background ratio, whilst not using 
excessive amounts of protein. For the following experiments, concentrations of 0.7µM of 
MAU-Bt and 0.15µM of ephrin receptor were selected.  
To expand these initial titrations, AlphaScreen experiments were conducted with TCR and 
ephrin receptor controls. These experiments typically showed strong specific binding 
between EphA2-Fc and MAU-Bt, with emission:background ratios of greater than 35 (Figure 
4.3B). In contrast, EphA2-Fc showed no binding to either LES-Bt (a Vγ4Vδ5 TCR) or LDN5-Bt 
(an αβ TCR), highlighting that this binding was TCR specific. Finally, EphA4-Fc failed to bind 
MAU-Bt. 
These results strongly indicated that AlphaScreen is a viable approach to detect γδ 
TCR/ligand interactions, and that MAU-Bt directly binds EphA2-Fc, supporting previous 
data described in Chapter 3. This is strengthened by the observation that EphA4-Fc, which 
does not activate JRT MAU, failed to bind MAU-Bt. 
 4 - 111 
The establishment of a direct binding assay for this interaction also allowed for the 
development of mutagenesis approaches to dissect the nature of the binding between 
EphA2 and MAU TCR. 
4.2.2 Modelling the interaction between EphA2 and MAU TCR 
4.2.2.1 Modelling of the MAU TCR 
To further characterise the interaction between EphA2 and the MAU TCR, molecular 
modelling was performed to generate hypotheses about their binding mode which would 
be used to inform future mutagenesis experiments. 
Currently, there is no structure available for the MAU TCR, and so a model was generated 
using Phyre112. This program predicts the three dimensional structure of a protein by 
comparing its amino acid sequence with previously determined protein structures. To 
model the MAU TCR, the MAU Vγ9 chain was modelled on the Vγ9 chain of the G115 human 
Vγ9Vδ2 TCR structure (PDB: 1HXM)58, and the MAU Vδ1 chain was modelled on the δ chain 
of the murine G8 TCR (PDB: 1YPZ)31. These templates were selected by the Phyre software 
due to their high sequence identity to the MAU γ and δ chains (94% and 54% respectively). 
During this analysis, the crystal structure of the Vδ1+ 9C2 TCR was unavailable51. The δ chain 
of this TCR possesses 98% sequence identity with the MAU δ chain, considerably higher 
than that for the G8 TCR δ chain used in this study. Despite this, the G8 based model used 
in this study was modelled with a 99.97% confidence, which the authors of the program 
suggest is sufficient to generate a model between 2-4Å root-mean-square deviation RMSD 
from the true structure112. Indeed, when aligned with the 9C2-derived δ chain model, the 
models are very similar (including the flexible CDR loops) and have an RMSD of 1.7Å, 
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suggesting that despite the lower sequence identity, the G8 based δ chain model is largely 
comparable to the 9C2 based model (data not shown). 
A complete model for the MAU γδ TCR heterodimer was formed by overlaying each chain 
onto the human G115 Vγ9Vδ2 structure (PDB: 1HXM58) using WinCoot111 (Figure 4.4). 
The resulting MAU γδ TCR model was then analysed and compared to previously 
determined γδ TCR structures to ensure that the model maintained core structural 
characteristics associated with these structures. The γδ TCR structures generated to date 
describe four characteristic Ig folds, two in each chain forming the variable (V) and constant 
(C) regions. In each chain of the MAU model, the V and C domains are clearly defined Ig 
folds, consisting of characteristic antiparallel β-sheets closely packed together and 
stabilised by a disulphide bond. The Ig core region is further stabilised by an invariant 
tryptophan residue (W36) , and various non-polar interactions mediated by hydrophobic 
residues143. The MAU Vδ1 variable domain is shown in Figure 4.5 as a representative 
example. 
The CDR1, 2 and 3 regions of MAU were defined by the IMGT V-QUEST tool144, and when 
mapped onto the MAU TCR model, they are represented as solvent exposed flexible loops 
(Figure 4.6), similar to previously determined γδ TCRs, suggesting that they may be involved 
in binding to ligands, as demonstrated for the T22/G831 and CD1d/9C251 interactions. MAU 
CDR loops were labelled using a two digit system, whereby the first digit represents the 
TCR chain (Vγ9 or Vδ1) and the second digit signifies the CDR. For example, the Vγ9 CDR3 
loop is referred to as 93. 
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This analysis, combined with the high sequence identity between MAU and the template 
structures, suggested that the Phyre-derived MAU model is a plausible representation of 
the MAU γδ TCR structure. 
4.2.2.2 Exploring models of EphA2 and MAU TCR 
Exploring potential models of the interaction between EphA2 and MAU TCR would help to 
shape future mutagenesis work by defining constraints for the interaction and to predict 
potential binding sites. Although computational models are available for the prediction of 
binding sites, these approaches are only reliable once the number of potential sites has 
been reduced, and potential residues involved have been experimentally verified. 
Firstly, surface electrostatics analysis of EphA2 using DelPhi (PDB:2X1080) was used to 
detect potential binding sites between EphA2 and MAU TCR, with the aim to identify 
specific electrostatic signatures which are often associated with protein-protein 
interactions, such as distinct complementary electropositive/electronegative patches on 
either molecule. The analysis revealed no such signatures (Figure 4.7). Therefore, given the 
large surface area of EphA2, more constraints were needed in order to restrict the number 
of potential MAU binding sites. 
To gain a better understanding of the relative size and shape of EphA2 and MAU TCR, 
attempts were made to manually model the tripartite complex formed between EphA2, 
ephrins and the MAU TCR. This model would assist in shaping further mutagenesis work by 
excluding any regions of EphA2 or MAU TCR which are unlikely to interact with each other, 
either through steric restrictions or size constraints. The complex structure of EphA2 and 
ephrinA5 (PDB 2X1180), as well as the Phyre-derived MAU TCR model, were manually 
modelled with WinCoot111 (Figure 4.8).  
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In order to reduce the number of potential binding sites, the size of the two molecules and 
their relative orientation of domains were carefully scrutinised, to determine if any 
domains of EphA2 and MAU TCR could be excluded from participating in this interaction, 
either through steric hindrance or inability to reach them from the surface of the T cell 
(Figure 4.8). Unfortunately, the protein structures and models do not provide any 
information on how the proteins are displayed on the cell surface, as the regions which 
connect the membrane proximal domain with the transmembrane region are likely to be 
flexible, and so it is not possible to determine either how the protein is situated relative to 
the membrane, but also how long the linker regions are spatially given the large number of 
conformations they can adopt. With these considerations in mind, the modelling suggested 
that the MAU TCR could theoretically contact all domains of EphA2, with no sites either out 
of reach, or sterically excluded by other domains. This was unexpected, given that EphA2 
is approximately twice the length of the MAU TCR (160Å to 80Å respectively). This is likely 
due to the observation that EphA2 is unlikely to extrude perpendicularly from the plasma 
membrane145, thereby reducing the distance it extends laterally from the cell surface. 
Comparison of multiple EphA2 structures revealed considerable flexibility in the membrane 
proximal region, with a relative rotation of approximately 71° between the two FN domains 
of EphA280,145, suggesting a hinge-like nature of the FN1-FN2 linker (Figure 4.9). These 
studies also noted points of flexion between the LBD-Sushi domains and within the EGF 
domain, but relative positions of these domains was largely stable80,145. Analysis of the 
crystal structure of EphA4 revealed considerably less flexibility between the FN1 and FN2 
domains of this protein compared to EphA2, resulting in the FN2 domain packing tightly to 
the FN1 domain, with little variation between crystals146. The functional consequences of 
this difference in flexibility between EphA2 and EphA4 is unclear, but may impact on 
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receptor-membrane interactions and orientation relative to the cell surface, implying that 
EphA2 can adopt a wider array of orientations on the cell surface, which further 
complicates the modelling process.  
In summary, this modelling revealed that the TCR could potentially bind to all domains of 
EphA2, and so if computational methods were to be used to generate a viable model of the 
trimeric complex, additional constraints through domain deletion mutagenesis would be 
required. 
4.2.3 Mutation of the MAU CDR loops 
Although it had been determined that the MAU TCR interacts with EphA2, which regions of 
the TCR are involved in the interaction was still unclear. The MAU TCR model revealed that 
the CDR loops are solvent exposed, flexible loops. This suggested that they were promising 
candidates to be involved in ligand binding, similar to the previously characterised γδ TCR 
ligand interactions31,51 (Figure 4.10A, B). 
In order to test this hypothesis, several CDR loop mutants of MAU-Bt were designed. Using 
the MAU Phyre model, residues encompassing the exposed CDR loops were selected for 
mutation. The prominent and flexible nature of the CDR loops indicated that they are 
unlikely to play an important role in maintaining the V-domain fold. Hence, these CDR loops 
could be subjected to relatively major changes to disrupt potential binding with EphA2, 
without compromising the overall fold of the V domain. For each CDR, four residues were 
selected for mutation, and substituted for residues of different size, hydrophobicity or 
charge. In addition, codon changes were also considered when selecting substitution 
residues in order to minimise changes to the WT sequence, which simplified PCR steps 
(Table 4.1). As an example, the MAU Vγ9 CDR3 loop contains the residues 102VQSV105 at 
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the tip of the loop (Figure 4.10C, left). The MAU Phyre model suggested that these residues 
were not involved in mediating contacts with the δ chain or the framework regions of the 
Vγ9 domain (Figure 4.6). It was therefore decided to mutate these residues to 
102EWRD105 (Figure 4.10C, right). 
To clone these mutants, site directed mutagenesis (SDM) was used to modify the WT MAU 
Vγ9 and Vδ1 constructs. With this approach, there is a maximum number of bases which 
can be changed per mutagenic primer pair, to ensure the primer can still bind the template. 
Therefore, the final mutants were formed through several rounds of SDM amplifications, 
using the previous mutant as the template for the subsequent SDM amplification. The base 
changes for each of the 6 MAU CDR loops are listed shown in Appendix 4.1. MAU mutants 
were classified using a two digit system, whereby the first digit represents the TCR chain 
(Vγ9 or Vδ1) and the second digit signifies the CDR. For example, the Vγ9 CDR3 loop mutant 
is referred to as MAU 93. 
Sequence-verified mutated constructs were expressed in the Drosophila S2 expression 
system, and purified using Ni-NTA chelate chromatography and biotinylated as previously 
described in Chapter 3. TCR yields were typically 1.5mg of specific protein per 1L of S2 
supernatant, equivalent to the yield of WT MAU TCR (Figure 4.11). To ensure correct folding 
of the mutant MAU chains, and formation of heterodimeric TCR, BIAcore was used to 
detect binding of pan γδ, Vγ9-specific and Vδ1-specific mAbs as previously described. In 
these experiments, biotinylated mutant MAU constructs were immobilised to a 
streptavidin coated CM5 chip, and TCR-specific monoclonal antibodies were injected over 
the immobilised TCRs (Figure 4.12). All mutant MAU TCRs successfully bound the mAbs, 
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suggesting that they were folded correctly, despite incorporating drastic mutations within 
their CDR loops. 
4.2.4 Generation of the EphA2ΔLBD mutant 
Concurrently with the production of the MAU TCR CDR loop mutations, an EphA2 mutant 
was produced which lacked the ligand binding domain (EphA2ΔLBD, Figure 4.13B), with the 
aim of using the AlphaScreen assay to determine whether this domain was critical for MAU 
TCR binding. 
While designing the EphA2ΔLBD mutant, the domain boundaries were carefully defined. 
Domains are independently folded regions of a protein, usually connected by short, flexible 
sections of amino acids. Therefore, if the protein is truncated at these short sections, the 
remaining domains should fold correctly. EphA2 domain boundaries were first identified 
using the UniProt database128, which predicts domains based on published studies and 
conserved amino acid motifs. These boundaries were then verified by examining the crystal 
structure of the EphA2 ectodomain (PDB: 2X1080). One of the important factors to consider 
was the amino acid environment proximal to the domain boundaries. For example, there 
is a disulphide bond formed between cysteine residues 201 and 205 of the Sushi domain 
near the boundary of the LBD (Figure 4.13A). Disulphide bonds are key components of 
tertiary structure, and disrupting them could potentially result in protein misfolding, so it 
was important to incorporate C201 into the Sushi domain in order to maintain this 
disulphide bond. The EphA2ΔLBD construct encompassed residues K119 to N534 (Figure 
4.13B). 
With the domain boundaries defined, the EphA2ΔLBD mutant was then cloned using domain-
specific PCR primers into the pHL-Fc vector. This construct was then expressed in the 293T 
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expression system and purified by Ni-NTA chelate chromatography as previously described. 
Yields of EphA2ΔLBD-Fc were consistent with WT EphA2-Fc, around 1.5mg of specific protein 
from 250ml of S2 supernatant. SDS-PAGE analysis of fractions eluted from the Ni-NTA 
column revealed that EphA2ΔLBD-Fc migrates at its predicted size of 63kDa under reducing 
conditions (Figure 4.14). 
To confirm correct folding of the EphA2ΔLBD-Fc construct, BIAcore was used to detect the 
binding of an anti-EphA2 pAb. This experiment revealed that despite lacking the LBD, 
EphA2ΔLBD-Fc successfully bound the anti-EphA2 pAb, suggesting that the remaining 
domains were correctly folded (Figure 4.15A). Consistent with the premise that ephrin 
binding is essential for activation of JRT MAU by EphA2, EphA2ΔLBD-Fc failed to activate JRT 
MAU (Figure 4.15B). 
4.2.5 AlphaScreen irregularities 
The EphA2ΔLBD and MAU CDR loop mutants were used in the AlphaScreen assay in order to 
determine whether the TCR bound the EphA2 LBD, and if binding was CDR-dependent. 
These initial AlphaScreen experiments suggested that the EphA2ΔLBD-Fc construct bound 
specifically to MAU-Bt, usually with a higher emission:background ratio than WT EphA2-Fc 
(Figure 4.16). These results suggested that the LBD of EphA2 was not critical for binding 
MAU TCR. 
However, as more data were collected, several anomalies were observed particularly with 
the controls, thereby raising doubt as to the reliability of the AlphaScreen assay. For 
example, on several occasions WT EphA2-Fc protein showed no binding with WT MAU-Bt, 
despite previous results demonstrating robust binding. Furthermore, in some experiments 
binding between the negative control EphA4-Fc and MAU-Bt was noted (data not shown). 
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Hence, it was deemed necessary to re-examine the reagents and controls used in these 
experiments with the aim of obtaining more consistent results before the AlphaScreen 
assay could be used to determine regions of EphA2 and MAU TCR that were critical for 
binding. 
Revisiting the titration assay to gain an improved understanding of the effect of varying 
concentrations of reagents in the experiment yielded further inconsistent results, ranging 
from unequivocal binding between EphA2-Fc and MAU-Bt to highlighting no binding 
between these molecules (data not shown). To further complicate matters, binding was 
occasionally observed between EphA4-Fc and MAU-Bt. In order to determine the 
underlying cause of these varying results, several steps were undertaken to control most 
variables in the assay.  
Firstly, preliminary experiments had shown that the buffer used in the AlphaScreen assay 
has a large effect on the binding observed. To account for this, significant care was taken 
to ensure buffer batches were as consistent as possible, and due to the addition of BSA, 
buffer was filter sterilised and stored at 4°C to inhibit bacterial growth. It was also 
noticeable that different batches of MAU-Bt from the same production system yielded 
variable binding results.  
In order to control for TCR purity and background contaminants, the TCR was further 
purified using size exclusion chromatography (SEC). Briefly, a batch of MAU TCR (MAU VII) 
was purified using Ni-NTA chromatography and a PD10 desalting column as previously 
described. Half of the purified protein was further purified using SEC, producing a much 
purer sample (data not shown). Further experimental details are available in Chapter 2. 
Interestingly, when these two proteins were used in the AlphaScreen assay to detect 
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binding to EphA2-Fc, the SEC purified MAU-Bt failed to bind, whereas the Ni-NTA purified 
MAU-Bt demonstrated binding at two concentrations (data not shown). This result 
suggested that the ability to detect MAU-Bt/EphA2-Fc interaction may be dependent upon 
the level of impurities present in the recombinant protein samples. 
Collectively these data suggested that the AlphaScreen assay is not a robust system in 
which to test this interaction between EphA2 and MAU. Although initial binding data 
appeared to be reproducible, which prompted the production of mutants to use in this 
assay, subsequent discrepancies and unpredictable controls raised doubts over the 
reliability of the data. Our collaborators also independently reported similar 
inconsistencies despite promising early results. For these reasons it was decided to 
abandon the AlphaScreen assay as means of detecting binding between EphA2 and MAU 
TCR. Potential reasons for this are discussed in section 4.3. 
Although not entirely reproducible, the early results do provide an indication that EphA2 
does indeed bind MAU TCR, enough to justify further characterisation of this interaction. 
The data also suggested that MAU TCR binds the EphA2ΔLBD construct, suggesting the TCR 
binds EphA2 at a domain other than the LBD. Again it is important to note that these results 
were only used to inform further experiments, and are not conclusive. 
4.2.6 The EphA2 LBD is sufficient for activation of JRT MAU 
In lieu of a reliable direct binding assay, the more robust and reproducible activation assay 
was used to determine the domain of EphA2 to which the MAU TCR binds. 
Firstly, to assess whether the MAU TCR interacted with the EphA2 LBD, an EphA2 LBD 
construct engineered to an Fc-tag was designed. This construct proved difficult to express 
in the 293T system, and several constructs were designed with different domain 
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boundaries to overcome potential protein folding errors. Ultimately, this domain could not 
be expressed as an Fc protein in the 293T expression system (data not shown). It was 
possible that the EphA2 Sushi domain is required for the correct folding of the LBD, as 
several interdomain interactions are formed between them145.  
In lieu of the EphA2 LBD-Fc construct, an alternative strategy was devised. Two constructs 
were generated in which the LBDs of EphA2 and EphA4 were swapped (Figure 4.17A). 
EphA22L4CF contains the LBD of EphA2 and the CRD and FN domains of EphA4 whereas the 
EphA24L2CF is comprised of LBD of EphA4 and the CRD and FN domains of EphA2. Domain-
specific primers were used to amplify the LBDs of EphA2 and EphA4 from a cDNA template, 
and these were cloned into the EphA2 and EphA4 ΔLBD constructs previously generated 
using the Gibson assembly protocol. These constructs were then expressed in the 293T 
expression system and purified as discussed in Chapter 3. Yields and purity of both mutants 
were equivalent to EphA2 WT (1.5mg from 250ml supernatant) and migrated equivalently 
to their WT counterparts based on analysis by SDS-PAGE (Figure 4.17B). 
Due to the chimeric nature of these constructs, binding of the EphA2 pAb to determine 
correct folding would not have been informative. Instead, binding to ephrins was used as 
an indicator of correct folding. This was measured by staining the surface of JRT MAU cells, 
as detailed in Chapter 3. Briefly, EphA22L4CF–Fc stained JRT MAU equivalently to WT EphA2-
Fc, and EphA24L2CF-Fc stained JRT MAU equivalently to WT EphA4-Fc (Figure 4.18). 
These domain-swap mutants were subsequently used in the activation assay with JRT MAU 
cells. This revealed that EphA22L4CF-Fc (the construct containing the EphA2 LBD) specifically 
activated JRT MAU at levels equivalent to WT EphA2-Fc. The inverse construct, EphA24L2CF-
Fc failed to activate JRT MAU (Figure 4.19). These results demonstrated that the EphA2 LBD 
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is sufficient for activating JRT MAU. As the presence of the MAU TCR is essential for this 
interaction, this suggested that the MAU TCR binds EphA2 within the LBD. Since previously 
it has been established that ephrin and TCR binding occurs on the same EphA2 molecule, it 
can be concluded that the MAU TCR is binding the EphA2 LBD at a site distinct from the 
ephrin binding pocket. 
This finding contradicts the preliminary AlphaScreen data presented in this chapter, which 
suggested that the TCR binds distal to the EphA2 LBD (Figure 4.16). If this scenario was 
correct, the EphA24L2CF-Fc construct would be expected to activate JRT MAU, with the 
EphA4 LBD providing the ephrin signal, while the TCR would bind the EphA2 portion of the 
construct. Considering the reliability issues associated with the AlphaScreen, further 
characterisation of EphA2-MAU TCR interaction was undertaken using the activation assay. 
4.2.7 Determining the MAU TCR binding site of EphA2 
The data presented so far suggested that the MAU TCR binds the EphA2 LBD, contrary to 
the AlphaScreen data. In order to identify the TCR binding site in this domain, several EphA2 
constructs were designed with mutations at potential TCR binding sites. These ‘patch 
mutants’ were then used in the activation assay to assess their effect on activation of JRT 
MAU. 
To identify potential binding sites, the amino acid sequences of the LBDs of JRT MAU 
activating EphA2 and the non-activating EphA4 were aligned using Clustal147, in order to 
identify non-conserved residues between the two proteins (Figure 4.20). Since ephrin and 
TCR signals originate from the same EphA2 molecule (see Chapter 3), these interactions 
most likely occur at distinct sites. Therefore based on the crystal structure of the EphA2-
ephrinA5 receptor-ligand pair (PDB: 2X10)80 residues either involved in the binding of 
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ephrins, or those predicted to be inaccessible due to involvement in ephrin binding, were 
excluded (Appendix 4.2). In addition, EphA2 residues involved in the formation of 
multimeric signalling complexes were also omitted. These surfaces are important for the 
correct formation of EphA2-ligand clusters upon EphA2 binding ephrins80,145. As ephrin 
binding is essential for the recognition of EphA2 by MAU, this would likely result in 
clustering of EphA2 on the stressed cell. With this in mind, it is conceivable that the TCR 
binding site is unlikely to be located within the EphA2 clustering interfaces, and therefore 
these were also excluded as potential TCR contact residues (Appendix 4.2).  
In addition, the LBDs of EphA2 (PDB code 2X1080) and EphA4 (PDB code 4BK4146) were 
aligned (Figure 4.21), to investigate whether localised conformational changes existed 
between these ephrin receptor molecules which may account for differences in binding to 
MAU TCR. Again, ignoring areas of the LBD involved in clustering and ephrin binding, areas 
which differed structurally were noted. Moreover, comparisons between the liganded (PDB 
code 2X1180) and unliganded (PDB 2X1080) forms of EphA2 LBD were made to determine 
regions that differ in conformation upon binding ephrins, which may also suggest potential 
TCR binding sites. Finally, non-conservative residues that were likely to play a critical role 
in maintaining the overall LBD fold were excluded. For example, residues that are inward-
facing are likely to be involved in stabilising the core domain rather than binding to ligands, 
which is usually facilitated by surface-exposed residues. Combining these different filtering 
processes led to the identification of 18 residues eligible for mutation which were grouped 
according to location into five distinct patches (Figures 4.21 and 4.22). For this study, 
patches 1, 2, 4 and 5 were selected for mutation. Despite meeting the preceding criteria, 
patch 3 was excluded due to its close proximity to the Sushi domain, implying that MAU 
 4 - 124 
TCR is unlikely to interact with this region (Figure 4.22). This strategy yielded a final list of 
candidate residues for mutation (Appendix 4.3). 
Unlike the TCR mutagenesis strategy, the EphA2 patch mutants incorporated more 
conservative substitutions, as several of the residues were close to key structural regions, 
and hence drastic substitutions may have impeded correct protein folding and ephrin 
binding activity. The strategy underlying the introduction of mutations was such that any 
change should hopefully be significant enough to affect TCR binding. With this in mind, 
alanine scanning mutagenesis was deemed inappropriate, as changes may not significantly 
impact TCR binding. Sequence alignments of the LBDs of the ephrin receptor family were 
used (Appendix 4.2) in order to assess which residues could be tolerated at each position 
with minimal impact on the overall fold of the LBD (descriptions of the substitutions are 
detailed in Appendix 4.3). Final sequences are shown in Appendix 4.4. 
For cloning of the patch mutants, mutant LBD regions were synthesised using gBlock 
technology (Integrated DNA Technologies). These were then cloned into the WT EphA2ΔLBD-
Fc constructs using the Gibson assembly methodology. These mutant constructs were then 
transfected into 293T cells and purified by Ni-NTA chelate chromatography as previously 
described. Protein yields were slightly higher than for WT EphA2-Fc, averaging 2mg of 
protein per 250ml of S2 supernatant. SDS-PAGE analysis of Ni-NTA purified EphA2 patch 
mutants revealed that they migrated equivalently to WT EphA2-Fc and displayed similar 
levels of purity (Figure 4.23). Correct folding was again confirmed by surface staining of JRT 
MAU, and all 4 patch mutants stained the surface equivalently, slightly higher than the WT 
EphA2-Fc batch (Figure 4.24A). More importantly, this confirmed that none of the 
mutations had affected ephrin binding to EphA2-Fc. 
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The ability of these EphA2 patch mutants to activate JRT MAU was determined using the 
activation assay. Patch mutants 1, 2 and 4 activated JRT MAU equivalently to WT EphA2, 
whereas EphA2PATCH5-Fc failed to do so, with activation levels comparable to EphA4-Fc 
(Figure 4.24B). These results suggested that the area of EphA2 covered by the patch 5 
mutant is vital for the activation of JRT MAU by EphA2. The observation that EphA2PATCH5-
Fc successfully stained the surface of JRT MAU strongly suggested that this was not due to 
defective ephrin binding, and therefore represents a region that is essential for activation, 
but distinct from ephrin binding. Detailed analysis of patch 5 reveals the exposed nature of 
these mutated residues, and despite their proximity to the ephrin binding pocket, they are 
unlikely to affect the fold of the J-K loop of EphA282, which forms the roof of the ephrin 
binding pocket (Figure 4.25). Furthermore, the side chains of these patch 5 residues do not 
protrude into the binding pocket, and so are unlikely to effect the hydrophobic interactions 
which are likely to energetically drive the ephrin binding interaction. 
Therefore, this approach identified a potential MAU TCR binding site in the LBD of EphA2, 
which is not involved in the binding of ephrins, but critical for the activation of JRT MAU by 
EphA2-Fc. 
4.3 Discussion 
In Chapter 3, the broad requirements for the activation of MAU by EphA2 were established, 
highlighting that both ephrins and MAU TCR were required to interact with the same EphA2 
molecule. This chapter aimed to further characterise the role of the MAU TCR in this 
interaction. 
The results presented in the preceding sections of this chapter strongly suggest that the 
MAU TCR binds EphA2 within the LBD. A surface patch of ~355Å2 on the LBD of EphA2 was 
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also identified as being crucial for the activation of JRT MAU by EphA2-Fc. This region could 
constitute the MAU TCR binding site. 
AlphaScreen was used as a potential methodology to detect direct binding between 
recombinant EphA2-Fc and MAU-Bt. Despite promising early results, the reliability of this 
approach was questioned, and the technique was ultimately not pursued further. During 
the troubleshooting process, it was determined that the AlphaScreen assay was extremely 
sensitive to several variables including buffer conditions and contaminants, which varied 
between protein batches. Such sensitivity renders this assay unsuitable for this study. 
Because of this, conclusive direct binding between EphA2 and MAU TCR has yet to be 
demonstrated, despite strong evidence for this interaction. Undoubtedly, the 
demonstration of direct binding would greatly strengthen the proposal that EphA2 is a 
ligand for the γδ TCR MAU. Therefore it is necessary to expand this study, and explore new 
approaches for the detection of direct binding between these molecules, such as 
Isothermal titration calorimetry, which is used to determine the thermodynamic properties 
of interactions in solution. 
Although the MAU CDR loop mutants were not used in this study due to AlphaScreen 
reliability issues, their design, production and conformational verification provides a strong 
foundation for further research to elucidate the role of the MAU CDR loops in this 
interaction. In lieu of a reliable binding assay to determine the EphA2 binding capability of 
the soluble versions of these mutants, these constructs could readily be cloned into 
lentiviral transduction vectors and expressed as functional, surface-bound TCRs in JRT3 
cells. These transductants could then be used to screen for EphA2 reactivity. As the folding 
capacity of the soluble versions of these mutants has already been verified in this study 
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using BIAcore, it indicates that these TCRs are likely to express well in the JRT3 cells, 
similarly to the WT MAU TCR construct.  
The EphA2/EphA4 LBD swap experiments demonstrated that the EphA2 LBD can confer 
TCR specificity, and is sufficient for activation of JRT MAU. This strongly suggests that the 
MAU TCR binds the LBD of EphA2. This finding directly contradicts the AlphaScreen data, 
which suggested binding betweenEphA2ΔLBD –Fc and MAU-Bt. Although this observation 
carries less weight due to unreliable controls, it could nevertheless represent a legitimate 
result. Indeed, as the results of WT EphA2 binding to MAU-Bt were taken to suggest a 
strong possibility of binding, it is important to consider the EphA2ΔLBD result in the same 
fashion, and therefore establish how these contradictory results align with each other. 
Although the EphA2 4L2CF EphA4/EphA2 domain-swap mutant failed to activate JRT MAU, 
this does not exclude the possibility that the TCR may interact with both LBD and Sushi 
domains, and so the MAU TCR could still bind the EphA2 ΔLBD region in some capacity. It 
is possible that this interaction can be sufficiently detected by AlphaScreen, but is 
inadequate for activating JRT MAU. Conversely, the remaining TCR footprint on the EphA2 
LBD region of the EphA22L4CF-Fc construct may provide sufficient binding affinity to 
successfully activate JRT MAU, without the need for the EphA2 Sushi domain. Another 
possibility, if the AlphaScreen result is valid, is that the EphA2 LBD specifically acts on the 
Sushi domains of both EphA2 and EphA4, conferring TCR binding to this domain. 
To conclusively demonstrate the sole importance of the EphA2 LBD in activating JRT MAU, 
it would be ideal to recombinantly express the EphA2 LBD alone. Attempts to express this 
construct were unsuccessful, despite several constructs reported in the literature produced 
in both 293T82 and Drosophila SF9145 expression systems. Perhaps the engineering of a 
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construct with irrelevant globular domains to promote folding will allow for successful 
expression, and this should be explored further. 
The EphA2 surface patch mutagenesis identified a 355Å2 region of the LBD as crucial for 
the activation of JRT MAU by EphA2-Fc. Despite this patch’s proximity to the ephrin-binding 
pocket of EphA2, successful binding of EphA2PATCH5-Fc to ephrins on the surface of JRT MAU 
demonstrated that ephrin binding was unaffected by this mutation. It may be that this 
patch represents either part of, or the entire TCR binding site. It is also possible however 
that this region is involved in activation of JRT MAU by EphA2-Fc, but does so without 
directly interacting with the MAU TCR. 
By analysing the EphA2/ephrinA5/MAU complex modelling, it is difficult to envisage how 
the TCR could potentially interact with this region, given its proximity to the T cell surface. 
However, as discussed in the modelling section, the molecules involved in this interaction 
are likely to be highly flexible with regard to their position relative to the cell surface, and 
so this possibility cannot be excluded. For example, studies of EphA2 and EphA4 crystal 
structures demonstrate considerable changes in relative orientations upon clustering, 
which likely impact their orientation on the cell surface81. Furthermore, GPI-linked A 
ephrins have been shown to localise in caveolae microdomains, which form small 
invaginations in the plasma membrane148. These are thought facilitate the formation of A 
ephrin signalling complexes148, and it is conceivable that these changes in membrane 
structure may facilitate binding of the MAU TCR to EphA2. 
It is tempting to use these results to computationally model a binding interaction between 
EphA2 and the MAU TCR. However, since the region of the TCR in involved in binding has 
not yet been established, this would likely not yield reliable results, due to the large number 
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of possible binding sites. Therefore, developments in the understanding of which regions 
of the MAU TCR are involved with binding EphA2 are needed to facilitate such modelling. 
A model of the binding mode would provide greater insight into the residues involved, 
allowing for more specific and subtle mutagenesis studies, such as alanine scanning 
mutagenesis. 
It cannot be excluded that the interaction of MAU with EphA2 is facilitated by the V region 
framework regions of the γ and/or δ chains, and not the CDR loops. Such regions would 
appear to be able to more readily interact with Patch 5, as judged by the modelling. Despite 
the proximity of the C domains of the MAU TCR to patch 5 in the model, they are unlikely 
to be involved in binding, as γδ TCRs have only two distinct Cγ regions and one Cδ region149. 
If these regions were providing specificity, many more γδ T cells would demonstrate 
reactivity towards EphA2. 
The ultimate analysis of the binding mode between two proteins could be achieved by 
obtaining a complex structure by X-ray crystallography. This would allow for detailed 
analysis of the residues involved in binding. Typically, receptor/ligand crystallographic 
studies are likely to be challenging for low affinity interactions, however based on the 
finding of the study that the MAU TCR likely binds the EphA2 LBD, crystal complex trials of 
MAU TCR and the EphA2 LBD could be attempted. If the two proteins bind, such an analysis 
would not only confirm this, but also provide unparalleled detail into the nature of the 
binding mode. 
It is possible however that this patch 5 region of EphA2 is not involved with binding to the 
MAU TCR, and plays another critical role in the activation of MAU by EphA2, perhaps by 
interacting with another molecule on the surface of MAU T cells. The previous chapter 
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discussed the possible role of A-ephrins in this interaction as localising Lck to the MAU TCR. 
However, due to A-ephrins’ lack of transmembrane (TM) or cytosolic domains, they likely 
associate with Lck through other TM proteins135. Perhaps these A-ephrin-associated TM 
proteins also interact with EphA2-Fc to facilitate activation of MAU. This could also explain 
the difficulty in obtaining evidence of binding between EphA2 and MAU, as MAU may 
directly interact with these Lck/ephrin-associated molecules, forming a more complicated 
recognition complex. 
In order to identify such molecules, immunoprecipitation experiments could be used to 
extract A-ephrin-associated molecules from activated JRT MAU lysates, and ultimately 
identified by mass spectrometry. 
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4.5 Figures  
Figure 4.1: Structural diversity of γδ TCR ligands 
Structures of a selection of the proposed γδ TCR ligands, grouped into MHC-like (A-D) and 
non-MHC-like (E-G). (A)EPCR (PDB: 1L8J) (B) CD1d (PDB: 4LHU) (C) MICA (PDB: 1B3J) (D) T22 
(PDB: 1C16) (E) EphA2 (PDB: 2X10) (F) F1-ATPase (PDB: 1BMF) (G) BTN3A1 (PDB: 4F80). To 
date, the TCR binding mode has only been described in detail for CD1d (B) and T22 (D). 
Structures not to scale. Structures obtained from the Protein Dank Bank. 
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Figure 4.2: Validation of the AlphaScreen methodology 
(A) Biotinylated rabbit IgG, which binds both the donor and acceptor beads simultaneously, 
was used as a control for the AlphaScreen assay (B) MAU-Bt (0.74µM) and an anti-Vγ9 
antibody (0.15µM) were incubated with both donor and acceptor beads for 2 hours. 
Diagrammatic representation of the experiment shown in each figure. (n=3, error bars =SD). 
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Figure 4.3 : Analysis of the EphA2-Fc/MAU-Bt interaction using AlphaScreen 
(A) EphA2-Fc and MAU-Bt were titrated against each other with both the donor and acceptor 
beads. Optimal concentrations for future experiments is highlighted with a red arrow. (B) Fc-
tagged ephrin receptors were incubated with biotinylated TCRs for 2h at RT, demonstrating 
specific binding between EphA2-Fc and MAU-Bt. 
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Figure 4.5: Stabilisation of the IgV domain of the Phyre-derived MAU δ chain model 
The IgV domain of the MAU δ chain is comprised of 2 characteristic antiparallel β-sheets, 
stabilised by a disulphide bond formed between C23 and C91, an invariant tryptophan residue 
(W36), and multiple non-polar interactions mediated by hydrophobic residues, which are 
represented in stick format. 
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Figure 4.6 : Structural features of the MAU TCR model 
Phyre generated model of the MAU γδ TCR. The CDR loops (red) were identified using IMGT 
and labelled using a two digit system: first digit = Vγ chain and second digit = CDR loop. e.g. 
91 = Vγ9 CDR 1. 
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Figure 4.7: Molecular surface electrostatic analysis of EphA2 and MAU TCR 
Electrostatic potential map were calculated using DelPhi for (A) ephrinA5-bound EphA2 (PDB: 
2X11) and (B) the Phyre generated MAU TCR model. The analysis revealed no distinct 
complementary electropositive/electronegative patches on either molecule. The scale ranges 
from -7 (negative potential, red) to +7 (positive potential, blue) in units of kT/e. 
Structure obtained from the Protein Dank Bank. 
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Figure 4.8: Comparison of the size and structure of EphA2 and MAU TCR 
Structures of the Phyre generated MAU TCR model and ephrinA5 bound EphA2 (PDB: 2X11) 
were manually modelled to compare their size and relative orientation of domains. ‘?’ 
represents the uncertainty with how these molecules are orientated relative to the plasma 
membrane. MAU CDR loops coloured in red. This model suggests that the MAU TCR is not 
prevented from binding any region of EphA2. 
Structure obtained from the Protein Dank Bank. 
MAU T cell 
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Figure 4.9 : Flexibility between the FN1 and FN2 domains of EphA2 
Structural alignment of the EphA2 ectodomain either bound (Blue, PDB: 2X11), and unbound 
(Green, PDB: 2X10) to ephrinA5. This comparison reveals considerable flexibility of 
approximately 71° between the FN1 and FN2 domains, which may impact the orientation of 
EphA2 relative to the cell surface. Structures aligned by FN1 domains. 
Structures obtained from the Protein Dank Bank 
 4 - 141 
  
Figure 4.10: The use of CDR loops in γδ ligand recognition 
Crystal complexes of the 92C TCR complexed with lipid bound (blue spheres) CD1d (A, 
PDB: 4LHU) and G8 TCR complexed with T22 (B, PDB: 1YPZ). Both complexes demonstrate 
the involvement of various CDR loops (red) in ligand recognition. (C) Model of the 
mutation strategy of the MAU Vγ9 CDR3 loop. WT residues 102VQSV105 (left) and MAU 
93 mutant residues 102EWRD105 (right). CDR loops highlighted in red, two digit CDR 
labelling system: first digit = Vγ chain and second digit = CDR loop. e.g. 93 = Vγ9 CDR 3. 
Structures obtained from the Protein Dank Bank. 
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Figure 4.11 : Production of Drosophila S2-derived MAU Vδ1 CDR2 mutant (MAU 12) 
SDS PAGE analysis (Instant Blue) of the MAU 12 mutant reveals discrete γ and δ chains under 
reducing conditions, and a single band representing the TCR under non-reducing conditions. 
The MAU 12 mutant expressed with equivalent yield and purity to the WT control. 
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Figure 4.12 : Verification of MAU 12 folding 
BIAcore analysis demonstrating binding of pan-γδ, anti-Vγ9 and anti-Vδ1 specific mAbs to the 
biotinylated MAU Vδ1 CDR2 mutant (MAU 12-Bt). Number in brackets represents amount of 
TCR immobilised on streptavidin coated CM5 chip. 
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Figure 4.13 : Design of the EphA2ΔLBD construct 
(A) Close-up view of the domain boundary between the LBD and Sushi domains of EphA2. 
C201 was retained in the EphA2ΔLBD-Fc construct as it is involved in forming a disulphide bond 
with C245, and is therefore important for maintaining the Sushi fold (B) Schematic 
representation of EphA2WT and EphA2ΔLBD constructs. Residue numbers represent construct 
boundaries. 
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Figure 4.14 : Production of 293T-derived EphA2ΔLBD-Fc 
SDS PAGE analysis (Instant Blue) of the Ni-NTA purified EphA2ΔLBD-Fc construct under 
reducing (R) and non-reducing (NR) conditions. Yield and purity were equivalent to WT 
EphA2-Fc. 
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Figure 4.15: Verification and characterisation of EphA2ΔLBD-Fc 
(A) BIAcore analysis of anti-EphA2 pAb binding to EphA2ΔLBD-Fc, which was immobilised on a 
R10Z8E9 coated CM5 chip. Number in brackets represents amount of receptor immobilised 
on the chip. Binding to a control protein (EphA4-Fc) was not observed (data not shown). (B) 
Fc-tagged ephrin receptors were bound to a 96-well plate and incubated with JRT MAU cells 
for 4 hours. Activation was measured by CD69 upregulation. EphA2ΔLBD-Fc failed to activate 
JRT MAU. (n=3, error bars =SD). 
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Figure 4.16: Characterising the role of the EphA2 LBD using AlphaScreen 
Fc-tagged Ephrin receptors and biotinylated TCRs were incubated with donor and acceptor 
beads for 2 hours. Specific binding was detected between EphA2ΔLBD-Fc and MAU-Bt. 
Emission:Background ratios for this experiment were substantially than those recorded in 
Figure 4.3, and the AlphsScreen approach was not used further because of these inconsistent 
results. 
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Figure 4.17: Production of EphA2 and EphA4 LBD domain-swap mutants using the 293T 
expression system 
(A) Schematic representation of the EphA2 domain-swap mutants. Residue numbers 
represent construct boundaries. Domains are coloured based on their source protein; blue = 
EphA2 and red = EphA4. (B) SDS PAGE analysis (Instant Blue) of Ni-NTA purified LBD swap 
EphA2-Fc mutants under reducing (R) and non-reducing (NR) conditions. Migration pattern 
and yields equivalent to the WT EphA2-Fc construct. 
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Figure 4.18: Analysis of EphA2 LBD domain-swap mutants binding to ephrins 
JRT MAU cells were stained with Fc-tagged ephrin receptors, which were detected using an 
AF488 conjugated goat anti-human Fc secondary antibody. Equivalent staining was 
demonstrated between each domain-swap mutant and the WT equivalent. (Representative, 
n=3). 
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Figure 4.19: JRT MAU activation potential of the EphA2 LBD domain-swap mutants  
Fc-tagged ephrin receptors were immobilised on a 96-well plate and incubated with JRT MAU 
cells for 4 hours. Activation was measured by CD69 upregulation. EphA22L4CF-Fc activated JRT 
MAU equivalently to the WT construct, demonstrating that the EphA2 LBD is required for 
activation (n=3, error bars =SD). 
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Figure 4.21: Structural comparison of the EphA2 and EphA4 LBDs 
Structural overlay of EphA2 (dark blue) and EphA4 (light blue) LBDs. Potential EphA2 residues 
selected for mutation are highlighted in stick format, and grouped into patches. 
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Figure 4.22: Molecular surface representation of the EphA2/ephrinA5 complex 
Surface patches to be mutated are highlighted in green, and residues involved in the 
formation of EphA2 clustering complexes shown in yellow (Structure obtained from the 
Protein Dank Bank, PDB= 2X11). 
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Figure 4.23: Purification of 293T-derived EphA2 patch mutants 
Reducing SDS PAGE analysis (Instant Blue) of Ni-NTA purified EphA2 patch mutants, 
demonstrating equivalent, yield, migration and purity to the WT EphA2-Fc construct. 
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Figure 4.24: Characterisation of EphA2 surface patch mutants 
(A) Fc-tagged ephrin receptors were sued to stain JRT MAU cells, which were detected using 
an AF488 conjugated goat anti-human Fc secondary antibody. All patch mutants stain JRT 
cells equivalently to the ET construct. (B) Fc-tagged ephrin receptors were immobilised on a 
96-well plate and incubated with JRT MAU cells for 4 hours. Activation was measured by CD69 
upregulation. EphA2PATCH5-Fc failed to activate JRT MAU. (n=3, error bars =SD). 
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5.1 Introduction 
The two preceding chapters have focused on elucidating the molecular basis of the 
interaction between a Vδ1+ γδ T cell, MAU, and an epithelial stress ligand, EphA2. This 
chapter aims to explore the potential of using sequence-level TCR repertoire analysis to 
analyse the γδ T cell compartment in human tissue samples, and to refine these approaches 
to inform future studies. This approach will also be used to explore the diversity of the γδ 
TCR repertoire and to attempt to identify γδ TCRs of interest, such as MAU, as well as 
potential public γδ TCRs in these samples. 
The majority of studies characterising γδ TCRs and their ligands have been focused on T 
cells generated by cloning150. While these studies provide insights into the molecular 
nature of γδ TCR interactions, it is unclear how representative these examples are of the 
whole γδ T cell compartment. Furthermore, as γδ T cell clones are typically derived from 
peripheral blood (PB) for these clone-based studies, it is unclear whether these cells are 
active in PB, or if they can encounter ligand in that environment. For example, the MAU γδ 
T cell clone was derived from an expanded Vδ2negative γδ T cell population in PB of a renal 
transplant patient73. However, as the previous chapters in this study have discussed, the 
putative ligand for this clone is an epithelial stress ligand, and Vδ1+ γδ T cells are thought 
to predominantly be associated with epithelial surfaces2. Furthermore, the MAU clone 
expressed high levels of integrin β7, which is associated with gut localisation73. It is 
therefore preferable to research such cells in the environment in which they are active and 
encounter ligand and therefore in this study I will investigate the repertoire in two tissue 
types, liver and colon, which have been demonstrated to contain large numbers of Vδ1+ γδ 
T cells2. 
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The intestinal mucosa consists of an epithelial layer and underlying connective tissue 
known as the lamina propria (LP). Colonic lymphocytes are found in both compartments 
and are characterised depending on their tissue sublocalisation. Intraepithelial 
lymphocytes (IELs) are present in the intercellular space between the epithelial cells of 
mucosal linings, and lamina propria lymphocytes (LPLs) are present in the LP151 (Figure 5.1). 
In mice, the IEL population is largely populated by Vγ7+ γδ T cells152, which is suggestive of 
a clonal population, although this has yet to be determined. 
Previous studies have suggested that in humans, these IEL and LPL populations are distinct, 
with individual functional and TCR profiles153, although there is evidence that γδ T cells can 
migrate from the epithelium into the LP in mice upon microbial challenge154. This highlights 
the potential difference between tissue subsets, let alone between blood and tissues, 
further emphasizing the need to expand on blood-focused γδ T cell studies by analysing γδ 
T cells in tissues. 
Repertoire analysis is a powerful tool which has been used extensively to study populations 
of αβ T cells in various infections and diseases155. Despite this, there has been no extensive 
repertoire analysis of γδ T cell populations at the TCR sequence-level, and it is unclear 
whether the human γδ repertoire will be diverse or of limited diversity as observed in 
murine epithelial γδ compartments. Spectratyping analysis has been used to classify 
populations of γδ T cells and provide limited information on V region usage, particularly in 
response to CMV infection56. While these studies provide some information on how the 
size and proportions of γδ T cell repertoires alter in response to infection, they have failed 
to provide information on individual TCR usages, which is only possible with sequence-level 
TCR analysis. Furthermore, repertoire studies have the potential to facilitate more targeted 
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and unbiased γδ T cell ligand identification. Critically, such approaches allow for the 
identification of γδ T cell populations that are likely to play a physiological role in response 
to infection, which can then be characterised at a molecular level. 
Sequence-level TCR repertoire analysis techniques can broadly be characterised into either 
DNA-based or RNA-based155. DNA-based approaches, such as the immunoSEQ platform 
(Adaptive Biosystems), amplify recombined genomic DNA regions using V and J region 
specific primers116, and these PCR products are then sequenced. RNA-based approaches, 
such as the anchored 5’-RACE (rapid amplification of cDNA ends) methodology, generate 
cDNA from mRNA sequences, from which TCR specific sequences are subsequently 
sequenced117. For this study the DNA-based immunoSEQ platform was selected, as it is 
capable of deeper sequence analysis than the RNA methodology available during this study, 
allowing for the detection of lower abundance sequences117. At the time of this study, 
immunoSEQ offered only γ chain analysis, and so all sequences discussed in this chapter 
represent only the γ chain, and therefore no δ chain information is available. 
This chapter will explore the feasibility of using DNA-based high throughput, sequence-
level TCR repertoire analysis to investigate γδ T cell repertoires in human tissue samples, 
and to refine such approaches to shape future experiments. This constitutes a brief analysis 
of the γ chains of γδ T cell populations in three human samples, two colon and one liver. 
Finally, sample preparation and processing techniques to prepare human tissue samples 
for these analyses will be developed and advanced. 
Because of the low number of samples, limited conclusions about these samples can be 
drawn. However, these studies provide valuable insights into the data, as well as potential 
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differences which can be exploited to inform more comprehensive hypothesis-driven 
studies. 
5.2 Results 
5.2.1 Sample preparation 
Refinement of tissue preparation techniques was performed on numerous samples prior 
to the ones selected for repertoire analysis, and the following section details this process. 
Preparation of tissue samples was either carried out mechanically or enzymatically. The 
liver samples were not to be separated into tissue sub-populations, and so mechanical 
digestion was used to isolate lymphocytes from the whole tissue. The colon samples were 
to be separated by tissue compartment, into IEL and LPL populations. Therefore a 
combination of chemical and enzymatic digestion was used to specifically disrupt the tissue 
structures containing the required lymphocytes. 
The luminal facing epithelial surface of colon tissue was specifically disrupted using a 
combination of EDTA and DTT to disrupt the cadherin-mediated cell-cell junctions of the 
epithelium, thus releasing IELs156. As this approach does not disrupt the basal membrane, 
LPLs should remain in the tissue. To release the LPLs, collagenase A was used on the 
EDTA/DTT-treated samples to digest the basal membrane and liberate the LPLs (Figure 5.1). 
Several strategies were used to verify the isolation of pure IEL and LPL populations. Firstly, 
the number of cells released from the tissue after each successive EDTA/DTT treatment 
was measured. The absolute cell number in the media following washing plateaus after the 
second 20 minute treatment suggested that 3 to 4 washes of a sample this size results in 
the complete removal of the IEL population (Figure 5.2A). Secondly, a study has suggested 
  5 - 162 
that the FSC and SSC profiles of IEL and LPL populations in rats are distinct when analysed 
by flow cytometry156. This pattern was also observed with these colon samples, as the LPL 
populations appeared to be larger and more granular than their IEL counterparts, 
suggesting successful isolation of distinct lymphocyte populations from the colon (Figure 
5.2B). 
Finally, the tissues were imaged at various stages of the digestion process to visualise the 
tissue disruption. Four samples were analysed in total, one of the native tissue, one after 2 
and 4 EDTA/DTT treatments and one after 4 collagenase washes. These samples were fixed, 
sectioned and then visualised by hematoxylin and eosin (H&E) staining (Figure 5.3). These 
images demonstrate incremental disruption of the epithelial cells after EDTA/DTT 
treatment, compared to the native sample, in line with previous studies156. It is also 
apparent that the EDTA/DTT treatment does not disrupt the basal membrane of the tissue, 
which is fully intact, with the tissue maintaining the original architecture of the crypts 
(Figure 5.3B, C). However, despite their disrupted morphology, epithelial cells are still 
present in the crypts after four treatments of EDTA/DTT. Colon tissue treated with 
collagenase demonstrates considerable disruption of the tissue histology, with no clearly 
distinct crypt architecture present, and complete disruption of the basal membrane (Figure 
5.3D). 
Collectively, these data suggest that two discrete populations of lymphocytes are being 
isolated by this colon sample preparation protocol. The imaging data demonstrate that the 
basal membrane is not disrupted by the EDTA/DTT treatment, which strongly suggests that 
the isolated IEL population is devoid of LPLs, which were still in the LP, contained by the 
basal membrane. However, it is less clear whether IELs are present in the LPL population. 
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Although EDTA/DTT treatments were applied until no more cells were released, this does 
not necessarily imply complete disruption of the epithelium, and may represent the limits 
of the reagents or approach used. Furthermore, the imaging data demonstrate that 
epithelial cells are still present in the tissue despite 4 treatments with EDTA/DTT, 
suggesting that IELs may also still be present in the tissue following this treatment, and 
therefore could be released by the collagenase treatment into the LPL population, which 
should be considered when analysing the results. 
A further tissue processing technique which was refined was the purification of γδ T cells. 
Rearrangement of the γ TCR chain is an early recombination event in the development of 
T cells, concurrent with β and δ chain rearrangement. Therefore, the γ chain is recombined 
in some αβ T cells, as well as γδ T cells157. The immunoSEQ platform specifically amplifies 
recombined γ chains, and so if αβ cells were present in the sample, their γ chains would be 
sequenced, even though they do not represent surface-expressed γδ TCRs. To avoid this, 
two approaches were compared for the removal of αβ T cells from the single cell 
suspension from both colon and liver samples. Magnetic beads (Miltenyi) were used to 
either select cells expressing the γδ TCR (positive selection, data not shown), or deplete 
cells expressing an αβ TCR (negative selection). Negative selection resulted in the highest 
purity of γδ T cells in the CD3+ lymphocyte population, with up to 99.9% purity (Figure 5.4). 
Following this refinement, several samples were processed and analysed by immunoSEQ. 
A summary of these samples used in this analysis is shown in Table 5.1. 
  5 - 164 
5.2.2 Contamination and the presence of PB-associated γ chains 
Initial analysis of the repertoire sequencing data revealed significant contamination of γδ 
TCR γ chains, as well as the presence of typically pAg reactive Vγ9Vδ2 PB-associated Vγ9 
sequences. 
The γ chain sequence for the MAU γδ TCR was present in considerable frequencies in all 
samples and represented up to 90% of sequences (Figure 5.5A). This is likely due to 
contamination of MAU γ chain DNA used for cloning experiments in the Willcox laboratory. 
Furthermore, a significant portion of these contaminant sequences matched the mutants 
generated for MAU TCR mutagenesis studies outlined in Chapter 4. This suggested that 
these sequences are a result of contamination rather than being genuinely present in the 
tissues. Therefore, these sequences were disregarded from the subsequent analyses. 
However, this resulted in potential MAU γ chain sequences legitimately present in the 
tissue being excluded from the analysis, as it is not possible to differentiate between 
contamination and sequences present in the original sample. 
γ chain sequences associated with the pAg reactive Vγ9Vδ2 PB subset of γδ T cells were 
also identified in some of the samples (Figure 5.5B). The Vγ9Vδ2 γ chain typically comprises 
the Vγ9 V gene segment paired with the JgP*01 joining segment, with the amino acid motif 
*ELG* in the CDR3 region59. Such sequences were highly prevalent in the liver sample, 
representing 12% of all γ chain sequences. This blood subset signature was also present in 
both the IEL and LPL populations of the S024141 colon sample. The presence of the PB-
associated γ chain in these tissues may be due to the manner in which the samples are 
washed and processed following resection, and prior to samples being received in our 
laboratory. Also, the tissue extraction method used to isolate T cells may result in the 
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presence of PB-associated γ chains in the samples. For example, the liver samples were 
mechanically digested, and perhaps this is more likely to disrupt blood vessels in the tissue 
compared to colon samples that were subjected to more specific enzymatic treatments. 
Moreover, it may also be that there are inherent differences in the vascularisation of the 
tissue types. 
It is unclear whether the PB-associated γ chain sequences are from blood present in the 
tissue or constitute a component of the tissue resident γδ TCR repertoire. For these 
reasons, cells with this signature were excluded from further analysis in this study. 
However, as will be shown in Chapter 6, γ chains bearing the PB motif can sometimes pair 
with non Vδ2 δ chains, and so these will not be represented. Finally, sequences which were 
unproductive, or contained either pseudo-gene or non-functional gene segments according 
to the IMGT (Vγ1, Vγ6, Vγ7, Vγ10, Vγ11) were also excluded from the analysis144. 
5.2.3 Clonality and shared sequences 
Clonality of a repertoire is an important metric, and is currently not well understood for 
human γδ T cell repertoires, particularly in tissues. High degrees of clonality are often 
associated with γδ T cell populations, particularly in response to CMV infection56,158. While 
these clonality measurements can provide useful information on the physiological role of 
γδ T cells in these conditions, limited studies have been carried out on the individual γδ 
TCRs that constitute these populations. 
Clonality of the repertoires can be analysed in several ways. Firstly, the abundance of the 
10 most prevalent sequences in each sample was plotted, excluding MAU and PB-
associated sequences, as previously discussed (Figure 5.6A). This analysis demonstrates 
that all of the samples have approximately equivalent abundance and diversity of their top 
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sequences, with the top sequence in each sample representing between 11% and 20% of 
all sequences. Aside from these most abundant sequences, the remainder of the repertoire 
appears to be relatively diverse, with the frequency of sequences plateauing after the first 
3 top ranking sequences. The clonality metric allows for the quantification of the diversity 
of sequences in the repertoire analysis, and direct comparison of clonality between 
samples of the same analysis. The clonality ranges from 0 (diverse, with equal 
representation of all sequences) to 1 (clonal, only one sequence is present) (Figure 5.6A). 
This clonality measurement is similar for all 5 samples analysed, ranging between 0.19 and 
0.29. This suggested a similar diversity of sequences between all samples. This metric is 
derived from the normalised Shannon entropy of the TCR γ frequency distribution, which 
is a measure of the uncertainty in the distribution of the frequencies of the sequences159. 
The equation for this calculation is shown below, where 𝑛 represents the total number of 
sequences in the sample, and 𝑝𝑖 is the fraction of residues of sequence 𝑖: 
Clonality =  1 − (− ∑
𝑝𝑖 log10 𝑝𝑖
log10 𝑛
𝑛
𝑖=1
) 
Sequence overlap is represented as a proportion of sequences shared between samples 
(Figure 5.6B). This analysis reveals that the IEL and LPL populations within an individual 
contain a large number of shared sequences, compared to the equivalent populations 
between donors. For example, the S024121 IEL and LPL populations share ~90% of their γ 
chain sequences. This data therefore suggests that in these samples, the IELs and LPLs are 
not distinct populations, and share a substantial number of γ chain sequences.  
To determine whether there was any overlap in these top sequences between samples, the 
top 10 most abundant sequences from each sample were analysed (Figure 5.7). None of 
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the top 10 ranking sequences for any sample were present between samples derived from 
different patients, suggesting highly private, non-overlapping repertoires of γ chains in 
these tissues. There is a high degree of shared sequences between the IEL and LPL 
population of each colon sample, again reinforcing that these populations do not appear 
to have distinct γδ T cell repertoires. 
5.2.4 V region usage 
The sequence data collected in this study also allow for the comparison of γ chain V region 
usage between samples. V region usage for both γ and δ chains is thought to be strongly 
associated with the localisation and function of γδ T cells8. For example, the pAg reactive 
PB subset invariably use the Vγ9 and Vδ2 gene segments. Therefore improved 
understanding of V region usage in tissues may allow for similar characterisation of 
potentially tissue-associated γδ T cell subsets. 
Similar to the sequence overlap analysis discussed previously in this chapter, this 
comparison revealed similar V region usage of γ chain sequences between the IEL and LPL 
populations of the individual colon samples (Figure 5.8A). Between patients however, the 
V region usage is less conserved. This further supports the observation that the IEL and LPL 
compartments are not distinct with regards to their γ chain sequences. Due to the small 
sample sizes, it was not prudent to analyse particular V region usage patterns of the 
samples, but this has demonstrated the potential importance of such studies in the future. 
A further analysis investigated the clonality of sequences with particular V region usage, 
which is only possible with sequence-level TCR data. All of the samples were combined for 
this analysis, as when analysed individually, a similar pattern was apparent for all of the 
samples. This suggests that these patterns may relate to many repertoires and therefore 
  5 - 168 
warrants further investigation (data not shown). This analysis compared the frequency of 
the V region usage with the proportion of unique sequences which constitute that V region, 
again omitting MAU and PB-associated sequences (Figure 5.8B). For these samples, ~5% of 
sequences contained the Vγ9 gene segment, but these chains contained over 30% of the 
unique nucleotide sequences. This suggests that γ chains containing Vγ9 gene segment are 
relatively diverse in these samples with regards to their CDR3 region. In contrast, Vγ8 chains 
account for proportionally much fewer unique nucleotide sequences, suggesting that 
chains containing this V segment have less diverse CDR3 regions. 
5.2.5 Identification of clones of interest 
Repertoire studies can also be used to identify previously published clones, or clones 
currently being investigated in various samples (Table 5.2). This provides information on 
their relative abundance, information which is not available during the cloning process. 
This study revealed the presence of several γ chain sequences from both published clones 
and TCRs currently being investigated by various groups (Figure 5.9). Most of these 
sequences are present at low levels and do not constitute the top ranking sequences for 
each sample. As discussed previously in this chapter, the high prevalence of the MAU γ 
chain in these samples means it was excluded from this analysis. The LES γ chain was 
observed in several of the samples, up to 6% in sample S026278I. However, this DNA 
sequence has also been used in cloning experiments in the Willcox laboratory, and so 
although not present at exceptionally high levels in all samples like MAU, it cannot be 
excluded that this also represents contamination. Alternatively, the LES Vγ4 chain is a fairly 
simple rearrangement, as it does not include many N-nucleotide additions, and so is more 
likely to be produced by recombination events than chains with more complicated 
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rearrangements, which may explain its relatively substantial presence in these samples 
compared to other γ chains123. 
Despite the uncertainty with clones being researched by our group due to contamination, 
this study has demonstrated that this approach is viable for analysing the presence of these 
clones, and give useful information as to their relative abundance, which may have 
implications for their physiological functions. 
5.3 Discussion 
In this chapter I aimed to determine the feasibility of using sequence-level repertoire 
studies to analyse the γδ TCR compartment in human tissue samples. Repertoire studies 
investigating αβ T cells have greatly increased the understanding of how these cells 
respond to various viral infections at a population level, and are currently being expanded 
to include diagnostic applications155. However, to date there has been limited sequence-
level repertoire analysis of human γδ T cells, and hopefully such studies will increase the 
understanding of how these cells function. Although the sample number in this study is too 
low to draw many significant conclusions, these experiments have provided valuable 
insights into the limitations and possibilities of repertoire studies on γδ T cells in human 
tissue samples. 
This study revealed significant issues with using DNA-based repertoire sequencing in our 
laboratory. Primarily, the sequencing methodology is extremely sensitive, and as a result, 
background contamination from DNA constructs used in the Willcox laboratory were 
sequenced. Although further steps can be taken to prevent such contamination, such as 
ensuring procedures are carried out in a PCR clean environment as much as possible, this 
is logistically difficult when dealing with patient samples. Furthermore, over 50 unique 
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sequences which matched the MAU γ chain CDR3 region were detected. These sequences 
all differed in the germline-encoded V gene segment, and therefore are not products of 
recombination (data not shown). It is likely that these sequences represent intermediate 
PCR products generated during the MAU TCR mutagenesis study, as the V regions align with 
the SDM primer complementarity regions. This further demonstrates the sensitivity of the 
immunoSEQ platform, and the difficulty in processing of samples in a laboratory which 
routinely handles γδ TCR DNA. To control for contamination in samples, media controls can 
be used containing no T cells, which would provide a baseline which can be subtracted from 
samples to differentiate between contaminant sequences and sequences present in the 
samples. However, due to the relatively large cost per sample of this technique, this would 
significantly increase the cost of the study, and work would have to be done to ensure 
contamination levels in the controls are equivalent to those in the samples. Using an RNA-
based repertoire analysis would also mitigate these DNA contamination issues, due to the 
specific amplification of cDNA constructs generated by the reverse transcription of 
mRNA117. 
Further issues were encountered with the preparation of the colon samples and the 
generation of pure IEL and LPL populations from colon tissue. The experiments regarding 
the development of the isolation protocols suggested that distinct populations were 
generated from the assay, however the sub populations in each colon sample analysed 
demonstrated considerable sequence overlap and V region usage profiles, which does not 
align completely with previously published reports153. It could be that the IEL and LPL 
populations in these colon samples are not discrete compartments, and their γ chain 
repertoires are not specific to each compartment. However, it may also be that the tissue 
preparation protocol has not successfully produced two pure populations, and are thus 
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represented as demonstrating substantial overlap. Although the imaging data revealed 
clear disruption of the epithelial cells after EDTA/DTT treatment, some epithelial cells were 
still present. Whether these remaining cells still include IELs is unclear, and if these cells are 
still present in the tissue used for collagenase treatment, then IELs would be expected to 
be present in the LPL population. What is clear from the imaging data is that the EDTA/DTT 
treatment does not disrupt the basal membrane, strongly suggesting that the IEL 
population does not contain any LPLs, and so studies focusing on IEL populations are 
unlikely to be affected by the presence of LPLs. 
To clarify this situation, immunostaining could be used to detect CD3+ cells in the fixed 
samples, and study their localisation over the course of the treatments. This confirmation 
would allow for more reliable comparison of the IEL and LPL populations, and determine 
whether they contain distinct repertoires of γδ T cells, which would provide novel insights 
into the immunobiology of gut-associated γδ T cells in humans. 
Furthermore, the presence of γ chain sequences commonly associated with the PB-
associated Vγ9Vδ2+ TCRs emphasizes the importance of large sample sizes and consistency 
in the handling of these tissue samples. It is unclear whether these sequences are tissue-
associated or present as a result of blood in the tissue.  
Despite the limitations of this study, several key observations were made, which provide 
novel insights into the role of γδ T cells in these tissues. Firstly, analysis of the top 10 ranking 
sequences in each sample revealed that none of these sequences are shared between 
patient samples, although there is considerable overlap between the IEL and LPL sub-
populations of the colon samples. This suggests that the γδ T cell compartment in the colon 
is private, although the sample size is too small to draw definitive conclusions. 
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Secondly, the γ chain V region usage and clonality analysis provided insights into the V 
region usage profiles of γδ T cells, as well as the clonality of γ chains containing particular 
V regions. The analysis demonstrated that γ chains containing the Vγ9 gene segment have 
more diverse CDR3 regions than γ chains containing other V regions. Conversely, Vγ8 
containing γ chains are less diverse in terms of CDR3 region. These findings could provide 
novel insights into the immunobiology of Vγ9+ and Vγ8+ γδ T cells in these tissues, implying 
that different γ chains may participate differently in the immune response. Interestingly 
these findings are consistent among all of the samples analysed, suggesting that this may 
apply to Vγ9 and Vγ8 chains from various tissues, which warrants further study. 
Finally, an omission from repertoire studies using this platform is the δ chain. Although γ 
chain sequences can provide novel insights into the immunobiology of tissue-associated γδ 
T cells, γδ TCRs function as heterodimeric antigen receptors, therefore information about 
δ chain sequences as well chain pairing is critical to fully understand these subsets. 
Overall, the data presented in this chapter strongly suggest that, despite the inherent 
difficulties in handling human tissue samples, repertoire analysis of tissue-associated γδ T 
cells could provide unique insights into the immunobiology of these cells, and therefore 
justifies pursuing further controlled, hypothesis-driven studies. Therefore, in the next 
chapter I specifically address the hypothesis that CMV infection results in clonal expansion 
of Vδ2negative γδ T cell populations in the blood. 
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5.4 Tables 
  
Table 5.1: Overview of the samples used in the immunoSEQ analysis  
Sample column denotes how data sets are referenced through the text. Subpopulation 
identifies the either the IEL or LPL population of the colon sample. 
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Clone Vγ Jγ CDR3 Cγ Ref 
LES 4 1*01 CATWDGFYYKKLF 1a 123 
CHAM 4 1*01 CATWEGYKKLF 1b 123 
POS4 8 P1*01 CATWDTTGWFKIF 1b 109 
Wendy 9 P*01 CALWEVTELGKKIKVF 1b N/A 
Clone 26 9 2*01 CALWEGNHYYKKLF 2 N/A 
Table 5.2: γδ clones of interest 
CDR3 amino acid sequences of γ chains from γδ clones either published or currently under 
investigation in various laboratories. 
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5.5 Figures 
  
Image modified from160 
Figure 5.1: Overview of colon histology 
Intraepithelial lymphocytes (IELs) are contained within the lumen facing epithelium, 
which is separated from the lamina propria lymphocyte (LPL) containing lamina propria 
(LP) by the basal membrane. Top-down view of the luminal surface. H&E Stain, 40X 
Magnification. 
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Figure 5.2: Validation of chemical and enzymatic disruption of colon samples 
(A) Colon samples were treated with EDTA/DTT to disrupt the epithelium, and the number of 
cells released into the supernatant was counted. The number of cells being removed by the 
EDTA/DTT treatment plateaus after the second treatment. (B) The size and granularity (FSC 
and SSC profiles) of cell populations from the IEL and LPL samples are distinct. 
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Figure 5.4: Depletion of αβ T cells from single cell suspensions 
αβ T cells were depleted from the single cell suspensions of liver and colon samples using 
magnetic bead based separation. An anti αβ PE-conjugated antibody was used to stain αβ T 
cells, and PE-conjugated magnetic beads were used to select stained cells. Representative 
example from IEL and LPL populations from a colon sample. 
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Figure 5.5: Contamination of samples by MAU and the presence of PB-associated γ chains 
(A) The MAU γ chain nucleotide sequence was present at high levels in all samples analysed. 
(B) γ chains associated with the pAg reactive PB γδ T cell subset present in the majority of 
samples. 
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Figure 5.6: Diversity and overlap of γ chain sequences 
(A) Frequency of the top 10 ranking γ chain sequences for each sample. Sequence frequency 
plateaus rapidly after the top 2-3 clones. Clonality was quantified using the clonality index, 
which was similar for all samples. (Rang 0-1. 0= Diverse, 1=Clonal). (B) Proportion of 
sequences shared between samples. Relative colour coding ranks overlap from green (low) 
to red (high). 
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Figure 5.7: Overlap of top ranking sequences 
The highest 10 ranking sequences for each sample plotted for all samples. Each of the top 50 
sequences only present in samples from the same patient, with shared sequences designated 
by a coloured line. Sequences not present plotted with no line. 
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Figure 5.8: γ chain V region usage and clonality 
(A) V region usage of γ chain sequences in each sample. (B) Comparison of V region frequency 
and percentage of unique nucleotide sequences to signify clonality by V region in all samples 
(pooled). MAU and PB-associated γ chains were excluded from this analysis. 
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Figure 5.9: Identifying clones of interest in sequencing data 
Frequency of γ chains from γδ clones either published or currently under investigation in 
various laboratories across all samples. Clone detailed are listed in Table 5.2. 
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6.1 Introduction 
In Chapter 5, sequence-level repertoire analysis of γδ TCRs was established as a viable and 
useful approach for analysing γδ T cell populations in human tissue samples. In this chapter, 
these results were expanded by using repertoire analysis to characterise the effect of 
chronic CMV infection on the Vδ1+ γδ T cell repertoire in PB of healthy donors. 
CMV is a double-stranded DNA β-herpes virus which chronically infects between 50- 90% 
of the population52. Following acute infection, CMV enters a non-symptomatic latent 
phase, characterised by a reduction in the production and expression of viral proteins53. 
Initiation and maintenance of this latent cycle is thought to be largely influenced by chronic 
immune-suppression of the CMV lytic processes53. Therefore, CMV reactivation often 
occurs in immunocompromised patients, and can result in severe clinical implications54. 
CMV reactivation can be treated with adoptive transfer of CD8+ αβ T cells161, further 
demonstrating the importance of the immune system in maintaining a safe, latent 
infection. 
CMV infection has been directly implicated in the induction of both transient and 
permanent changes to the immune system. For example, infection often drives the clonal 
expansion of highly differentiated memory CD8+ αβ T cells162, with individual CMV-specific 
CD8+ T cells occasionally representing up to 10% of the total T cell compartment163. These 
expansions are more pronounced in elderly donors164, and this process is reflective of 
immune senescence, which is characterised by an increase in memory responses whilst 
immune responsiveness to new challenges is decreased165. 
γδ T cells, particularly the Vδ2negative subset, have also been predicted to contribute towards 
the immune response to CMV, perhaps in a complementary manner to CD8+ αβ T cells46. 
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One of the immune evasion strategies of CMV is to inhibit the loading of class I MHC 
molecules with peptide166, a strategy ineffective at inhibiting γδ T cells due to their non-
MHC-restricted ligand recognition. Therefore γδ T cells may play a role in controlling virally 
infected cells which have evaded detection by αβ T cells. Large expansions of Vδ2negative γδ 
T cells are often observed in the PB of immunocompromised CMV-seropositive donors46 as 
well as, to some extent, in healthy individuals158. This strongly suggests that these cells are 
somehow involved in the immune response to CMV. Indeed, expansions of γδ T cells in 
CMV reactivation in immunocompromised transplant patients correlates with resolution of 
viraemia, suggesting a protective antiviral role for these cells55. Finally, several Vδ2negative 
γδ T cell clones, including MAU and LES, were established from donors possessing such 
expansions73. Strikingly, the LES clone represented 25% of patient T cells, and the LES γδ 
TCR ligand, EPCR, is present on CMV infected cells and critical for CMV-dependent 
recognition by the LES clone123. However, as these TCRs were isolated by cloning, it is 
currently unclear how representative these examples are of the whole subset. 
Similar to CMV specific αβ T cells, these expanded Vδ2negative populations are highly 
differentiated158, and spectratyping studies often characterise these expansions as 
oligoclonal46,56, suggesting that the expansion is antigen-driven. Such studies provide no 
information on the particular γδ TCR chains present in these populations however, and 
cannot determine diversity of recombined CDR3 regions which, according to the previous 
structural studies highlighted in Chapters 3 and 4, play a critical role in the recognition of 
ligands for γδ TCRs50,51. Furthermore, it is important to determine whether these expanded 
populations are private or public, with common γδ TCR chains shared between the donors, 
as this may have implications for the ligands and ligand recognition strategies for these 
receptors. 
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Increased understanding of how γδ T cells interact with this model virus may expand the 
potential for advances in existing treatments. For example, immunotherapeutic strategies 
based on adoptive transfer of CMV-specific CD8+ αβ T cells are currently used in 
immunocompromised patients undergoing CMV reactivation161, and there is potential for 
these to be replaced with γδ T cells, which are not MHC-restricted and therefore can be 
applied more broadly and overcome MHC down regulation, a common immune evasion 
mechanism of CMV. 
To address these questions, I analysed Vδ2negative γδ T cell populations from the PB of 
healthy donors, and analysed the TCR repertoire of 6 donors at the sequence-level, 
constituting the first analysis of this type. Unlike in the previous chapter which utilised a 
genomic DNA-based amplification technology, an anchored 5’-RACE RNA approach was 
used for repertoire analysis of these samples, as this technique allows for the simultaneous 
analysis of both the γ and δ chains of γδ T cells in these samples, although it does not 
provide conclusive information on chain pairings. Furthermore, the DNA contamination 
issues encountered with the immunoSEQ technology are likely not to effect this study, as 
sequences generated by the reverse transcription of mRNA are specifically sequenced117. 
6.2 Results 
6.2.1 Study design and development 
When designing studies involving patient samples it is important to consider the wide 
variation present in many aspects of these samples. The immune system is a highly adaptive 
and dynamic collection of cells which respond rapidly to a wide range of environmental 
stimuli, and these stimuli can have large effects on the size and distribution of various 
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immune cells. Immune senescence results in the abundance of highly differentiated 
memory T cells, which leaves little proliferative ‘space’ for the expansion of naïve T cells 
after encountering antigen, hence reducing the adaptive ability of the immune system165. 
This has mainly been described for αβ T cells in chronic CMV infection, with expansions of 
highly differentiated effector memory cells163. 
It is therefore important when considering changes in the immune repertoire due to CMV 
infection for age to be controlled. Both age and CMV infection have been demonstrated to 
act independently on the Vδ2negative subset of γδ T cells in the PB of donors167. The Vδ2negative 
γδ T cell population was observed to decrease with age, but increase in response to chronic 
CMV infection. In aging CMV-seropositive donors, the ageing-related decrease in the 
Vδ2negative compartment was counteracted by the effect of CMV, resulting in the 
maintenance of a relatively stable Vδ2negative population. The Vδ2+ PB population of γδ T 
cells was found to be unaffected by both of these factors167. The most prominent difference 
in the Vδ2negative population is observed in the youngest donor group (median age 23.96 
years), who are not also experiencing a decrease in Vδ2negative cells due to age. Therefore 
for this study donors under the age of 30 were selected and analysed, to control for the 
effect of age on the Vδ2negative population. 
Sample size is a further consideration when designing comparative experiments using 
donor blood samples. As previously mentioned, the immune compartment is highly 
dynamic, and responds rapidly to a range of stimuli. Donors may also have other chronic 
viral infections such as EBV, which has also been shown to permanently alter the T cell 
compartment168. In addition, exercise prior to blood donation has been shown to 
significantly affect the makeup of the γδ T cell compartment169. Ideally, a large sample size 
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is therefore required to account for these uncontrollable variables, in order to minimise 
the impact of natural variation on the significance of the results. While this is more readily 
achievable in more focused studies, such as flow cytometry and spectratyping, repertoire 
studies are often considerably more expensive and time-consuming, and so large sample 
sizes are not necessarily always possible. 
For this study, 3 CMV-seropositive and 3 CMV-seronegative age-matched donors were 
selected. CMV-serostatus in these donors was determined by ELISA, which detected CMV 
antigen-specific antibodies in the plasma of the donors. 
6.2.1.1 Immune profiling 
Peripheral blood mononuclear cells (PBMCs) were isolated from PB and analysed using flow 
cytometry. Samples were stained with three antibody panels, each containing different 
combinations of antibodies and conjugates, to provide a comprehensive analysis of the γδ 
T cells in these samples. These panels are detailed in Table 2.3. 
Initially it was intended that all Vδ2negative γδ T cells were to be sorted by fluorescence 
activated cell sorting (FACS) using a combination of pan-γδ and Vδ2 antibodies that has 
been used previously56,167. Upon closer inspection of the staining data, it appeared that the 
Vδ2-FITC and pan-γδ-PE antibodies cannot be used in combination, as in some donors the 
number of Vδ2+ γδ T cells identified was substantially lower than in the panel in which the 
Vδ2-PE antibody was used without a pan-γδ antibody (Figure 6.1). This suggested that in 
some donors, the epitopes for the two antibodies were similar or overlapped, resulting in 
competition to occupy the epitope and hence a decrease in the number of Vδ2+ cells 
reported, therefore suggesting the presence of Vδ2+ cells in the Vδ2negative population. For 
this reason it was decided to instead sort on the Vδ1+, CD3+ T cell population, an antibody 
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combination which has not demonstrated such issues previously in our group. While this 
strategy omits both the Vδ3 and Vδ5 chains, the majority of Vδ2negative γδ T cells in most 
donors is comprised of Vδ1+ cells, when analysed with the ‘Phenotyping’ panel (Table 2.3 
and data not shown). Furthermore this approach would also provide limited chain pairing 
information, as all γ chains sequenced would be paired with a Vδ1 chain, although specific 
chain pairings would not necessarily be known. An example of the phenotypic analysis is 
shown in Figure 6.2. 
The Vδ1+ population was not found to be expanded in the CMV-seropositive donors when 
analysed by flow cytometry (Figure 6.3A). Also, no expansions of Vγ9Vδ1+ populations were 
observed in this cohort (Figure 6.3B). 
6.2.2 Analysis of sequencing data 
Vδ1+ γδ T cells were isolated by FACS, and the anchored 5’-RACE TCR sequencing protocol 
(Detailed in section 2.6.2) was conducted by our collaborator Professor David Price at the 
University of Cardiff. cDNA products amplified by Cγ/Cδ specific and anchor-
complementary primers were cloned in to E. coli, and 96 transformed colonies were 
selected for sequencing. The sequence results for the 6 samples are included as Appendix 
6.2. 
Initial analysis of the data demonstrated that all but two δ chains contained the Vδ1 gene 
segment, with the two exceptions containing the Vδ2 and Vδ5 gene segments. These 
sequences may have arisen from cells in which the Vδ2 or Vδ5 were successfully 
recombined on one chromosome, but due to the relative low stringency of allelic exclusion 
mechanisms in the development of γδ T cells170, expressed a Vδ1+ TCR originating from the 
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sister chromosome. Despite these non-Vδ1 chains, these findings validate the sorting 
technique and confirm that largely Vδ1+ chains were analysed. 
In two donors, some of the Vγ9 sequences had hallmarks of Vγ9 chains of the pAg reactive 
Vγ9Vδ2 population, namely the JgP*01 J region and an *ELG* motif in the CDR3 region 
(Figure 6.4)59. If these Vγ9Vδ2-associated Vγ9 chains predominantly pair with Vδ2, one 
possible explanation for the presence of these cells is that the Vδ2 chain failed to 
recombine. It could also be that these motifs are not unique to pAg reactive Vγ9Vδ2 TCRs, 
and form functional TCRs with non-Vδ2 δ chains. Such γ chains were also observed in liver 
and colon samples in the previous chapter, and were discounted as blood contamination 
of the samples. However, this observation suggests that these chains could constitute 
genuine non-Vδ2 chain pairings, and perhaps should not be discounted in future studies. 
However, the antigen specificity of these cells is unknown, and so further investigation as 
to whether they can confer pAg reactivity is warranted, although it is thought that the Vδ2 
chain is required for reactivity59. 
6.2.3 MAU and other clones of interest were not represented in these 
samples 
The Vγ9 chain was the most common γ chain in all of the samples, suggesting that the 
Vγ9Vδ1 pairing is common in these donors (Figures 6.6A), which is interesting as Vγ9Vδ1 
pairings have not previously been described to a great extent. Despite the abundance of 
Vγ9Vδ1 receptors however, none of the Vγ9+ or Vδ1+ CDR3 sequences matched the MAU 
TCR amino acid sequence exactly. However, exact requirements for EphA2 reactivity by γδ 
T cells have not yet been fully determined, so although the CDR3 sequences do not match 
exactly some sequences may still satisfy the reactivity criteria, and so should ideally be 
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tested for EphA2 reactivity. Identification of further EphA2 reactive γδ TCRs would greatly 
enhance understanding of the recognition modality of MAU and EphA2. 
In addition to MAU, the γ or δ chain sequences of other clones of interest, either in 
published studies or currently under investigation in our laboratory, were not identified in 
these samples (Table 5.2). The anchored 5’-RACE RNA-based clonotyping approach used in 
this chapter represents a limited sample of the overall γδ T cell repertoire, and provides 
approximately 100 sequences per sample. This therefore means that the most abundant 
sequences are more likely to be sequenced. The absence of particular clones of interest 
from these samples therefore does not necessarily imply that they are absent in PB of these 
donors, as conceivably they may be present at levels low enough to be excluded from this 
representative sample. As this procedure provides sequences derived from RNA, cells 
which are actively proliferating will also be more highly represented by this approach by 
virtue of an increase in intracellular RNA during the mitotic stage of the cell cycle171. This 
therefore implies that active cells are more likely to be represented, and therefore such 
clones may alternatively conceivably be present in the donors but not necessarily actively 
involved in immune responses to persistent viral infection. 
6.2.4 Vδ1+ TCR repertoires are highly private 
Murine γδ T cells, and to an extent certain human populations, have been proposed to 
recognise a limited range of ligands150. If similar criteria apply to Vδ1+ γδ T cells in humans, 
it might be expected that there would be a high degree of overlap in the γδ TCR sequences 
between donors. 
Between all 6 donors, only two amino acid sequences were found to be shared between 
individuals, both of which were δ chains (Appendix 6.2). Although these sequences were 
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present at low frequencies, the samples containing the shared sequences were processed 
on separate days, substantially reducing the possibility that these represent contamination 
between the samples. Furthermore, no conserved γ chains were observed between these 
donors, and so the conserved δ chains do not necessarily constitute conserved TCR 
heterodimers. 
Interestingly, in a CMV-seropositive donor KM, two γ chain mosaics were observed 
(Appendix 6.2). These sequences possessed different Vγ gene elements (hence distinct 
CDR1 and CDR2 regions) yet have identical CDR3 regions, and the presence of these 
mosaics suggests an antigen-driven expansion of these cells based on their suspected role 
in αβ TCR mediated responses, but their significance in γδ T cells has not yet been 
explored172. 
6.2.5 Vδ1+ populations are polyclonal 
The sequencing data were also used to determine if there are any differences in the Vδ1+ 
γδ T cell repertoire of CMV-seropositive and CMV-seronegative donors. Given the large 
spread of the data collected by inherently variable human donors, the number of samples 
collected in this study is not sufficient to draw robust conclusions from specific 
comparisons, but it can be used to provide novel and important insights into the effect of 
CMV infection on the size and diversity of the Vδ1+ γδ T cell population, as well as highlight 
potentially significant γ or δ chains. 
Analysis of the top 30 sequences for either the CMV-seropositive and CMV-seronegative 
donors reveals a similar distribution of the top ranking γ and δ chains (Figure 6.5). For both 
the γ and δ chains, the CMV-seronegative donors appear to have a more restricted Vδ1+ γδ 
T cell population, particularly with the highest ranked clone for each chain, however the 
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sample size is insufficient to definitively conclude this. This property of the samples can 
also be expressed numerically using the clonality metric, which is derived from the Shannon 
entropy of the frequency distribution of individual sequences (Figure 6.5C)159. The clonality 
ranges from 0 (diverse, with equal representation of all sequences) to 1 (clonal, only one 
sequence is present). The equation for this calculation is shown below, where 𝑛 represents 
the total number of sequences in the sample, and 𝑝𝑖  is the fraction of residues of 
sequence 𝑖: 
Clonality =  1 − (− ∑
𝑝𝑖 log10 𝑝𝑖
log10 𝑛
𝑛
𝑖=1
) 
When both the γ and δ chains are collectively analysed in this way, the clonality of the Vδ1+ 
populations of CMV-seronegative donors is 0.17, higher than the CMV-seropositive value 
of 0.09. Therefore, this numerical analysis also suggests that for these donors, the CMV-
seronegative donors have a more restricted Vδ1+ population than their CMV-seronegative 
counterparts. 
Previous studies suggest that chronic CMV infection results in a clonal expansion of 
Vδ2negative γδ T cells (which in many donors consists mainly of Vδ1+ γδ T cells), and the data 
presented so far does not align with these reports (Figure 6.5). These previous studies 
largely determine clonality using spectratyping analysis, which measures CDR3 length 
distribution between samples, and the size of this distribution is then inferred as clonality, 
assuming that populations with a large number of cells with similar CDR3 lengths are 
comprised of identical cells. However, when comparable analyses are performed using this 
current repertoire data, no comparable differences were detected, despite the variances 
in clonality observed (data not shown). Given that previous spectratyping studies that have 
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noted significant differences in clonality of Vδ2negative subset from CMV-seropositive and 
CMV-seronegative individuals have been based on large sample sizes, it is likely that the 
limited number of samples in our current study is the reason I was not able to draw 
equivalent, statistically-significant conclusions. In one such spectratyping study, the sample 
size was 186 donors, and demonstrated substantial overlap in relative Vδ2negative population 
sizes158, highlighting that smaller sample sizes are unlikely to significantly demonstrate this 
difference. 
6.2.6 V region usage of γ chain sequences 
Another analysis that can be uniquely performed using TCR sequence-level repertoire data 
is an unbiased analysis of γ chain usage. Such approaches are not possible using flow 
cytometry, which relies on the availability and compatibility of antibodies for all γ chains, 
and as shown in this chapter, γδ TCR-specific antibodies are sometimes incompatible in 
certain combinations. As with the clonality measurements, the spread of data is large for 
Vγ chain usage, with a large amount of variation between donors. Therefore although 
specific conclusions cannot be drawn regarding the γ chain usage of receptors in these 
samples, this analysis can provide novel information of Vγ chain distributions in the Vδ1+ 
γδ T cell compartment. 
Analysis of the Vγ region usage of the sequences revealed that the Vγ9 chain is heavily 
represented across all samples, suggesting that the Vγ9Vδ1 pairing is common amongst all 
donors (Figure 6.6A). Interestingly, the Vγ5 chain is exclusively present in the CMV-
seropositive donors. The Vγ5 chain is present in all 3 of the CMV-seropositive donors 
(Figure 6.6B), and is therefore not due to a-typical Vγ5 usage in one donor. It may be that 
TCRs bearing the Vγ5 chain play a role in the control of chronic CMV infection, and so is 
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expanded in CMV-seropositive donors. This has not previously been noted, perhaps due to 
the lack of a Vγ5 specific antibody, and therefore this clearly warrants validation in a larger 
cohort, and further investigation of Vγ5Vδ1+ T cells in terms of function and ligand 
recognition.  
Another advantage of sequence-level TCR repertoire analysis is that it also allows for 
determination of the diversity of chains bearing particular V regions. This analysis is 
achieved by comparing the proportion of sequences using a particular V region to the 
number of unique sequences which constitute chains with that V region (Figure 6.7). 
Therefore, V regions with a large percentage of the total unique nucleotide sequences 
compared to their V region usage can be considered more diverse than V regions with a 
comparatively small number of unique sequences. These data are particularly interesting 
as the spread of data seems relatively small compared to other measurements in this 
chapter, suggesting that these patterns may be representative of a large number of donors. 
In the CMV-seronegative donors, although the Vγ9 chain is the most highly represented, it 
is comprised of only 30% of the unique sequences for all of the donors, suggesting that γ 
chains bearing this V region element are relatively restricted compared to the other chains. 
Conversely, Vγ8+ chains are comprised of relatively more unique sequences which suggests 
that these chains are much more diverse than Vγ9 chains. This is the opposite of the finding 
in Chapter 5, which established Vγ9 chains as being highly diverse in colon and liver samples 
and Vγ8 chains being less diverse (Figure 5.8). This disparity may represent the small sample 
number in both studies, but if this finding is reproducible, it signifies the importance of 
differentiating studies of γδ T cells between tissue and blood samples. 
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The Vγ5 sequences present in the CMV-seropositive donors appear to be equally as diverse 
as sequences containing other V gene segments (Figure 6.7B), suggesting that although 
cells bearing Vγ5+ chain are likely expanded in CMV-seropositive donors, the expansion 
does not appear to be clonal. This comparison also appears to demonstrate an increase in 
the diversity of Vγ9 chains and a decrease in the clonality of Vγ8 chains in CMV-seropositive 
donors compared to their CMV-seronegative counterparts. Again, although the sample 
sizes are too small to draw definitive conclusions from these data, it does strongly suggest 
that chronic CMV infection may have an impact on the clonality of γ chains with particular 
Vγ regions, which may be an indication that particular chains play a more important role in 
the immune response to CMV than other Vγ chains. 
6.3 Discussion 
The primary aim of this chapter was to determine how CMV infection affects the Vδ1+ γδ T 
cell repertoire, and to detect any public γ or δ TCR chains in in the PB of either CMV-
seronegative or CMV-seropositive healthy donors. No shared γ chains were detected 
between the donors, although two conserved δ chains were observed. Although the 
sample size is too small to draw statistically robust conclusions, it does provide several 
insights into the nature of the Vδ1+ repertoire in CMV-seropositive and CMV-seronegative 
donors, and also provides a basis for generating hypotheses as to how these receptors may 
be interacting with their ligands. Overall, the data presented in this chapter suggests that 
the Vδ1+ γδ T cell repertoire in both CMV-seropositive and CMV-seronegative healthy 
donors is predominantly private, with little CDR3 overlap between donors. 
Unfortunately the study had to be limited to the Vδ1+ population, due to issues 
encountered with the FACS-based sorting of Vδ2negative populations. These issues 
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demonstrate the limitations of using antibodies to analyse γδ TCR chain usages of 
populations, as these studies rely on having a panel of compatible antibodies which do not 
compete for epitopes on a single receptor. Furthermore, antibodies for all γ and δ chains 
are not yet available. In this study, antibody combinations which have previously been used 
in published studies were found to give unreliable results and do not always accurately 
represent the chain usage of γδ TCR populations. This highlights a significant advantage of 
unbiased repertoire analyses which are not affected by these biases, and give a more 
accurate representation of all chains. 
Previous studies have shown slight increase in the frequency of Vδ2negative γδ T cells in CMV-
seropositive healthy donors158, and spectratyping studies have suggested that these cells 
are more restricted than the non-expanded, CMV negative populations56. The results 
obtained in this chapter do not align with these previous studies, as Vδ1+ populations were 
not found to be larger in CMV-seropositive donors, and no significant difference in clonality 
of TCR sequences was observed. Although in a study by Pitard et al., the average age of 
donors was 40 years, and so maybe these differences were exaggerated by the effect of 
age on the Vδ2negative population. 
The sample size of this study is small compared to previous samples, and given the large 
spread of data observed in the previous studies56,158, it is not surprising that such 
differences are not apparent with a smaller sample size. The large sample sizes required to 
identify such differences are not viable for repertoire studies, due to the relatively high cost 
per sample. One potential approach would be to limit the study to donors who display 
expanded Vδ1+ populations by flow cytometry, to determine if these expanded populations 
differ to the non-expanded ones discussed in this chapter. It may be that increases in 
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clonality are associated with the expanded populations, which does not occur in all CMV-
seropositive donors. However, the Vγ5 sequences exclusively found in the CMV-
seropositive donors do not appear to be clonally expanded, further demonstrating that the 
Vδ2negative populations may not be homologous with regards to the immune response to 
CMV. 
With these sample size limitations in mind, assuming the data accurately represents the 
repertoires of these respective donor groups, it does have some interesting implications 
for how these γδ T cells may interact with their targets. The diverse, unique CDR3 regions 
of both γ and δ chains suggest the recognition of wide range of antigens by these cells, 
when viewed in the context of αβ T cells72. In αβ T cells, ligand recognition is facilitated by 
all three CDR regions, CDR1 and CDR2 interact mainly with the two α-helices of the MHC 
peptide-binding platform, and CDR3 specifically recognised the bound peptide72. 
Therefore, in ligand recognition by αβ TCRs, specific CDR3 sequences enable TCRs to 
recognise a specific peptide, although there is substantial degeneracy in this recognition, 
as multiple different clonotypes can recognise the same peptide-MHC combination. 
Recognition of ligands by γδ T cells is not mediated by class I and class II MHC molecules, 
and antigen presentation machinery is unlikely to be involved, as the majority of the ligands 
characterised so far for the Vδ2negative subset are whole protein antigens. Indeed, even 
though recognition of CD1d by γδ T cells is often reported to be lipid dependent, it cannot 
be excluded that it is being recognised as a whole protein antigen, due to the observation 
of Vδ1+ γδ T cells which can recognise CD1d independently of lipid50, and the differences in 
TCR binding footprint of different reactive T cells33. 
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Given such fundamental differences between ligand recognition strategies between αβ and 
γδ T cells, it is unlikely that the roles of the CDR loops would be conserved. For example, 
EPCR is an MHC-like molecule, and even with related α1/α2 platforms forming a lipid 
binding pocket, is recognised by a γδ clone LES at a distal site123. Also, T22 is an MHC-like 
molecule recognised by the murine γδ TCR G8 in a mechanism distinct from αβ TCR/MHC 
interactions31. These studies suggest that the recognition modalities of αβ and γδ TCRs are 
substantially distinct, and therefore it is not necessarily accurate to assume that distinctive 
γ or δ CDR3 sequences denote the recognition of a unique ligand. 
This is further supported by the distinct tissue distribution of γδ T cells by their V region. 
This is particularly well documented in mice, but is also partly characterised in humans. In 
mice, the Vγ5Vδ1 DETC subset is uniquely found in the skin, although no peripheral ligand 
has yet been identified. In humans the best defined subset is the Vγ9Vδ2 blood subset, 
which recognises non-peptidic pAgs via BTN3A1. This conservation of V regions has several 
possibilities as to how it affects antigen recognition. It may be that the V regions facilitate 
migration and maintain residence in the required tissues, or that these V regions (i.e. non-
CDR3 regions) are directly involved in the recognition of ligands which are present at these 
anatomical sites. There is also evidence to suggest that V regions are responsible for γδ T 
cell selection in the murine thymus, and contribute towards the upregulation of 
transcriptional signatures promoting homing receptors, as has been demonstrated for the 
Vγ5Vδ1 DETC subset173. 
If this latter suggestion is the case, it is unclear which parts of the V region are involved in 
antigen recognition. In the γδ TCR and complexes characterised so far, CDR1 and CDR2 are 
exposed, flexible loops, making them viable candidates for ligand recognition, and are 
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inherent components of the V region, and so is consistent with involvement of particular V 
regions in ligand recognition at different tissues. It could also be that non CDR framework 
regions play a key role in ligand recognition, although these regions are more closely 
conserved between V regions. 
These insights into the molecular nature of ligand recognition of the Vδ1+ γδ T cell subset 
demonstrate a previously unexplored use of the repertoire data, but studying the 
composition of these cells can help to direct more focused clone based experiments such 
as those described in earlier chapters using physiological information, instead of the more 
clone-dependent approaches used here. In order to investigate this area further, it is 
important to characterise a range of γδ TCR interactions to establish such patterns, such as 
the significance of CDR3. Repertoire studies such as this complement such ligand 
recognition studies by directing focus to areas of biological interest, allowing further 
hypothesis-driven molecular studies. 
In terms of future experiments building on the results comparing the repertoires of CMV-
seropositive and CMV-seronegative donors, they would be greatly improved by an 
increased sample size, in order to increase the chance of identifying public clones. What 
these results do show is that in order to identify differences between the two cohorts, 
increasing the sample size is not necessarily going to yield statistically significant results, 
and to do so, statistical power calculations would be advisable. 
The spread of data is large, and in order to reach significant conclusions the number of 
samples would have to very large, which is not very efficient and arguably a waste of the 
depth of such a technique. The results discussed in this chapter clearly suggest a difference 
in the use of the Vγ5 chain between CMV-seropositive and CMV-seronegative donors. To 
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expand on these findings, a real-time RT-PCR (qRT-PCR) experiment could be designed in 
which Vγ5-specific primers are used to detect the presence of the Vγ5 sequence in Vδ1+ γδ 
T cells in a larger cohort of donors at much higher throughput. 
Another obvious extension to the study is to more accurately categorise infection status. 
This study defined the cohorts as either CMV-seropositive or CMV-seronegative depending 
on the presence of CMV-antigen specific antibodies in serum. Previous studies have shown 
an expansion with acute infection and so a repertoire study on such samples would likely 
yield interesting results55. Furthermore, recent data suggest that, in acute CMV infection 
the Vδ2negative γδ T cell repertoire highly focused in chronic myeloid leukaemia (CML) 
patients, significantly more so than in patients with chronic CMV infection (D. Lewis, 
unpublished). The ultimate study would be a longitudinal one, whereby a cohort is 
monitored over a period of a few years, and repertoire analyses performed before and 
after infection on donors that contract CMV during the study.  
This study has compared the use of two approaches to γδ TCR repertoire analysis, DNA-
based immunoSEQ and RNA-based anchored 5’-RACE. immunoSEQ used high throughput 
sequencing and provides a relatively deep view of the repertoire116, whereas the RNA-
based anchored 5’-RACE approach is much lower throughput and yields around 100 
sequences for each sample117. It would be useful to determine how representative the 
anchored 5’-RACE-acquired sequences are of the entire repertoire. To achieve this, 
identical samples could be processed by both techniques and compared. This would also 
give an indication of how much of an effect activation and proliferation status has on the 
sequences gained by the RNA approach. 
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Finally, neither of these approaches offers paired chain sequences. Large expansions can 
be tentatively paired by matched chains with similar abundances, but this is not useful for 
the lower frequency sequences. γδ TCRs exist as heterodimer pairs, and so information on 
only one of the chain pairs is unlikely to convey all of the characteristics of the complete 
receptor. Low-throughput, single-cell PCR approaches are available to analyse both the γ 
and δ chains of single γδ TCRs174. Such an analysis would be able to expand upon the 
observation that that only conserved δ chains were identified in this study, whereas no γ 
chains were conserved. If it is assumed that these chains are conserved because they 
recognise the same antigen it could be that the majority of antigen recognition is facilitated 
by one chain, with the other either redundant or changeable, in order to add fine sensitivity 
to antigen recognition, or conceivably affect the kinetics of the response. However, the 
extent of γδ TCR redundancy in recognition of specific ligands is unclear. This is also 
supported by data for the Vγ9Vδ1 clone MAU, where our collaborators have preliminary 
evidence suggesting that the gamma chain can be swapped with other chains and some 
activity towards EphA2 is maintained, whereas the Vδ1 chain appears to be critical to 
recognition. 
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6.4 Figures 
  
Figure 6.1: Development of γδ T cell sorting strategy 
PBMCs from the same KKHD sample were stained with CD3-APC. PBMCs in (A) were also 
stained with pan-γδ-PE and Vδ2-FITC antibodies and PBMCs in (B) were instead stained with 
a Vδ2-PE antibody. Histograms are gated on the Vδ2+ populations. The Vδ2 populations differ 
between the antibody panels used in panels A and B, and the Vδ2-FITC antibody used in 
conjunction with the pan-γδ-PE antibody stained fewer cells than the Vδ2-PE antibody alone. 
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Figure 6.2: Representative phenotyping of γδ T cells 
PBMCs frm the AWHD donor were stained with CD3-APC and various γδ phenotyping 
antibodies. Gating strategy shown in Appendix 6.1. 
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Figure 6.3: The effect of CMV infection on γδ T cell populations 
All donors (including those not sequenced) were grouped into CMV-seropositive or 
seronegative cohorts using an IgG ELISA and populations were gated on CD3. Demonstration 
of the effect of CMV-serostatus on (A) Vδ1 cells and (B) Vγ9Vδ1 cells. 
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Figure 6.4: Vγ9Vδ2-associated γ chain sequences 
Proportion of γ chains with characteristics of pAg reactive Vγ9Vδ2-associated γ chains. These 
chains are characterised by the Vγ9 gene segment joined with the JgP*01 joining segment, 
with the short *ELG* amino acid motif in the CDR3 region. 
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Figure 6.5: Clonality of the top 30 γ and δ chains 
The relative abundance 30 most abundant δ (A) and γ (B) chains for the CMV-seropositive 
and CMV-seronegative donors were compared. (C) Clonality measurement of both γ and δ 
chains for CMV-seropositive and CMV-seronegative donors. 0 = Diverse and 1 = clonal. 
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Figure 6.6: Usage of γ chain gene segments by CMV-serostatus 
(A) γ chain usage by CMV-serostatus for all donors analysed. (B) Percentage of γ chain 
sequences containing Vγ5 gene segment for individual donors. 
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Figure 6.7: Clonality of specific γ chains 
The relative proportion of sequences containing γ chain gene segments compared to 
the number of unique amino acid sequences which constitute those chains for (A) CMV-
seronegative and (B) CMV-seropositive donors. Populations which demonstrate a large 
number of unique sequences relative to the proportion of sequences bearing that chain 
are considered more diverse than populations with a low number of unique sequences 
relative to the proportion of sequences bearing that chain. 
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7.1 Introduction 
In this thesis I aimed to explore the role of Vδ1+ γδ T cells in lymphoid stress surveillance. 
This involved the determination of the molecular basis for recognition of an epithelial stress 
ligand, EphA2, by a Vδ1+ γδ T cell, MAU. This resulted in the proposal of a model of a tri-
partite recognition complex, with a requirement for ephrin binding by EphA2. Additionally, 
I identified a 355Å2 patch on the LBD of EphA2, which potentially constitutes the MAU TCR 
binding site. 
I also explored the potential of using various sequence-level TCR repertoire analysis 
techniques to analyse γδ T cell populations in human tissue and blood samples. This study 
was concluded by investigating the effects of CMV infection on the Vδ1+ γδ T cell 
compartment in PB of healthy donors. Collectively, these studies have contributed to the 
understanding of how vδ1+ γδ T cells function in stress surveillance. 
7.2 Ligand recognition by γδ T cells 
Despite their increasing implication in immune responses to a range of conditions, and 
continued exploration for therapeutic use34, γδ T cells are still poorly understood, both in 
terms of our knowledge of the ligands they recognise and the molecular nature of 
TCR/ligand interactions. 
There have recently been significant advances in the understanding of how pAg-reactive 
Vγ9Vδ2+ γδ T cells interact with infected and stressed cells, as butyrophilin family member 
BTN3A1 has been shown to be essential for the recognition of cells with increased levels of 
intracellular pAgs by these Vγ9Vδ2+ γδ T cells175. However, even within this well-
characterised subset the exact molecular requirements of this interaction are still unclear. 
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Despite significant advances in this area69, direct binding has yet to be convincingly 
demonstrated between a Vγ9Vδ2 TCR and BTN3A1 by BIAcore, even though these two 
components have been found to be essential for the detection of stressed cells by Vγ9Vδ2+ 
γδ T cells.  
7.2.1 Ligand recognition by Vδ2negative γδ T cells 
Ligand recognition by Vδ2negative γδ T cells is less clearly understood than for Vγ9Vδ2+ γδ T 
cells, and unlike for Vγ9Vδ2+ γδ T cells, there is currently no discrete subset of ligand or 
recognition strategy for these cells, suggesting that ligand recognition by this subset is 
much less conserved. 
In Chapter 3 I characterised the molecular requirements for the recognition of EphA2 by 
MAU γδ T cells. Despite the weight of evidence suggesting that this interaction is mediated 
by the MAU TCR, such as being able to confer reactivity to EphA2 by transducing JRT3.5 
cells with MAU TCR genes, I was unable to detect direct binding between recombinant 
versions of EphA2 and MAU TCR proteins by BIAcore. This result is perhaps similar to the 
difficulty in the detection of binding between Vγ9Vδ2 TCRs and BTN3A1, mentioned above, 
and suggests that either the molecular requirements for these interactions have not been 
met in in vitro experimental systems, or that the interactions exhibit an affinity beyond the 
sensitivity of techniques such as BIAcore. The strength of the accompanying evidence for 
the involvement of BTN3A1 in the recognition of pAgs by Vγ9Vδ2+ γδ T cells reinforces the 
conclusion that, although direct binding cannot be detected by BIAcore between EphA2 
and MAU TCR, it likely still represents a physiologically relevant interaction. 
  7 - 214 
Collectively, these observations suggest that ligand recognition by some γδ TCRs may not 
always be easily modelled with a simple binary receptor-ligand interaction, and the 
involvement of other molecules, co-receptors or clustering requires further investigation. 
7.2.1.1 Recognition of non-MHC-like ligands by Vδ2negative γδ T cells 
The majority of ligands proposed to date for Vδ2negative γδ T cells, such as EPCR123 and 
CD1d33, are MHC-like molecules. However, there is currently insufficient evidence to 
conclusively suggest that Vδ2negative γδ T cells exclusively recognise MHC-like molecules. 
Therefore non-MHC-like ligands, such as EphA2, are still viable candidates as ligands for 
Vδ2negative γδ T cells, and future research should not be restricted to the identification of 
MHC-like ligands. 
This view is consistent with the observation that some Vδ2negative γδ TCRs interact with 
MHC-like ligands in a manner unlike conventional αβ TCR/MHC interactions. One such 
example is the Vδ2negative γδ TCR LES, which has been shown to interact with the MHC-like 
molecule EPCR. TCR specificity was determined to be mediated by residues located on the 
underside of the lipid binding platform123, which suggests that the LES TCR does not form 
any contacts with the lipid binding platform. Furthermore, TCR binding was shown to be 
dependent on all 6 CDR loops of the LES TCR (C. Willcox, unpublished), suggesting an 
antibody-like method of recognition of a 3D epitope, as opposed to the CDR1 and CDR2 
mediated recognition of the lipid binding platform demonstrated by αβ T cells72. 
Another example of this is the variation in recognition mode of the same MHC-like 
molecule, CD1d, by different Vδ1+ γδ TCRs50,51. The two structures demonstrated strikingly 
distinct TCR binding modes to the CD1d lipid binding platform, which does not align with 
conserved recognition of an individual ligand. Furthermore, in these studies CD1d 
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tetramers occasionally stained <1% of Vδ1+ γδ T cells, strongly suggesting that CD1d 
recognition is restricted to a small subset of Vδ1+ γδ T cells. 
This apparent over-representation of MHC-like molecules as ligands for Vδ2negative γδ T cells 
in published studies could be explained by the familiarity with MHC-like molecules in 
structural immunology research. Such familiarity can greatly expedite research involving 
these molecules, particularly in X-ray crystallographic studies, which use previously 
resolved structures as a template for model building. Therefore structures and complexes 
involving less well-characterised molecules may take longer to elucidate, and therefore 
would not be reported as readily. Furthermore, the cloning process by which the majority 
of γδ TCRs used for ligand identification studies were isolated could conceivably introduce 
biases to expand cells reactive towards particular types of molecules, depending on the 
expansion protocol used. 
These issues highlight the importance for advancing unbiased ligand identification studies, 
to gain a better understanding of the molecules Vδ2negative γδ T cells are interacting with in 
vivo. Such an approach would be greatly facilitated by sequence-level TCR repertoire 
analyses, such as the technologies utilised in Chapters 5 and 6 of this thesis. These 
approaches allow for the identification of γδ T cell populations which demonstrate 
characteristics of being physiologically important, such as bearing TCRs which are shared 
between donors, or that are clonally expanded during infection, tumourigenesis, or even 
during therapeutic expansion protocols. This would then allow for the unbiased focusing of 
ligand determination attempts on these receptors, using molecular approaches such as 
those employed in Chapters 3 and 4.  
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7.2.2 The role of the γδ TCR and additional molecules in ligand recognition 
To date, the role of co-receptors in γδ T cells is largely undetermined. This study highlights 
the potential importance of additional molecules for antigen recognition by these cells. The 
results from Chapter 3 suggest that that, despite being essential for the interaction, the 
MAU γδ TCR may not be the main determining factor for recognition of EphA2, with 
specificity being partly determined by A-ephrins. It may be that the ephrins on the surface 
of the T cell are serving as the conventional ligand recognition molecule, and the MAU TCR 
is recruited to the signalling complex to provide co-stimulatory-like functions.  
In Chapter 4 I identified a potential TCR binding site on the LBD of EphA2. It was not possible 
to definitively prove this region was the MAU TCR binding site, as it may represent a region 
which mediates contacts to additional, as yet unidentified, molecules on the surface of 
MAU T cells that are critical for activation by EphA2. Viable candidates for these molecules 
are the TM signalling molecules which facilitate reverse signalling by the GPI linked A-
ephrins136. Therefore it may be that the MAU TCR is not directly interacting with EphA2, 
but interacts with these signalling molecules, which would explain the difficulty in obtaining 
BIAcore data establishing a direct interaction between EphA2 and MAU TCR. Such 
molecules could potentially be identified by conducting co-IP experiments to isolate 
molecules involved in the signalling complex, with subsequent identification of them by 
mass spectrometry. 
To date, only one signalling partner has been identified for A-ephrins, P75(NTR), which is 
involved in neuronal development and positioning139. However, it is unknown whether this 
molecule is also involved in facilitating A-ephrin reverse signalling in T cells. Therefore the 
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identification of other A-ephrin-associated signalling molecules may contribute towards 
other fields where A-ephrin reverse signalling is important, not solely in immune function. 
These findings raise important questions regarding the role of the γδ TCR in these γδ T cell 
populations, and suggest that it is unlikely to act solely as an antigen receptor in some 
cases. This emphasises the difficulty of studying these receptors in isolation, and the 
current dependence on direct binding studies to validate ligands is one such challenge.  
7.2.3 The significance of the γδ TCR CDR loops 
The significance of the γδ TCR CDR loops has yet to be established for ligand binding by γδ 
T cells. Their role is unlikely to be conserved between all receptors, since several studies 
have suggested the requirement of different CDR loops, on different TCR chains, for ligand 
recognition150. Indeed, even different models of the same ligand with different TCRs 
demonstrate different CDR loop involvement50,51. Understanding of CDR loop involvement 
for γδ TCRs has implications for many areas of γδ T cell immunobiology, such as 
development and trafficking, not just the molecular nature of their interactions with 
ligands. 
αβ T cells typically use the less variable CDR1 and CDR2 loops to form interactions with the 
helices of the antigen binding pocket and use the more variable CDR3 to differentiate 
between presented peptides72. Antibodies however typically utilise all of the CDR loops to 
recognise three-dimensional epitopes of whole protein antigens176. Therefore, determining 
which of these approaches utilised by γδ T cells may provide insights into how they 
recognise ligands and interact with their target molecules.  
Unfortunately, I was unable to establish the importance of the CDR loops of the MAU TCR 
in the interaction with EphA2 in this study, due to the lack of a reliable direct binding assay. 
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However, this remains an important question, and the MAU CDR mutant constructs that I 
created in Chapter 4 could be used for the transduction of JRT cells in future studies, to 
assess the impact of the CDR mutations on EphA2 reactivity. 
7.2.4 Classification of Vδ2negative γδ T cell subpopulations 
A further aspect which is still unclear regarding Vδ2negative γδ T cells is the heterogeneity of 
this population, pertaining to the ligands they recognise and their ligand recognition 
strategies. There is currently insufficient evidence to establish whether the population can 
be further sub-categorised into populations with conserved ligands or recognition 
modalities. 
In Chapter 3 of this thesis I established that recognition of EphA2 by MAU T cells requires 
the presence of GPI-linked A-ephrins on the T cell surface to form a tripartite recognition 
complex with EphA2 and the MAU TCR. This potentially represents a novel recognition 
modality which has not been described previously for γδ TCRs. It is important to establish 
whether this recognition strategy is employed by other, as yet unidentified, γδ T cells or 
represents a completely unique utilisation of non-immune receptor/ligand interaction by 
immune cells to detect stress. Therefore, full characterisation of this interaction will assist 
in research to determine whether this mode of recognition can be extended to other 
receptors. Furthermore, it could potentially act as a template to expedite discovery of 
similar ligands, equivalently to how to knowledge of MHC-like molecules may be facilitating 
the identification of MHC-like ligands for Vδ2negative γδ T cells. 
This study has also highlighted the importance of antigenic context in immune receptor 
studies. According to the model generated in Chapter 3, MAU is specifically recognising 
mislocalised EphA2, i.e. EphA2 that is not bound to ligand or localised at cell-cell junctions. 
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This therefore demonstrates that it is important to exercise caution when interpreting data 
from analyses such as microarray studies, as they only provide information on whether 
proteins are likely either upregulated or downregulated under certain conditions. For 
ligand identification however, this does not necessarily indicate their viability as an antigen, 
therefore it is important to consider antigen context, such as localisation or whether it is 
able to bind ligand, when considering candidate γδ TCR ligands emerging from such studies. 
7.3 Using TCR repertoire analysis to analyse γδ T cell populations 
The use of repertoire studies to analyse populations of γδ T cells in human blood and tissue 
samples was addressed in Chapters 5 and 6. The study detailed in Chapter 6 constitutes, to 
my knowledge, the first sequence-level analysis of γδ TCRs in response to CMV infection. 
These studies drew novel conclusions about the use of these technologies to examine γδ T 
cell populations, and will greatly inform future experiments in this field.  
TCR repertoire studies can be conducted using either DNA-based or RNA-based 
approaches. In this study I utilised both technologies to analyse γδ T cell subsets in either 
tissue or blood samples, and the advantages and limitations of each approach were 
appraised. This evaluation could prove to be highly beneficial when selecting which 
technology to use in future studies, depending on the research objectives. 
The repertoire study analysing colon and liver samples described in Chapter 5 was 
performed using the DNA-based sequencing platform by immunoSEQ. This approach yields 
a very large number of sequences and can detect much lower abundance sequences than 
the anchored 5’-RACE RNA methodology available for my studies at the time. This 
technology is extremely sensitive to DNA contamination however, which became a 
significant issue as our group routinely works with the DNA of various γδ TCRs. In future 
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studies great care would need to be taken to ensure all stages of the sample preparation 
were undertaken in PCR-clean conditions, to minimise such issues. 
The RNA-based anchored 5’-RACE technology as utilised in Chapter 6 yields much fewer 
sequences than the DNA approach, but there was no evidence of sequence contamination 
using this technology. What remains undetermined is how representative this subset of 
sequences is of the entire repertoire. Therefore it would be desirable to perform both the 
DNA- and RNA- based techniques on the same sample, to assess how much of the 
repertoire the this RNA-based approach covers, and also determine if there are any further 
differences between the sequences obtained by either approach. This would also prove 
useful to determine the impact of variation in mRNA levels, for example due to expansion 
of activated γδ T cells, on results from RNA-based approaches compared to the sequencing 
of genomic DNA by immunoSEQ. 
A further issue encountered with the repertoire studies was that that experiments with 
human samples need to be large to account for the substantial amount of variation 
inherent between samples. However, given the scope and relative expense of repertoire 
studies, the use of larger sample sizes to reach statistical significance is not always possible. 
These issues can be countered by expanding these studies to include more donors, but 
considering the spread of data observed in this study, careful calculation of ideal sample 
sizes using power-calculations is required177. 
Alternatively, these studies could be complemented by more focused, smaller scale 
approaches with have a lower cost-per-sample. An example of such an approach would be 
the use of qRT-PCR to analyse the presence of recombined Vγ5 chains in Vδ1+ γδ T cells in 
PB. This could be used to determine the significance of the results discussed in Chapter 6 
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that Vγ5 chains were exclusively found in the Vδ1+ γδ T cell populations in the PB CMV-
seropositive donors, by analysing a much larger cohort of donors. 
If the observation that Vγ5 chains are either exclusive or more abundant in the Vδ1+ γδ T 
cell populations in CMV-seropositive donors is determined to be significant after expanding 
the study, this finding could provide novel insights into the molecular nature of how these 
γδ T cells interact with CMV-associated antigens. The observation that responses may be V 
region specific suggests a role for CDR loops 1 and 2 in the response of γδ T cells to CMV, 
and perhaps they play a central role in antigen recognition.  
7.3.1 Combining repertoire and ligand identification studies 
Sequence-level TCR repertoire studies provide a unique platform from which to investigate 
ligand recognition by γδ T cells, and if combined with detailed molecular studies such as 
those performed in Chapters 3 and 4, could point the way towards novel insights into ligand 
recognition strategies of not only individual receptors, but also whole γδ T cell populations. 
Both of the repertoire studies discussed in Chapters 5 and 6 of this thesis suggest very 
diverse CDR3 regions of γδ TCRs in both blood and tissues samples. This can be interpreted 
in several ways, and so molecular studies need to be expanded to better understand the 
significance or the CDR3 loop in γδ T cell immunobiology. One possibility is that each 
individual CDR3 region is specific for an individual ligand, with an unknown contribution by 
the CDR 1 and 2 loops. Alternatively, it could also be that there is a large amount of 
tolerance of variation in the CDR3 sequence for recognition of individual ligands. This is 
similar to the Vγ9 chain of the pAg reactive Vγ9Vδ2+ γδ T cell subset, whose criteria for pAg 
reactivity has been shown to require a specific J region and a three amino acid motif in the 
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CDR3 loop59, therefore although other chains may not match each other perfectly, they are 
still reactive for the same antigen. 
Ultimately, the significance of the CDR3 loops cannot be known unless molecular studies 
into ligand recognition by γδ T cells are progressed, and a more complete understanding of 
the roles of the individual CDR loops is determined for other γδ TCRs. However, if such 
advances can be made, the combination of repertoire and molecular approaches may 
provide a powerful perspective on the activity and ligand recognition capabilities of these 
cells. 
7.3.2 Expanding γδ TCR repertoire studies 
There is scope to extend the repertoire study from Chapter 6 to viruses other than CMV, 
such as viruses with more wide-spread clinical significance, where the understanding how 
γδ T cells are involved in the immune response to these viruses may influence clinical 
intervention. 
Finally, expansion of the repertoire studies would benefit from single cell PCR approaches. 
These technologies amplify both the γ and δ chains from single cells, which is the only 
approach to obtain definitive chain pair information. This information is important because 
γδ TCRs function as heterodimers, and so it is likely that both the γ and δ chains contribute 
to antigen recognition. If the link between Vγ5Vδ1+ γδ T cell populations and CMV-positivity 
were firmly established in additional repertoire studies, then single cell PCR approaches 
would be crucial in highlighting paired Vγ5 and Vδ1 TCR sequences that could be used for 
subsequent ligand identification and molecular studies. 
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Appendix 6.1: HD PB Gating Strategy 
Gating strategy for the selection of A) Single cells, B) Lymphocytes and C) CD3 
positive/Viability stain negative cells from mononuclear cells isolated from donors 
peripheral blood for flow cytometry analysis 
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Appendix 6.2: CMV Sequencing Data 
CMV Sequencing data from RNA-based anchored 5’-RACE analysis of heathy donor 
peripheral blood. CDR3 column represents amino acid translation of nucleotide 
sequences. Highlighted rows of the same colour denote shared sequences between 
multiple samples. 
Mosaic sequences with identical CDR3 regions but different Vγ segments are coloured 
and labelled.  
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